Document:

EX-10.6

 Exhibit 10.6 

Execution Version 

ASSET PURCHASE AGREEMENT 

by and between 
 FINCH
THERAPEUTICS, INC., 
 and 

MICROBIOME HEALTH RESEARCH INSTITUTE, INC. 

DATED AS OF NOVEMBER 19, 2020 
  

 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
		
	 ARTICLE I DEFINITIONS AND TERMS
	  	 	1	 
			
	 Section 1.1.
	 	Definitions	  	 	1	 
			
	 Section 1.2.
	 	Other Definitional Provisions	  	 	16	 
		
	 ARTICLE II PURCHASE AND SALE; GRANT OF LICENSES
	  	 	16	 
			
	 Section 2.1.
	 	Purchase and Sale of Assets; Know-How Transfer; Grant of Licenses	  	 	16	 
			
	 Section 2.2.
	 	Excluded Assets	  	 	18	 
			
	 Section 2.3.
	 	Assumed Liabilities	  	 	18	 
			
	 Section 2.4.
	 	Excluded Liabilities	  	 	18	 
			
	 Section 2.5.
	 	Purchase Price	  	 	18	 
			
	 Section 2.6.
	 	Closing	  	 	19	 
			
	 Section 2.7.
	 	Purchased Assets Not Transferred at the Closing	  	 	20	 
			
	 Section 2.8.
	 	Taxes	  	 	20	 
			
	 Section 2.9.
	 	Wrong Pockets	  	 	21	 
		
	 ARTICLE III MILESTONES AND OTHER FINANCIAL OBLIGATIONS
	  	 	22	 
			
	 Section 3.1.
	 	Natural Product Milestone Payments	  	 	22	 
			
	 Section 3.2.
	 	Natural Product Royalties and Sublicensing Revenue Payments	  	 	23	 
			
	 Section 3.3.
	 	Cultured Product Royalties and Sublicensing Revenue	  	 	24	 
			
	 Section 3.4.
	 	Royalty Reports	  	 	25	 
			
	 Section 3.5.
	 	Records	  	 	25	 
			
	 Section 3.6.
	 	Audit Rights	  	 	25	 
			
	 Section 3.7.
	 	Foreign Sales	  	 	26	 
			
	 Section 3.8.
	 	Tax Withholding	  	 	26	 
			
	 Section 3.9.
	 	No Other Royalty Payments	  	 	26	 
		
	 ARTICLE IV REPRESENTATIONS AND WARRANTIES OF SELLER
	  	 	26	 
			
	 Section 4.1.
	 	Organization and Good Standing	  	 	26	 
			
	 Section 4.2.
	 	Authority	  	 	27	 
			
	 Section 4.3.
	 	No Conflict	  	 	27	 
			
	 Section 4.4.
	 	Required Filings and Consents	  	 	27	 
			
	 Section 4.5.
	 	Solvency	  	 	28	 
			
	 Section 4.6.
	 	Purchased Assets	  	 	28	 
			
	 Section 4.7.
	 	Contracts	  	 	28	 
			
	 Section 4.8.
	 	Intellectual Property	  	 	29	 

  
 i 

							
	 Section 4.9.
	 	Compliance with Laws; Regulatory Compliance	  	 	31	 
			
	 Section 4.10.
	 	Taxes	  	 	33	 
			
	 Section 4.11.
	 	Brokers	  	 	34	 
			
	 Section 4.12.
	 	No Other Representations and Warranties	  	 	34	 
		
	 ARTICLE V REPRESENTATIONS AND WARRANTIES OF PURCHASER
	  	 	34	 
			
	 Section 5.1.
	 	Organization and Good Standing	  	 	34	 
			
	 Section 5.2.
	 	Authority	  	 	34	 
			
	 Section 5.3.
	 	No Conflict	  	 	34	 
			
	 Section 5.4.
	 	Required Filings and Consents	  	 	35	 
			
	 Section 5.5.
	 	Action	  	 	35	 
			
	 Section 5.6.
	 	Third Party License Fees for Natural Products	  	 	35	 
			
	 Section 5.7.
	 	Brokers	  	 	35	 
			
	 Section 5.8.
	 	Withholding	  	 	35	 
			
	 Section 5.9.
	 	No Other Representations and Warranties	  	 	35	 
		
	 ARTICLE VI INTELLECTUAL PROPERTY; KNOW-HOW TRANSFER
	  	 	36	 
			
	 Section 6.1.
	 	Defense of Claims Brought by Third Parties Against Seller or Purchaser	  	 	36	 
			
	 Section 6.2.
	 	Settlement	  	 	36	 
			
	 Section 6.3.
	 	Other Actions by Third Parties Not Involving Seller	  	 	36	 
			
	 Section 6.4.
	 	Certain Costs	  	 	37	 
			
	 Section 6.5.
	 	License Granted to Purchaser and its Affiliates	  	 	37	 
			
	 Section 6.6.
	 	Know-How Transfer	  	 	38	 
			
	 Section 6.7.
	 	In-Licenses	  	 	38	 
			
	 Section 6.8.
	 	Licenses Granted to Seller	  	 	38	 
		
	 ARTICLE VII CERTAIN COVENANTS
	  	 	40	 
			
	 Section 7.1.
	 	Solicitation of Non-Objection from the Massachusetts Attorney General	  	 	40	 
			
	 Section 7.2.
	 	Pre-Closing Actions	  	 	40	 
			
	 Section 7.3.
	 	Purchaser’s Access and Inspection	  	 	41	 
			
	 Section 7.4.
	 	Notification of Certain Matters; Supplemental Schedules	  	 	41	 
			
	 Section 7.5.
	 	Exclusive Dealing	  	 	43	 
			
	 Section 7.6.
	 	Conduct of Business Pending Closing	  	 	43	 
			
	 Section 7.7.
	 	Grant of Licenses	  	 	44	 
			
	 Section 7.8.
	 	Intentionally omitted	  	 	45	 
			
	 Section 7.9.
	 	Termination of Contracts	  	 	45	 
			
	 Section 7.10.
	 	[***]	  	 	45	 

  
 ii 

							
	 Section 7.11.
	 	Restrictions on Clinical Research and Studies	  	 	45	 
			
	 Section 7.12.
	 	Subject Matter Agreement	  	 	45	 
			
	 Section 7.13.
	 	Seller’s Disclosure Schedules	  	 	45	 
			
	 Section 7.14.
	 	Independent and Competitive Activities	  	 	45	 
		
	 ARTICLE VIII CLOSING CONDITIONS
	  	 	46	 
			
	 Section 8.1.
	 	Conditions to the Obligation of each Party to Effect the Closing	  	 	46	 
			
	 Section 8.2.
	 	Additional Conditions to Purchaser’s Obligation	  	 	46	 
			
	 Section 8.3.
	 	Additional Conditions to Seller’s Obligation	  	 	47	 
		
	 ARTICLE IX INDEMNIFICATION
	  	 	47	 
			
	 Section 9.1.
	 	Indemnification by Seller	  	 	47	 
			
	 Section 9.2.
	 	Indemnification by Purchaser	  	 	49	 
			
	 Section 9.3.
	 	Time for Claims	  	 	50	 
			
	 Section 9.4.
	 	Notice of Claims	  	 	50	 
			
	 Section 9.5.
	 	Indemnification Procedures	  	 	50	 
			
	 Section 9.6.
	 	Set-Off	  	 	51	 
			
	 Section 9.7.
	 	Exclusive Remedy	  	 	51	 
		
	 ARTICLE X TERMINATION
	  	 	52	 
			
	 Section 10.1.
	 	Termination	  	 	52	 
			
	 Section 10.2.
	 	Effect of Termination	  	 	53	 
		
	 ARTICLE XI MISCELLANEOUS
	  	 	53	 
			
	 Section 11.1.
	 	Further Assurances and Post-Closing Covenants	  	 	53	 
			
	 Section 11.2.
	 	Notices	  	 	53	 
			
	 Section 11.3.
	 	Amendment; Waiver	  	 	54	 
			
	 Section 11.4.
	 	Assignment	  	 	54	 
			
	 Section 11.5.
	 	Entire Agreement	  	 	54	 
			
	 Section 11.6.
	 	No Third-Party Beneficiaries	  	 	55	 
			
	 Section 11.7.
	 	Public Disclosure	  	 	55	 
			
	 Section 11.8.
	 	Publishing and Use of Trademarks	  	 	55	 
			
	 Section 11.9.
	 	Confidentiality	  	 	55	 
			
	 Section 11.10.
	 	Equitable Relief	  	 	56	 
			
	 Section 11.11.
	 	Expenses	  	 	56	 
			
	 Section 11.12.
	 	Governing Law; Dispute Resolution	  	 	57	 
			
	 Section 11.13.
	 	Counterparts	  	 	57	 

  
 iii 

							
	 Section 11.14.
	 	Headings	  	 	57	 
			
	 Section 11.15.
	 	Severability	  	 	58	 
			
	 Section 11.16.
	 	Force Majeure	  	 	58	 
			
	 Section 11.17.
	 	Payments under	  	 	58	 

 EXHIBITS 
  

			
	A	  	Amended and Restated Master Agreement
	B	  	Form of Bill of Sale
	C	  	License Agreement
	D	  	Subject Matter Agreement Services
	E	  	Express Indemnities

 ANNEXES 
  

			
	Annex 1.1(a)(i)(A)	  	Stool Donors
	Annex 1.1(a)(i)(B)	  	Finch Exclusive MALA Donors
	Annex 1.1(a)(i)(C)	  	Finch Proprietary Method
	Annex 1.1(a)(ii)	  	CP101 Technology
	Annex 1.1(b)	  	QSL Licensed Technology
	Annex 2.1(c)	  	Exclusive Donor Materials in Purchaser’s Possession
	Annex 2.1(d)(i)(A)	  	Capital Equipment
	Annex 2.1(d)(i)(B)	  	Assumed Contracts
	Annex 2.1(d)(i)(C)	  	Contract Services IP
	Annex 2.2	  	Excluded Assets
	Annex 5.6	  	Third Party License Fees for Natural Products
	Annex 6.8(e)	  	Elective Technology Transfer Raw Materials, Consumables and Equipment
	Annex 6.8(f)	  	Permitted Activities
	Annex 7.9(a)	  	Terminated Contracts on the date hereof
	Annex 7.9(b)	  	Terminated Contracts on the Closing Date
	Annex 8.2(e)	  	Seller Consents

  
 iv 

 ASSET PURCHASE AGREEMENT 

This Asset Purchase Agreement, dated as of November 19, 2020, is made by and between Microbiome Health Research Institute, Inc. d/b/a
OpenBiome, a Massachusetts nonprofit corporation (“Seller”) and Finch Therapeutics, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are collectively referred to herein as the
“Parties” and individually as a “Party.” 
 W I T N E S E
T H: 
 WHEREAS, Seller desires to sell to Purchaser and Purchaser wishes to purchase from Seller, all of Seller’s right,
title and interest in, to and under the Purchased Assets upon the terms and subject to the conditions set forth herein; 
 WHEREAS, the
Parties desire to grant certain licenses to each other upon the terms and conditions provided herein; 
 WHEREAS, upon the conditions set
forth in this Agreement and the License Agreement by the parties, Purchaser and Seller desire to consummate the transactions set forth in this Agreement and the License Agreement. 

NOW, THEREFORE, in consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, the Parties
hereby agree as follows: 
 ARTICLE I 

DEFINITIONS AND TERMS 

Section 1.1. Definitions. As used in this Agreement, the following terms shall have the meanings set forth or as referenced below:

 “200 Inner Belt Premises” shall mean the premises at 200 Inner Belt Road, Somerville, Massachusetts 02143. 

“Action” shall mean any claim, suit, action, investigation, audit, hearing, charge, complaint, demand, indictment,
administrative proceeding, arbitration, mediation or other similar proceeding. 
 “Active Pharmaceutical Ingredient” Any
substance or mixture of substances [***] intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish
pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body. For clarity, “Active Pharmaceutical Ingredient” excludes all
excipients and other inactive ingredients such as fillers, extenders, diluents, wetting agents, solvents, emulsifiers, preservatives, flavors, absorption enhancers, sustained-release matrices, and coloring agents. 

  
 1 

 “Additional Technology” shall have the meaning set forth in
Section 7.14. 
 “Affiliate” shall mean, with respect to any Person, any other Person that directly, or
indirectly through one or more intermediaries, controls, is under common control with, or is controlled by such Party or party. For the purpose of this definition only, “control” means the actual power, either directly or indirectly
through one (1) or more intermediaries, to direct or cause the direction of the management and policies of a Person, whether by the ownership of more than fifty percent (50%) of the voting equity of such Person, by contract or
otherwise.  
 “Agreement” shall mean this Asset Purchase Agreement, including all Schedules and Exhibits
attached hereto, as the same may be amended, modified or supplemented from time to time in accordance with the terms hereof. 

“Aliquot” shall have the meaning set forth in Section 6.8(f). 

“Amended and Restated Master Agreement” shall mean the amended and restated master agreement, executed by each of the
Parties, attached hereto as Exhibit A, amending and restating the Master Strategic Affiliation Agreement in its entirety. 

“Ancillary Agreements” shall mean the Bill of Sale, the License Agreement, the Subject Matter Agreement and the Amended and
Restated Master Agreement. 
 “Annexes” shall have the meaning set forth in Section 1.2(i). 

“APLA” shall mean the Asset Purchase and License Agreement by and between Purchaser and Seller, dated February 1, 2019.

 “Assumed Contracts” shall have the meaning set forth in Annex 2.1(d)(i)(B). 

“Assumed Liabilities” shall have the meaning set forth in Section 2.3. 

“Bankruptcy Code” shall have the meaning set forth in Section 7.7. 

“Bill of Sale” shall mean the bill of sale and assignment and assumption agreement, substantially in the form attached hereto
as Exhibit B. 
 “BLA” shall mean (a) in the United States, a Biologics License Application, as defined in the
United States Public Health Service Act (42 U.S.C. § 262), and applicable regulations promulgated thereunder by the FDA, or any equivalent application that replaces such application, (b) in the European Union, a marketing authorization
application, as defined in applicable regulations of the European Medicines Agency, or any equivalent application that replaces such application and (c) in any other country, the relevant equivalent to the foregoing. 

“Business” shall mean the operation of the Manufacturing Platform. 

“Business Day” shall mean any day other than a Saturday, a Sunday or any other day on which commercial banks located in the
State of Massachusetts are authorized or obligated by applicable Law to close. 

  
 2 

 “Capital Equipment” shall mean the capital equipment owned or Controlled by
Seller or its Affiliates as of the Closing Date, set forth on Annex 2.1(d)(i)(A), used or held for use by Seller or its Affiliates in connection with the Manufacturing Platform, which includes [***]. For clarity, all other raw and finished
material that is not identified on Annex 2.1(d)(i)(A) is and shall remain the property of Seller. 
 “CARES Act”
means the Coronavirus Aid, Relief and Economic Security Act and any similar or conforming legislation in any U.S. jurisdiction, and any subsequent legislation relating to the COVID-19 pandemic, including the Health and Economic Recovery Omnibus
Emergency Solutions Act and the Presidential Memorandum on Authorizing the Other Needs Assistance Program for Major Disaster Declarations Related to Coronavirus Disease 2019 issued on August 8, 2020. 

[***] 
 [***] 

“Challenge” shall mean, with respect to any Patent under the Contract Services IP, to commence or voluntarily join a legal
action to contest the validity or enforceability of any such Patent, in whole or in part, in any court, arbitration proceeding or other tribunal, including the United States Patent and Trademark Office, the European Patent Office, and the United
States International Trade Commission. As used in this term “Challenge”, the term “contest” includes (a) filing an action under 28 U.S.C. §§ 2201-2202 seeking a declaration of invalidity or unenforceability of any
such Patent; (b) filing, or joining in, a petition under 35 U.S.C. § 311 to institute inter partes review of any such Patent, or any portion thereof; (c) filing, or joining in, a petition under 35 U.S.C. § 321 to institute
post-grant review of any such Patent, or any portion thereof; (d) any foreign equivalent of clauses (a), (b) or (c) in any country outside of the United States; or (e) filing or commencing any opposition, nullity or similar
proceedings challenging the validity of any such Patent in any country outside the United States; but excludes (i) filing a request under 35 U.S.C. § 302 for re-examination of any such Patent, (ii) filing a request under 35 U.S.C.
§ 251 for a reissue of any such Patent, or (iii) any foreign equivalents of clause (i) or (ii) applicable in a country outside of the United States. 

“Clinical Hold” shall mean that there are regulatory restrictions in place from FDA preventing the sale and distribution of
OpenBiome FMT Product by Seller under enforcement discretion. 
 “Clinical Research and Studies” shall mean the use of any
OpenBiome FMT Product for any preclinical or clinical research activity including (a) any preclinical laboratory work, experimentation, analysis or academic research not involving human test subjects; (b) clinical studies in humans
(conducted pursuant to applicable Laws) concerning or relating to the safety, pharmacodynamics, pharmacokinetics, dosage ranging and/or efficacy of using OpenBiome FMT Product; or (c) the use of OpenBiome FMT Products under an Emergency IND.

 “Code” shall mean the United States Internal Revenue Code of 1986, as amended. 

“Commercial Competitor” means [***]. 

  
 3 

 “Commercialization” means any and all activities directed to the marketing,
promotion, distribution, pricing, reimbursement, offering for sale, and sale of a product and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable country or region for such product regarding the
foregoing, but excluding activities directed to Manufacturing or Development. “Commercialize,” “Commercializing,” and “Commercialized” will be construed accordingly. 

“Commissioner” shall have the meaning set forth in Section 7.15. 

“Commissioner Notice” shall have the meaning set forth in Section 7.15. 

“Confidential Information” shall have that meaning set forth in Section 11.9(b). 

“Contract” shall mean any written or oral agreement, contract, subcontract, settlement agreement, lease, sublease, binding
understanding, instrument, note, option, bond, mortgage, indenture, trust document, loan or credit agreement, license, sublicense, insurance policy or legally binding commitment or undertaking of any nature, as in effect as of the date hereof or as
may hereinafter be in effect. 
 “Contract Services IP” shall mean all of the following items that are owned or Controlled
by Seller as of the Closing Date (a) Technology by Seller of related to the manufacture of the CP101 drug substance, which is listed on Annex 1.1(a)(ii); (b) all data, information, and results that were made, obtained or generated
by Seller or its Affiliates in the performance of manufacture, supply, product testing, and other services for Purchaser or its Affiliates under the APLA or that certain Clinical Supply and Services Agreement dated February 10, 2020, between
Purchaser and Seller, including as a result of testing CP101 drug substance or drug product; and (c) all Technology related to the Finch Proprietary Method (other than data and results generated by Seller or its Affiliates using the Finch
Proprietary Method in connection with the manufacture of OpenBiome FMT Product). 
 “Contract Services IP Action” shall
have the meaning set forth in Section 6.3(a). 
 “Control” or “Controlled by” shall mean, with
respect to any Technology (including any Patent or Know-How), the possession of, whether by ownership or license, other than by a license granted pursuant to this Agreement, of the ability of a Person or its Affiliates to assign, transfer or grant a
license, sublicense or other right to or under such Technology, without violating (a) the terms of any agreement or other arrangement with any Third Party existing as of the time a Person or its Affiliates would be required hereunder to grant
such license, sublicense or other right and (b) any applicable Law. 
 “Copyrights” shall mean all copyrightable works
and all copyrights and applications, including in and to works of authorship and all other rights corresponding thereto throughout the world, whether published or unpublished, including rights to prepare, reproduce, perform, display and distribute
copyrighted works and copies, compilations and derivative works thereof (including all unregistered copyrights). 

  
 4 

 “Cultured Product” shall mean each of (a) FIN-524, (b) FIN-525,
and (c) any Product sold by Purchaser, its Affiliates, and Sublicensees that (i) is not a Natural Product or an Enriched Product and (ii) contains one or more isolates derived from a Finch Exclusive MALA Donor.  

“Cultured Product Royalties” shall have the meaning set forth in Section 3.3(a)(i). 

“Development” shall mean, together with all correlative meanings, research and pre-clinical and clinical drug development
activities, conducted before obtaining Regulatory Approval, that are reasonably related to or leading to the development, preparation, and submission of data and information to a Regulatory Authority for the purpose of obtaining, supporting or
expanding a Regulatory Approval, including without limitation, all research and other activities related to preclinical testing, assay development and validation, in vivo testing, biomarker development and validation, toxicology, pharmacokinetic
profiling, design and conduct of clinical trials or studies, regulatory affairs, statistical analysis, report writing, and Regulatory Materials creation and submission (including the services of outside advisors and consultants in connection
therewith). “Develop” has a correlative meaning. 
 “Donor Exclusivity Notice” shall mean written notice provided
by Purchaser to Seller under the MALA prior to the date hereof with sufficient detail to specify the donor, his or her material and program. 

“Elective Period End Date” shall have the meaning set forth in Section 6.8(e). 

“Elective Technology Transfer Period” shall have the meaning set forth in Section 6.8(e). 

“Emergency IND” shall mean the emergency use, as defined in 21 CFR § 56.102(d), of an investigational drug or biological
product in compliance with 21 CFR § 56.104(c) and other applicable Regulatory Laws. 
 “Encumbrance” shall mean, with
respect to any Purchased Asset, any pledges, claims, liens, licenses, charges, encumbrances and security interests of any kind or nature whatsoever, whether arising by Contract or by operation of Law. 

“Enriched Product” shall mean a Product that comprises both (a) material manufactured directly from stool from a stool
donor source without the use of culturing or replication and (b) drug substance or drug product comprising one or more Active Pharmaceutical Ingredients, whether or not regulated as a combination product under 21 CFR 3.2(e); provided
that, CP101 is not an “Enriched Product”. 
 “Excluded Assets” shall have the meaning set forth in
Section 2.2. 
 “Excluded Liabilities” shall have the meaning set forth in Section 2.4. 

“Exhibits” shall have the meaning set forth in Section 1.2(i). 

“Exploit” or “Exploiting” shall mean to make, have made, import, use, sell or offer for sale, including to
discover, research, Develop, modify, enhance, improve, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise) store, formulate, optimize, have used, export, transport, distribute, promote and market or have sold or
otherwise dispose or offer to dispose of, a product or process. “Exploitation” means the act of Exploiting a product or process. 

  
 5 

 “FDA” shall mean the United States Food and Drug Administration and any
successor agency. 
 “Finch Exclusive Donors” shall mean (i) the Finch Exclusive MALA Donors; and (ii) the stool
donors, which are collectively set forth on Annex 1.1(a)(i)(A). Annex 1.1(a)(i)(A) also includes a list of any exceptions to exclusivity and permitted activities for each such donor. For the avoidance of doubt, no new donors may be
added to the list set forth in Annex 1.1(a)(i)(A) on or after the date of this Agreement without mutual consent of Purchaser and Seller. 

“Finch Exclusive MALA Donors” shall mean the stool donors for which Purchaser has provided a Donor Exclusivity Notice to
Seller under the MALA prior to the date hereof, as set forth in Annex 1.1(a)(i)(B). Annex 1.1(a)(i)(B) also includes a list of any exceptions to exclusivity and permitted activities for each such donor. For the avoidance of doubt, no
new donors may be added to the list set forth in Annex 1.1(a)(i)(B) on or after the date of this Agreement without mutual consent of Purchaser and Seller. 

“Finch Intellectual Property” shall mean the Finch Patents and the Finch Know-How; provided that the “Finch
Intellectual Property” shall not include any intellectual property that is the subject of a New In-License that is not an Included New In-License. 

“Finch Know-How” shall mean all information (including regulatory data) and other Know-How owned or Controlled by Purchaser
and its Affiliates [***], and that is not generally known and is reasonably necessary or useful for the Exploitation of Natural Products (other than Lyophilized Products), and any improvements, modifications or enhancements thereto. 

“Finch Patents” shall mean all Patent applications and issued Patents (including all continuations, continuations-in-part,
continued prosecution and divisions thereof, reissues, renewals, extensions, substitutions, reexaminations, supplementary protection certificates, pediatric exclusivity periods and the like, of any such Patents and Patent applications, and foreign
equivalents thereof) owned or Controlled by Purchaser and its Affiliates [***] that are reasonably necessary or useful for the Exploitation of Natural Products. 

“Finch Proprietary Method” shall mean the proprietary method conceived and developed by Purchaser and its Affiliates as
described on Annex 1.1(a)(i)(C). 
 “FIRPTA Certificate” shall mean a certificate of Seller in compliance with Section 1.1445-2(b)(2) of the regulations under the Code (relating to FIRPTA), listing Seller’s name, address and U.S. employer identification number and stating that Seller is not a foreign person. 

“First Commercial Sale” shall mean, on a Product-by-Product and country-by-country basis, the first sale of such Product to a
Third Party in an arm’s-length transaction for end use or consumption of such Product in such country following receipt of Regulatory Approval for such Product in such country. [***]. 

“Fiscal Year” shall mean January 1st to December 31st. 

  
 6 

 “Follow-up Analysis” shall have the meaning set forth in
Section 6.8(f). 
 “Force Majeure” shall mean any occurrence beyond the reasonable control of a Party that
(a) prevents or substantially interferes with or delays the performance by such Party of any of its obligations hereunder and (b) occurs by reason of any act of God, flood, fire, explosion, earthquake, strike, lockout, labor dispute,
casualty or accident, or war, revolution, civil commotion, act of terrorism, or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any Governmental Entity. 

“Fundamental Representations” shall mean the representations and warranties set forth in Section 4.1
(Organization and Good Standing), Section 4.2 (Authority), Section 4.3(a) (No Conflict), the first sentence of Section 4.6(a) (Purchased Assets), Section 4.10 (Taxes) and Section 4.11 (No
Brokers), Section 5.1 (Organization and Good Standing), Section 5.2 (Authority), Section 5.3(a) (No Conflict) and Section 5.6 (No Brokers). 

“GAAP” shall mean accounting principles generally accepted in the United States. 

“Generic Competition” shall mean with respect to a Natural Product in a given country in a given calendar quarter, if, during
such calendar quarter, [***]. The determination of whether Generic Competition exists in a particular country shall be made based on [***]; and any dispute regarding whether Generic Competition exists shall be resolved through the dispute resolution
provisions in Section 11.12(b). Should Purchaser believe that Generic Competition exists in a particular country, it shall include such belief in its Reporting Metrics and its Interim Report provided under Section 3.4. 

“Generic Product” shall mean, as to a Natural Product, any product (including a “generic product” approved by way
of an application for FDA approval under the Hatch-Waxman Act or a “biosimilar product” under the Biologics Price Competition and Innovation Act of 2009, or any certification under a similar statutory or regulatory requirement in any
non-United States country, “biogeneric,” “follow-on biologic,” “follow-on biological product,” “follow-on protein product,” “similar biological medicinal product,” or “biosimilar product”)
that, in each case, [***]. 
 “Governmental Entity” shall mean any federal, state or local or any foreign government or any
court, administrative or other governmental or government-authorized authority or agency, domestic or foreign, including any Regulatory Authority. 

“HSR Act” shall mean the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 

“Included New In-License” shall have the meaning set forth in
Section 6.7(a). 
 “IND” shall mean (a) an
Investigational New Drug Application as defined in the United States Federal Food, Drug and Cosmetics Act, as amended, and all regulations promulgated thereunder, or (b) an analogous application, filing or submission to the analogous Regulatory
Authority in a regulatory jurisdiction outside the United States, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 

  
 7 

 “Indemnified Party” shall have the meaning set forth in
Section 9.4. 
 “Indemnifying Party” shall have the meaning set forth in Section 9.4. 

“Indication” shall mean a separate and distinct disease or medical condition in humans or animals that a product is intended
to treat, prevent, diagnose, monitor or ameliorate, as set forth in the IND or label for such product, as applicable, as approved by the applicable Regulatory Authority. The Parties agree and acknowledge that [***]. 

“Initial Public Offering” shall mean the closing of Purchaser’s first firm commitment underwritten initial public
offering of the Purchaser’s common stock pursuant to a registration statement filed under the Securities Act of 1933, as amended. 

“Interim Report” shall have the meaning set forth in Section 3.4 

“IP Contracts” shall have the meaning set forth in Section 4.8(c). 

[***] 

“Know-How” means any proprietary information and materials, including records, discoveries, improvements, modifications,
processes, techniques, methods, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw data, clinical data, and analytical and quality control data),
dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in any form whatsoever, know-how and trade secrets (in each case,
whether or not patentable or copyrightable). 
 “Knowledge of Seller” shall mean [***]. 

“Law” shall mean, as applicable, any federal, state or local or any foreign statute, law, rule, regulation, ordinance, code
or any other requirement or rule of law including Regulatory Laws of any Governmental Entity. 
 “Liabilities” shall mean
any and all debts, Taxes, liabilities, costs, guarantees, commitments, assessments, expenses, claims, penalties, Losses, damages, deficiencies and obligations, whether accrued or fixed, known or unknown, liquidated or unliquidated, asserted or
unasserted, absolute or contingent, matured or unmatured, determined or determinable, accrued or not accrued, due or to become due, direct or indirect, whenever or however arising (including whether arising out of any Contract, common law or tort
based on negligence or strict liability) and whether or not the same would be required by GAAP to be reflected in financial statements or disclosed in the notes thereto. 

“License Agreement” shall mean the license agreement, executed by each of the Parties, attached hereto as Exhibit C.

 “Live Biotherapeutic Product” means a biological product that: (i) contains live organisms, such as bacteria;
(ii) is applicable to the prevention, treatment, or cure of a disease or condition of human beings; and (iii) is not a vaccine. Live Biotherapeutic Products are not filterable viruses, oncolytic bacteria, or products intended as gene
therapy agents and, as a general matter, are not administered by injection. 

  
 8 

 “Losses” shall have the meaning set forth in Section 9.1. 

“Lyophilized Product” shall mean a Natural Product wherein processed stool is lyophilized. As an example, and not by way of
limitation, Purchaser’s CP101 product is a “Lyophilized Product.” 
 “MALA” shall mean the Second Amended
and Restated Material Access and License Agreement by and between Purchaser and Seller, dated September 19, 2017. 

“Manufacture” means any and all activities directed to manufacturing, processing, packaging, labeling, filling, finishing,
assembly, quality assurance, quality control, testing, and release, shipping, or storage of any product (or any components or process steps involving any product), placebo, or comparator agent, as the case may be, including process development,
qualification, and validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development, product characterization, and stability testing, but excluding activities directed to Development or Commercialization.
“Manufacturing” and “Manufactured” will be construed accordingly. 
 “Manufacturing
Platform” shall mean Seller’s stool donor program and manufacturing operation and related Technology. 

“Massachusetts AG” shall have the meaning set forth in Section 7.1(a). 

“Massachusetts AG Approval” shall have the meaning set forth in Section 7.1(a). 

“Master Strategic Affiliation Agreement” shall mean that certain master strategic affiliation agreement, dated as of
December 14, 2016, between Purchaser and Seller. 
 “Material Adverse Effect” shall mean any change, effect, event,
occurrence, state of facts or development which individually or in the aggregate would reasonably be expected to result in, or has resulted in, any change or effect, that [***]. 

“Natural Product” shall mean any Product manufactured directly from stool from a stool donor source without the use of
culturing or replication; provided, that “Natural Product” does not include any Enriched Product. As an example, and not by way of limitation, CP101 is a “Natural Product.” 

“Natural Product Drug Substance” shall mean a formulated liquid suspension derived from the stool of a stool donor source that may
be incorporated into a Natural Product. 
 “Natural Product Milestone Event” shall have the meaning set forth in
Section 3.1(a). 
 “Natural Product Milestone Payment” shall have the meaning set forth in
Section 3.1(a). 
 “Natural Product Royalties” shall have the meaning set forth in
Section 3.2(a)(i). 

  
 9 

 “Natural Product Royalty Term” shall have the meaning set forth in
Section 3.2(a)(i). 
 “Net Sales” shall mean [***]. 

“New In-License” shall mean a license entered into by Purchaser or its Affiliates after the Closing Date concerning
Technology of a Third Party that would be reasonably useful or necessary for the Manufacture of OpenBiome FMT Product after the Closing Date. 

“Non-Assigned Assets” shall have the meaning set forth in Section 2.7(b). 

“OFAC” shall have the meaning set forth in Section 4.9(h). 

“OpenBiome CMC Technology” shall mean all Technology owned or Controlled by Seller as of the Closing Date that is necessary
or useful in the Manufacture of Natural Products, including Technology pertaining to the Manufacturing Platform (i.e. the selection of human stool donors, and the collection, processing, and preparation of stool from human donors for research,
clinical, commercial and other use, including the manufacture of OpenBiome FMT Products, Natural Products, and other products). For clarity, “OpenBiome CMC Technology” includes the QSL Licensed Technology and the QS Technology
Improvements. For the avoidance of doubt, OpenBiome CMC Technology does not include Contract Services IP. 
 “OpenBiome FMT
Product” shall mean any Natural Product other than a Lyophilized Product solely to the extent such Natural Product is made, used distributed or sold by Seller, its Affiliates or sublicensees for the treatment of recurrent clostridium
difficile (“rCDI”) under FDA enforcement discretion, pursuant to an Emergency IND or for Clinical Research and Studies, including, but not limited to, the following Natural Products: [***]. 

“OpenBiome Technology” shall have the meaning set forth in Section 4.8(b). 

“Order” shall mean any charge, temporary restraining order or other order, writ, injunction (whether preliminary, permanent
or otherwise), judgment, guideline, doctrine, guidance, decree, ruling, determination, directive, corporate integrity agreement or similar agreement, award or settlement, whether civil, criminal or administrative. 

“Party” shall have the meaning set forth in the preamble of this Agreement. 

“Patents” means (a) all patents and patent applications in any country or region, (b) all patent applications filed
either from such patents or patent applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications,
(c) any and all patents that have issued or in the future issue from the foregoing patent applications, and (d) any and all substitutions, renewals, registrations, confirmations, extensions, or restorations, including revalidations,
reissues, and re-examinations (including any supplementary protection certificates and the like) of the foregoing patents or patent applications. 

“Permitted Encumbrance” shall mean the following: (a) statutory Encumbrances for Taxes; (b) statutory or common law
Encumbrances to secure obligations to landlords, lessors or renters under leases or rental agreements; or (c) statutory or common law Encumbrances in favor of carriers, warehousemen, mechanics and materialmen, to secure claims for labor,
materials or supplies arising in the ordinary course of business, in each case of clauses (a), (b) and (c) for sums not yet due and payable and not otherwise in default. 

  
 10 

 “Person” means an individual, sole proprietorship, partnership, limited
partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political
subdivision or department or agency of a government. 
 “Phase II Clinical Trial” shall mean a human clinical trial of a
product, the principal purpose of which is to make a preliminary determination about such product’s efficacy, conducted in a manner that is generally consistent with 21 C.F.R. § 312.21(b), as amended (or any successor regulation), or a
similar clinical study prescribed by a Regulatory Authority outside the United States, and that is intended to explore one or more doses, dose response and duration of effect in the target patient population, and to generate initial evidence of
clinical activity and safety in such patient population; provided that the treatment of patients for compassionate use, including in an expanded access program, single patient program or named patient program shall not be included in determining
whether or not a clinical trial is a Phase II Clinical Trial or whether a patient has been dosed thereunder. 
 “Phase III Clinical
Trial” shall mean a clinical trial in a human patient population that is sufficient to support Regulatory Approval in the proposed Indication, as more fully defined in 21 C.F.R. § 312.21(c), as amended (or its successor regulation) and
that is designed to obtain data determining efficacy and safety of a pharmaceutical product to support such Regulatory Approval, or a similar clinical study prescribed by a Regulatory Authority outside the United States; provided, however, that the
FDA permits the treatment of patients in the U.S. under an open IND in such clinical trial; and provided, further, that treatment of patients for compassionate use, including in an expanded access program, single patient program or named patient
program shall not be included in determining whether or not a clinical trial is a Phase III Clinical Trial or whether a patient has been dosed thereunder. 

“Pre-Closing Tax Period” shall mean (i) any Tax period ending on or before the Closing Date, and (ii) with respect
to a Tax period that commences before but ends after the Closing Date, the portion of such period up to and including the Closing Date. 

“Product” shall mean any product developed or made from an isolated set of bacterial strains or a natural composition of
bacterial strains. 
 “Product Registrations” shall mean all Regulatory Approvals, authorizations, approvals,
registrations, clearances, consents, qualifications, certifications, licenses, permits and other rights from the FDA and other Regulatory Authorities that are necessary for the research, Development, clinical testing, commercialization, Manufacture,
service, distribution, marketing, promotion, offer for sale, use, import, export and sale of a Product. 
 “Purchase Price
Allocation” shall have the meaning set forth in Section 2.8(b). 
 “Purchased Assets” shall have the
meaning set forth in Section 2.1(d)(i). 

  
 11 

 “Purchaser” shall have the meaning set forth in the preamble of this
Agreement. 
 “Purchaser Indemnified Party” shall have the meaning set forth in Section 9.1(a). 

“Purchaser Manager” shall be the individual designated by Purchaser who will serve as Purchaser’s primary point of
contact regarding the technology transfer in Section 6.6 and Section 6.8(e), if applicable. Purchaser may designate a new Purchaser Manager at any time, provided that Purchaser provides prior written notice of any such change
to Seller. 
 “Purchaser’s Officer Certificate” shall mean a certificate, dated as of the Closing Date, duly executed
by an officer of Purchaser, certifying that each of the conditions specified in Section 8.3(a) and Section 8.3(b) are satisfied in all respects. 

“QS Technology Improvements” shall mean any improvements, modifications and enhancements to the QSL Licensed Technology
developed or made by or on behalf of Seller, whether or not patentable, or subject to copyright or trade secret protection). For the avoidance of doubt, QS Technology Improvements does not include Contract Services IP. 

“QSL Licensed Technology” shall mean (i) quality documentation Controlled by Seller, including, but not limited to,
those systems, files and software identified on Annex 1.1(b), and (ii) all related Know-How Controlled by Seller. 

“Records” shall mean all books and records in the possession of Seller or its Affiliates to the extent relating to the
Purchased Assets, including correspondence with the FDA or other Regulatory Authorities, all Product drawings, work instructions and bills of materials, customer lists and vendor lists, all data, results and related information from any studies or
trials related to the Contract Services IP or Products. 
 “Regulatory Approval” shall mean all approvals necessary for the
Manufacture, marketing, importation and sale of a Product for one or more Indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, including (where required for
sale) any pricing and reimbursement approvals. Regulatory Approvals include approvals by Regulatory Authorities of INDs. 

“Regulatory Authority” shall mean the FDA, the Federal Trade Commission, the United States Department of Health and Human
Services, Centers for Medicare and Medicaid Services or any other federal, state, local or foreign Governmental Entity that is concerned with or regulates the Development, testing, packaging, labeling, storage, sale, quality, safety, efficacy,
reliability or Manufacturing and servicing of drugs, biologics and medical devices, federal or state health care programs, or the provision of health care or similar services. 

“Regulatory Laws” shall mean the following Laws: (a) the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301
et seq), as amended, and all regulations promulgated thereunder, (b) the federal False Claims Act (42 U.S.C. § 1320a-7b(a)), as amended, (c) the Physician Payments Sunshine Act, as amended, and its implementing regulations,
(d) the Patient Protection and Affordable Care Act, (e) the federal Medicare and Medicaid statutes, (f) the federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, (g) the federal Physician Self-Referral (Stark) Law, 42 U.S.C.
§ 1395nn, (h) the federal Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a, (i) the Federal Trade Commission Act, (j) any other Laws governing research, Development, clinical testing, investigational use, marketing
clearance, marketing approval, Manufacturing, servicing, packaging, labeling, promotion, sale, import or export of pharmaceutical or biological products, and (k) all Laws similar to the foregoing within any other federal, state, local or
foreign jurisdiction. 

  
 12 

 “Regulatory Materials” shall mean copies of the Product Registrations and
any applications therefor, including currently pending, previously denied or previously withdrawn applications, together with copies of related correspondence between Seller and the applicable Regulatory Authority, and any other existing files and
dossiers relating to the Product Registrations, and the underlying data or information used to support, maintain or obtain Product Registrations. 

“Reporting Metrics” shall have the meaning set forth in Section 3.4. 

“Restricted Field” shall mean the diagnosis, treatment, palliation or prevention in humans of [***]; provided,
however, that Seller shall be permitted to continue any activity in a Restricted Field that was on-going as of February 1, 2019 under that certain Asset Purchase and License Agreement dated as of February 1, 2019 between the Parties or
that was subsequently approved by Purchaser or its Affiliates under such agreement. 
 “Royalties” shall mean Natural
Product Royalties and Cultured Product Royalties, as applicable. 
 “Royalty Term” shall mean a Natural Product Royalty
Term or a Cultured Product Royalty Term, as applicable. 
 “Schedules” shall have the meaning set forth in
Section 1.2(i). 
 “Seller” shall have the meaning set forth in the preamble of this Agreement. 

“Seller Disclosure Schedules” shall have the meaning set forth in Section 1.2(h). 

“Seller Indemnified Party” shall have the meaning set forth in Section 9.2(a). 

“Seller’s Legal Fees” shall have the meaning set forth in Section 2.1(b). 

“Seller Manager” shall be the individual designated by Seller who will serve as Seller’s primary point of contact
regarding the technology transfer in Section 6.6 and Section 6.8(e), if applicable. Seller may designate a new Seller Manager at any time, provided that Seller provides prior written notice of any such change to Purchaser

 “Seller Massachusetts Taxes” shall have the meaning set forth in Section 7.15. 

“Seller’s Officer’s Certificate” shall means a certificate, dated as of the Closing Date, duly executed by the
Executive Director of Seller, certifying that each of the conditions specified in Section 8.2(a), Section 8.2(b) and Section 8.2(c) are satisfied in all respects. 

  
 13 

 “Seller’s Secretary’s Certificate” shall mean a certificate,
dated as of the Closing Date, duly executed by the secretary of Seller, certifying that: (a) all documents to be executed by Seller and delivered at the Closing have been executed by a duly authorized officer of Seller; and
(b) (i) Seller’s certificate of incorporation and by-laws, attached to the certificate, are true and complete and has been in full force and effect in the form attached since the date of the adoption of the resolutions referred to in
clause (ii) below and no amendment, rescission or modification to such document has occurred since the date thereof; and (ii) the written consent adopted by the board of directors of Seller, authorizing the execution, delivery and
performance of this Agreement and the Ancillary Agreements, as attached to the certificate, was duly adopted by the board of directors, remains in full force and effect, and has not been amended, rescinded or modified. 

“Subject Matter Agreement” shall have the meaning set forth in Section 2.6(a)(vi). 

“Sublicensee” shall mean any Third Party to whom Purchaser or Seller, as applicable, grants or has granted, directly or
indirectly (e.g. a sublicensee of a sublicensee of Purchaser or Seller, as applicable), a permitted sublicense of rights licensed by Seller to Purchaser, or Purchaser to Seller, as applicable, under this Agreement. 

“Sublicensee Cultured Product Royalties” shall have the meaning set forth in Section 3.2(a)(ii) 

“Sublicensee Natural Product Royalties” shall have the meaning set forth in Section 3.2(a)(ii). 

“Sublicensing Revenue” shall mean [***]. 

“Tax Return” shall mean any return, report, declaration, information return, statement or other document filed or required to
be filed with any Taxing Authority in connection with the determination, assessment or collection of any Tax or the administration of any Laws relating to any Tax, including any attachment or schedule thereto and including any amendments thereof.

 “Taxes” shall mean all taxes, charges, duties, fees, levies or other assessments, including income, excise, real
property and personal property, sales or use, value added, profits, license, withholding (with respect to compensation or otherwise), payroll, employment, unemployment, disability, net worth, capital gains, transfer, documentary, stamp, social
security, environmental, occupation, and franchise, gross receipts, premium, escheat or unclaimed property obligation, ad valorem, alternative or add-on minimum, custom duty, and estimated taxes, imposed by any Taxing Authority, and including any
interest, penalties and additions attributable thereto, and all amounts payable pursuant to an agreement or arrangement with respect to taxes or payable with respect to taxes as successor or transferee. 

“Taxing Authority” shall mean any Governmental Entity exercising any authority to impose, regulate or administer the
imposition of Taxes. 
 “Technology” shall mean all Patents, Patent applications, trade secrets, Copyrights, Know-How,
methods, processes, techniques, data, technical documentation, manuals, regulatory submissions, specifications, standard operating procedures, instructions, and other intellectual property of any kind (whether or not protected or protectable under
Patent, Trademark, Copyright or similar Laws). 

  
 14 

 “Termination Date” shall have the meaning set forth in
Section 10.1(e). 
 “Territory” shall mean worldwide. 

“Third Party” shall mean any Person other than Purchaser or Seller or their respective Affiliates. 

“Third Party License Fees for Natural Products” shall mean any payments or fees (including royalties, milestones and
maintenance fees) owed by Purchaser or its Affiliates to Third Parties as a result of the practice of intellectual property licensed from such Third Parties in the Exploitation of Natural Products. For the avoidance of doubt, the Third Party License
Fees for Natural Products includes any royalties, milestones and other payments due to be paid by Purchaser or its Affiliates to [***]. 

“Third Party License Fees for OpenBiome FMT Product” shall mean any payments or fees (including royalties, milestones and
maintenance fees) owed by Purchaser or its Affiliates to Third Parties as a result of the practice of intellectual property licensed from such Third Parties in the Exploitation of OpenBiome FMT Product. 

“Third-Party Claim” shall have the meaning set forth in Section 9.4. 

“Third-Party Claim Notice” shall have the meaning set forth in Section 9.4. 

“Trademarks” shall mean any and all trademarks, service marks, trade dress, logos, slogans, trade names, all material
unregistered trademarks, together with all adaptations, derivations and combinations thereof, and all goodwill associated with any of the foregoing throughout the world. 

“Transaction Proposal” shall have the meaning set forth in Section 7.5(a). 

“Transfer Taxes” shall mean any federal, state, county, local, foreign or other sales, use, transfer, value added,
conveyance, documentary transfer, stamp duty, recording or other similar tax, fee or charge (including any penalties, interest and additions thereto) imposed in connection with the transactions contemplated by this Agreement or the recording of any
sale, transfer or assignment of property (or any interest therein) effected pursuant to this Agreement, provided that Transfer Taxes shall not include any income or withholding taxes. 

“Upfront Payment” shall have the meaning set forth in Section 2.1(b). 

“United States” or “U.S.” shall mean the United States of America and its territories, commonwealths and
possessions. 

  
 15 

 Section 1.2. Other Definitional Provisions. 

(a) The words “hereof,” “herein,” “hereto” and “hereunder” and words of similar import, when used in
this Agreement, shall refer to this Agreement as a whole and not to any particular provision of this Agreement. 
 (b) The terms defined in
the singular shall have a comparable meaning when used in the plural, and vice versa. 
 (c) The terms “Dollars” and
“$” shall mean lawful currency of the United States. 
 (d) The words “include,”
“includes” and “including” and words of similar import will be by way of example rather than by limitation. 

(e) The word “or” will have the inclusive meaning “and/or.” 

(f) The word “shall” will be construed to have the same meaning as the word “will.” 

(g) Time periods based on a number of days within or following which any payment is to be made or act is to be done shall be calculated by
excluding the day on which the period commences and including the day on which the period ends and, if applicable, by extending the period to the next Business Day following if the last day of the period is not a Business Day. 

(h) When a reference is made in this Agreement to an Article, a Section, an Exhibit, an Annex or a Schedule, such reference shall be to an
Article or a Section of, or an Exhibit, or an Annex or a Schedule to, this Agreement unless otherwise indicated. All references herein to a Schedule or Schedules, shall be to Seller’s disclosure schedules delivered by Seller contemporaneously
with the execution and delivery of this Agreement (the “Seller Disclosure Schedules”). The Seller Disclosure Schedules shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections
contained in this Agreement and the disclosures in any section or subsection of the Seller Disclosure Schedule shall qualify other sections and subsections to the extent it is readily apparent from a reading of the disclosure that such disclosure is
applicable to such other section or subsection. 
 (i) All schedules, exhibits and Annexes (the “Schedules,”
“Exhibits,” and Annexes, respectively) annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein and are an integral part of this Agreement. 

ARTICLE II 
 PURCHASE
AND SALE; GRANT OF LICENSES 
 Section 2.1. Purchase and Sale of Assets; Know-How Transfer; Grant of Licenses. 

(a) Pursuant to the terms and subject to the conditions of this Agreement, at the Closing, Seller shall, convey, deliver, transfer and assign
to Purchaser, free and clear of all Encumbrances, other than Permitted Encumbrances, and Purchaser shall purchase, take delivery of and acquire from Seller all of Seller’s right, title and interest in, to and under all of the Purchased Assets
and to assume, satisfy and discharge when due all Assumed Liabilities. At the Closing, Seller shall provide the know-how transfer to Purchaser pursuant to Section 6.6. 

  
 16 

 (b) Pursuant to the terms and subject to the conditions of this Agreement, on the date
hereof, Seller shall grant the licenses to Purchaser pursuant to Section 6.5, perform the obligations pursuant to Section 7.10, and sell, convey, assign and transfer to
Purchaser the exclusive donor materials in Purchaser’s possession set forth on Annex 2.1(c) and, in exchange, Purchaser shall (A) pay to Seller in immediately available funds by wire transfer and in accordance with written
instructions given by Seller to Purchaser reasonably in advance of the payment date (i) the amount of one million dollars ($1,000,000) (the “Upfront Payment”), payable upon the date hereof; (ii) the amount of Seller’s
reasonable, documented, out-of-pocket attorneys’ fees and expenses in connection with Seller’s negotiation of this Agreement, up to a maximum amount of one hundred fifty thousand dollars ($150,000), payable upon the date hereof (the
“Seller’s Legal Fees”); and (iii) the payments described in Article III, if, as and when due and payable thereunder; and (B) deliver to Seller a fully executed copy of the License Agreement. 

(c) Purchase and Sale of Assets on the Date Hereof. Upon the terms and subject to the conditions set forth herein, on the date hereof,
Seller and its Affiliates sell, convey, assign and transfer to Purchaser, and Purchaser purchases, acquires and accepts from Seller and its Affiliates, all of Seller’s and its Affiliates’ right, title and interest in, to and under the
exclusive donor materials in Purchaser’s possession, which are set forth on Annex 2.1(c), in each case free and clear of all Encumbrances, other than Permitted Encumbrances. 

(d) Purchase and Sale of Assets at the Closing. 

(i) Upon the terms and subject to the conditions set forth herein, at the Closing, Seller shall, and shall cause any of its
Affiliates who own or Control Purchased Assets to, sell, convey, assign and transfer to Purchaser, and Purchaser shall purchase, acquire and accept from Seller and its Affiliates, all of Seller’s and its Affiliates’ right, title and
interest in, to and under the following (collectively, the “Purchased Assets”), in each case free and clear of all Encumbrances, other than Permitted Encumbrances: 

(A) the Capital Equipment set forth on Annex 2.1(d)(i)(A); 

(B) all rights under Seller’s and its Affiliates’ Contracts related to the Manufacturing Platform that are set forth
on Annex 2.1(d)(i)(B) and all of Seller’s and its Affiliates’ agreements with donors, including research agreements and informed consents, (collectively, the “Assumed Contracts”); 

(C) all Contract Services IP, including the Contract Services IP set forth on Annex 2.1(d)(i)(C); 

(D) all Records, provided, however, that, subject to Section 11.9, Seller may retain copies of such Records to the
extent they relate to Excluded Assets or Excluded Liabilities; and 
 (E) all claims, counterclaims, credits, causes of
action, chooses in action, rights of recovery, and rights of indemnification or setoff against Third Parties and other claims arising out of or relating to the Purchased Assets and all other intangible property rights that relate to the Purchased
Assets or any Assumed Liabilities and the right to receive all proceeds and damages therefrom. 

  
 17 

 The Annexes set forth in this Section 2.1 shall be updated by Seller, as
necessary to make the Annexes complete as of the Closing Date, and Seller shall deliver such updated Annexes to Purchaser no later than five (5) Business Days prior to the Closing. 

Section 2.2. Excluded Assets. Purchaser acknowledges and agrees that it is not acquiring any right, title or interest in, to or
under any assets, property, rights and interests of Seller or any of its Affiliates other than the Purchased Assets (such assets collectively, the “Excluded Assets”). For the avoidance of doubt, the Excluded Assets shall include
Seller’s computers, laptops and other personal electronic devices and the other items set forth on Annex 2.2. 

Section 2.3. Assumed Liabilities. Upon the terms and subject to the conditions set forth herein, Purchaser shall, effective at the
Closing, assume, satisfy and thereafter discharge only the following Liabilities of Seller and its Affiliates and no others (collectively, the “Assumed Liabilities”): 

(a) Liabilities arising after the Closing (and not in any respect of any period prior to the Closing) under the Assumed Contracts, but only to
the extent that such Liabilities (i) do not arise in respect of any breach of or violation under such Assumed Contract by Seller, its Affiliates, sublicensees or representatives prior to or at the Closing or (ii) do no arise in respect of
any act or omission by Seller, its Affiliates, sublicensees or representatives under such Assumed Contract prior to or at the Closing; and 

(b) Liabilities arising after the Closing from Purchaser’s (or its successors’ or assignees’) ownership of the Purchased Assets
(other than the Assumed Contracts, which are subject to Section 2.3(a), and Taxes relating to or attributable to any Pre-Closing Tax Period). 

Section 2.4. Excluded Liabilities. Seller acknowledges and agrees that Purchaser will not assume any Liability or Taxes of Seller
or any of its Affiliates other than the Assumed Liabilities (such Liabilities collectively, the “Excluded Liabilities”). 

Section 2.5. Purchase Price. As consideration for the conveyance of the Purchased Assets and subject to the terms and conditions
set forth in this Agreement, Purchaser shall, 
 (a) on the Closing Date, deliver to Seller, in immediately available funds by wire transfer
and in accordance with written instructions given by Seller to Purchaser reasonably in advance of the payment date: 
 (i) an
amount equal to two million two hundred fifty thousand ($2,250,000); plus 
 (ii) only if, on the Closing Date, there is not
a Clinical Hold in place, an amount equal to one million six hundred thousand dollars ($1,600,000); and 
 (b) assume the Assumed
Liabilities. 

  
 18 

 Section 2.6. Closing. The Parties will use commercially reasonable efforts to
consummate the Closing on or before March 1, 2021, provided that the conditions precedent to the Closing specified in Article VIII have been satisfied or waived, or at such other time and date mutually agreed upon by the Parties,
remotely be exchange of electronic copies of the agreements, documents, certificates and other instruments set forth in this Section 2.6. At the Closing, Seller shall convey title to the Purchased Assets to Purchaser, and deliver or
otherwise put Purchaser in control of such Purchased Assets free and clear of all Encumbrances, other than Permitted Encumbrances, and perform the know-how transfer pursuant to Section 6.6. 

(a) Seller Closing Deliverables. At the Closing, Seller shall deliver or cause to be delivered to Purchaser: 

(i) the Seller’s Secretary Certificate; 

(ii) the Seller’s Officer’s Certificate; 

(iii) the Bill of Sale, duly executed by Seller; 

(iv) the FIRPTA Certificate, duly executed by Seller; 

(v) a duly completed and accurate Internal Revenue Service From W-9; 

(vi) a Subject Matter Agreement under the Amended and Restated Master Agreement, under which Purchaser would perform only the
services set forth on Exhibit D for Seller (the “Subject Matter Agreement”), duly executed by Seller; and 

(vii) evidence, acceptable to Purchaser in its reasonable discretion, that all Encumbrances (if any), other than Permitted
Encumbrances, have been properly terminated or released on or before the Closing, including either (i) a completed UCC-3 Termination Statement, in a proper form for filing, in respect of each such Encumbrance, or (ii) a payoff
letter from the secured party thereunder, in form and substance acceptable to Purchaser, certifying that upon receipt by or on behalf of Seller of the amount specified in such payoff letter, such Encumbrance shall be released with no further action
and that such secured party will, promptly upon receipt of the specified amount, deliver to Purchaser a duly executed UCC-3 Termination Statement, in a proper form for filing, in respect of such Encumbrance. 

(b) Purchaser Closing Deliverables. At the Closing, Purchaser shall deliver or cause to be delivered to Seller: 

(i) the Purchaser’s Officer’s Certificate; 

(ii) the Bill of Sale, duly executed by Purchaser; and 

(iii) the Subject Matter Agreement, duly executed by Purchaser. 

  
 19 

 Section 2.7. Purchased Assets Not Transferred at the Closing. 

(a) Notwithstanding anything in this Agreement to the contrary, this Agreement shall not constitute an agreement to assign or transfer any
Purchased Asset that is not assignable or transferable without the consent of any Third Party, to the extent that such consent shall not have been given prior to the Closing. Seller shall, and shall cause its Affiliates to use their respective
reasonable best efforts to obtain, and Purchaser shall cooperate with Seller in connection therewith, all necessary consents to the assignment and transfer thereof. 

(b) With respect to any Purchased Asset that is not transferred or assigned to Purchaser at the Closing by reason of Section 2.7(a)
(the “Non-Assigned Assets”), then, notwithstanding anything to the contrary set forth herein, (a) this Agreement and the related instruments of transfer shall not constitute an assignment or transfer of the applicable
Non-Assigned Asset, and Seller shall use its reasonable best efforts, to obtain such consent as soon as possible after the Closing, provided, that neither Seller nor any of its Affiliates shall be required to pay any money to any Third Party,
commence any Action against a Third Party or offer or grant any accommodation (financial or otherwise) to any Third Party in connection with such efforts; and (b) at Purchaser’s election, (i) the Non-Assigned Asset shall be an
Excluded Asset and Purchaser shall have no Liability whatsoever with respect to any such Non-Assigned Asset or any Liability with respect thereto until and unless such consent is obtained by Seller or (ii) Seller shall use its reasonable best
efforts to, and cause its Affiliates to, provide to Purchaser the benefits of such Non-Assigned Asset thereof, and shall enforce, at the request of and for the account of Purchaser, any rights of Seller arising thereunder against any Person,
including the right to elect to terminate in accordance with the terms thereof upon the request of Purchaser; provided that, to the extent that Purchaser is provided with the benefits of any Non-Assigned Asset, Purchaser shall perform the
related obligations of Seller thereunder. Notwithstanding anything to the contrary set forth herein, to the extent that any Assumed Liability relates to any Non-Assigned Asset, such Assumed Liability shall be deemed to be an Excluded Liability
unless and until such Non-Assigned Asset is transferred and assigned to Purchaser, at which point such Excluded Liability shall become an Assumed Liability. 

(c) Without limiting the foregoing, from time to time after the Closing, and for no further consideration, if Purchaser identifies for Seller
in writing any Contract that should be an Assumed Contract because it is necessary for the operation of the Business, and was not transferred to Purchaser at the Closing, then Seller shall promptly assign or otherwise transfer, or cause its
Affiliate to promptly assign or otherwise transfer, such Contract to Purchaser. 
 Section 2.8. Taxes. 

(a) Any Transfer Taxes incurred in connection with this Agreement and the transactions contemplated hereby shall be borne by Seller. Purchaser
and Seller shall cooperate in timely filing all Tax Returns as may be required to comply with the provisions of any applicable Transfer Tax Laws. All property Taxes and assessments on the Purchased Assets for any taxable period commencing prior to
the Closing Date and ending after the Closing Date shall be prorated on a per diem basis between Purchaser and Seller as of the Closing Date. 

  
 20 

 (b) No later than [***] after the Closing Date, Purchaser shall provide Seller with an
allocation of the purchase price (plus the Assumed Liabilities and any other liabilities deemed assumed by Purchaser for United States federal income Tax purposes) among the Purchased Assets, as determined by Purchaser (the “Purchase Price
Allocation”), and Seller shall timely and properly prepare, execute, file and deliver all such documents, forms and other information as Purchaser may reasonably request to prepare the Purchase Price Allocation and any adjustments
thereto. The Purchase Price Allocation will be prepared in good faith using commercially reasonable judgment in accordance with Section 1060 of the Code (and any similar provision of state, local or foreign law, as appropriate) and any
third-party valuation of the Purchased Assets. Thereafter, Seller shall have [***] either to (i) agree with and accept the Purchase Price Allocation or (ii) in good faith, suggest changes to the Purchase Price Allocation and attempt to
agree with Purchaser as to the contents of the Purchase Price Allocation. Purchaser and Seller shall consult in good faith on the Purchase Price Allocation to resolve any differences, but neither party shall be bound by the other party’s
suggestions. In the event that the Purchase Price Allocation has been agreed to between Purchaser and Seller, the Parties shall report, act and file their respective Tax Returns (including IRS Form 8594) in accordance with the Purchase Price
Allocation and any adjustments thereto and shall not take any position on a Tax Return or in a Tax audit or similar proceeding inconsistent with the Purchase Price Allocation or any adjustments thereto except upon a final determination by an
applicable Taxing Authority. If any subsequent adjustment is required to be made to the Purchase Price Allocation, the Purchase Price Allocation shall be revised to take such adjustment into account. Purchaser and Seller shall provide the other
promptly with any other information reasonably required to complete the Purchase Price Allocation and any adjustments thereto. 
 (c) Each
Party shall cooperate, to the extent reasonably requested by the other Party, in connection with any Tax matters relating to the Purchased Assets (including by the provision of reasonably relevant records or information). Notwithstanding the
foregoing, no Party shall have an obligation to provide any copies of its consolidated, combined or unitary Tax Returns to the other Party. 

(d) Seller shall have caused all Tax sharing or allocation agreements or arrangements and all powers of attorney with respect to the Purchased
Assets to be terminated as of Closing such that after the Closing, Purchaser will not be bound thereby or have any liability thereunder. 

Section 2.9. Wrong Pockets. 

(a) If, after the Closing, Purchaser or any of its Affiliates possesses any Excluded Asset, Purchaser shall, or shall cause its Affiliates to,
use commercially reasonable efforts to transfer such asset, at no cost to Seller. 
 (b) If, after the Closing, Seller or any of its
Affiliates possesses any Purchased Asset, Seller shall, or shall cause its Affiliates to, use commercially reasonable best efforts to transfer such asset, at no cost to Purchaser. 

  
 21 

 ARTICLE III 

MILESTONES AND OTHER FINANCIAL OBLIGATIONS 

Section 3.1. Natural Product Milestone Payments. 

(a) On the date hereof, Purchaser shall make the payments described in Table 1 below (each, a “Natural Product Milestone
Payment”) following the first achievement by Purchaser or an Affiliate (but not any other Sublicensee) of the corresponding event (each, a “Natural Product Milestone Event”) described in the row to the left of such payment
in Table 1. 
  

					
	 Table 1

			
	 No.
	 	 Natural Product Milestone Event
	 	 Natural Product Milestone Payment

	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

 (b) Each Natural Product Milestone Payment shall be payable only once and only on the first Natural Product
that achieves the corresponding Natural Product Milestone Event. In no event shall any of the Natural Product Milestone Payments be paid more than once, regardless of the number of times a Natural Product achieves each Natural Product Milestone
Event. Notwithstanding the foregoing, the [***] payable to Seller for achievement of the Natural Product Milestone Events, shall be deemed be have already been paid to Seller, and shall not be paid. For illustrative purposes only, if the first and
second Natural Product Milestone Events that are achieved are the Natural Milestone Events in rows 1 and 2, respectively, then upon the achievement of the Natural Product Milestone Event in rows 1 and 2, nothing will be paid by Purchaser to Seller.
For the avoidance of doubt, the maximum aggregate amount Purchaser shall be obligated to pay pursuant to this Section 3.1 shall be $[***]. 

  
 22 

 (c) Purchaser shall promptly (and in any event no later than [***] thereafter) notify Seller
of the achievement of any Natural Product Milestone Event set forth in Table 1 above. The Natural Milestone Events set forth in rows 8, 9 and 10 in Table 1 shall be deemed to be achieved [***] after the last day of the Fiscal Year in which they
occur, while all of the other Natural Milestone Events shall be deemed to be achieved on the date of such achievement. If Seller notifies Purchaser in writing that Seller believes a Natural Product Milestone Event has been achieved, Purchaser shall
have [***] to respond to Seller by written notice either with (a) Purchaser’s agreement that such Natural Product Milestone Event has been achieved, or (b) a detailed description of any remaining requirements for the achievement of
such Natural Product Milestone Event. Purchaser shall pay to Seller the applicable Natural Product Milestone Payment within [***] after achievement. Each such payment will be made by wire transfer of immediately available funds into an account
designated by Seller in writing reasonably in advance of the due date of the payment. All Natural Product Milestone Payments shall be payable in United States Dollars. A Natural Product Milestone Payments not paid when due shall accrue interest at
the rate of [***], from the date such Natural Product Milestone Payment was originally payable hereunder. 
 (d) For the avoidance of doubt,
as of the date hereof, the Natural Product Milestone Payments are the only milestone payments (as distinct from royalty payments or other payments set forth in this Agreement) that are payable to Seller by Purchaser (upon the achievement of the
Natural Milestone Events thereto), and the Parties hereby acknowledge and agree that there are no other milestone payments that are payable or potentially payable to Seller by Purchaser or its Affiliates upon the achievement of any other events in
this Agreement or any other agreement. 
 Section 3.2. Natural Product Royalties and Sublicensing Revenue Payments. 

(a) Subject to adjustment pursuant to Section 3.2(c), following the date of this Agreement, effective upon the First Commercial
Sale of any Natural Product, Purchaser shall pay to Seller, on a Natural Product-by-Natural Product basis, the following payments during the Natural Product Royalty Term: 

(i) a royalty of [***]% on all Net Sales of each Natural Product by Purchaser or its Affiliates (the “Natural Product
Royalties”); and 
 (ii) a payment of [***]% of all Sublicensing Revenue received by Purchaser from Sublicensees
(other than Affiliates) in connection with the development, use or sale of Natural Products (the “Sublicensee Natural Product Royalties”). 

(b) Natural Product Royalty Term. Purchaser will pay to Seller the Natural Product Royalties and the Sublicensee Natural Product
Royalties during the period commencing upon the First Commercial Sale of a Natural Product and ending on the twenty-five (25) year anniversary of the First Commercial Sale of such Natural Product in such country (each, a “Natural
Product Royalty Term”). 

  
 23 

 (c) Natural Product Royalty Reductions. 

(i) Generic Competition. If, on a Natural Product-by-Natural Product, country- by-country and calendar
quarter-by-calendar quarter basis, Generic Competition is present in such country with respect to any Natural Product, then Purchaser may reduce the royalty payments otherwise due for Net Sales of such Natural Product pursuant to
Section 3.2(a)(i) by [***] from and including any such calendar quarter and after such calendar quarter during which Generic Competition exists in such country. 

(ii) Third Party Payments. If Purchaser, in its reasonable judgment, obtains rights from a Third Party for any
technology that is necessary to develop, make, use or sell a Natural Product, then Purchaser may, beginning from the date of such third party agreement with such Third Party pursuant to which it obtained such rights, reduce the Natural Product
Royalties by [***] of the [***] payments paid to such Third Party on sales of Natural Products under such agreement; provided, that such deductions may not reduce by more than [***]% the Natural Product Royalties otherwise due to Seller with
respect to the sale of such Natural Product. [***]. 
 (d) Payments. Natural Product Royalties and Sublicensee Natural Product
Royalties shall be paid annually by Purchaser to Seller no later than [***] following the last day of each Fiscal Year based upon Net Sales accruing during the respective Fiscal Year. All such payments shall be made by wire transfer of immediately
available funds to an account specified in writing by Seller in writing reasonably in advance of the due date of the payment and shall be payable in United States Dollars. Natural Product Royalties and Sublicensee Natural Product Royalties not paid
when due shall accrue interest at the rate of [***], whichever is lower, from the date such amounts were originally payable hereunder. 

Section 3.3. Cultured Product Royalties and Sublicensing Revenue. 

(a) Following the execution of this Agreement, Purchaser shall pay to Seller, on a Cultured Product-by-Cultured Product basis, the following
payments during the Cultured Product Royalty Term: 
 (i) a royalty of [***]% on all Net Sales of each Cultured Product by
Purchaser or its Affiliates (the “Cultured Product Royalties”); and 
 (ii) a payment of [***]% of all
Sublicensing Revenue received by Purchaser from Sublicensees (other than Affiliates) in connection with the development, use or sale of Cultured Products (the “Sublicensee Cultured Product Royalties”). 

(b) Cultured Product Royalty Term. Purchaser will pay to Seller the Cultured Product Royalties and Sublicensee Cultured Product
Royalties during the period commencing upon First Commercial Sale of a Cultured Product and ending on the fifteen (15) year anniversary of the First Commercial Sale of such Cultured Product in a given country (each, a “Cultured Product
Royalty Term”). 
 (c) Cultured Product Royalty Payments. Cultured Product Royalties and Sublicensee Cultured Product
Royalties shall be paid annually by Purchaser to Seller no later than [***] following the last day of each Fiscal Year based upon Net Sales accruing during the respective Fiscal Year. All such payments shall be made by wire transfer of immediately
available funds to an account specified in writing by Seller reasonably in advance of the due date of the payment and 

  
 24 

 
shall be payable in United States Dollars. Cultured Product Royalties and Sublicensee Cultured Product Royalties due under Section 3.3(a)(i) and Section 3.3(a)(ii) that
are not paid when due shall accrue interest at the rate of [***], whichever is lower, from the date such amounts were originally payable hereunder. 

Section 3.4. Royalty Reports. Concurrently with each payment of Royalties and Sublicensing Revenue, Purchaser shall deliver to
Seller a report setting forth in reasonable detail for the applicable period relating to such Royalties and Sublicensing Revenue: [***] (the “Reporting Metrics”). Within [***] following June 30 of each Fiscal Year, Purchaser
shall deliver to Seller an informational report setting forth its best estimates as of such date of the Reporting Metrics for such six-month period (an “Interim Report”); such Interim Report shall be non-binding and will be
delivered for informational purposes only and any amounts presented therein shall be subject to update and revision in the applicable annual period report. 

Section 3.5. Records. During each Royalty Term and for a period of [***] thereafter, Purchaser shall keep accurate records of:
(a) all Net Sales in sufficient detail to enable Seller to verify the Royalties and Sublicensing Revenue payable thereon; (b) data and calculations used to determine, in each country, whether Generic Competition is present, for purposes of
Natural Products; and (c) all Sublicensing Revenue. 
 Section 3.6. Audit Rights. During each Royalty Term and for a period
of [***] thereafter, upon no less than [***] advance written notice to Purchaser from Seller, Purchaser shall provide access, during Purchaser’s normal business hours, to its books and records relating to its payment obligations under this
Agreement, including without limitation, sales records relating to the applicable Natural Product or Cultured Product, to an independent certified public accounting firm appointed by Seller, at Seller’s own cost and expense, to verify
Purchaser’s compliance with Purchaser’s Royalties and Sublicensing Revenue payment obligations hereunder. Seller and its representatives agree to protect the confidentiality of all information obtained in such inspection pursuant to
Section 11.9. Any such audit shall not be more frequently than once in any twelve (12) month period. Seller shall promptly provide Purchaser a copy of any report generated during such an audit. If any audit reveals an underpayment
of Royalties or Sublicensing Revenue in excess of [***] of the amount due with respect to the period being audited, Purchaser shall pay, within [***] of Purchaser’s receipt of a report of the audit results (a) the reasonable, documented
costs of such audit plus (b) such additional Royalties and Sublicensing Revenue that were payable to Seller at an earlier date but for Purchaser’s reporting error plus (c) interest on such Royalties and Sublicensing Revenue at the
rate of [***], whichever is lower, from the date such Royalties or Sublicensing Revenue were originally payable hereunder. In the event that such audit reveals an overpayment of Royalties or Sublicensing Revenue by Purchaser, (i) such
overpayment shall be credited against Purchaser’s future Royalty and Sublicensing Revenue payments to the extent due or (ii) Seller shall promptly refund such overpayment to Purchaser, as elected by Purchaser in writing. Notwithstanding
the foregoing, should any Governmental Entity audit Seller and should such audit relate to the Agreement, Purchaser shall provide access, during Purchaser’s normal business hours, to its books and records relating to its payment obligations
under this Agreement, including without limitation, sales records relating to the Natural Products and Cultured Products, to an independent certified public accounting firm appointed by Seller or directly to such Governmental Entity even if an audit
pursuant to this Section 3.6 has already occurred in the past twelve (12) months. Seller’s exercise of its audit rights under this Section 3.6 may not (i) be conducted for any Fiscal Year more than [***] after
the end of such Fiscal Year to which such books and records pertain. 

  
 25 

 Section 3.7. Foreign Sales. With respect to Net Sales invoiced in a currency
other than United States dollars, such Net Sales will be converted into the United States dollar equivalent using [***]. 

Section 3.8. Tax Withholding. Seller (or its successor, assignee or other transferee, if applicable) shall bear the Taxes to be
levied on its income arising under this Agreement. Where required by applicable Law, Purchaser shall have the right to withhold applicable Taxes from any payments to be made by Purchaser to any Person pursuant to this Agreement and pay to the
applicable Taxing Authority on behalf of such Person and, to the extent that any such amounts are so deducted or withheld, such amounts will be treated for all purposes of this Agreement as having been paid to such Person by Purchaser (and may be
deducted from any amounts due Seller hereunder). The original official government receipt evidencing payment of such taxes by Purchaser on Seller’s behalf shall be delivered by Purchaser to Seller after the date of payment, together with
supporting documentation identifying the Royalties, Sublicensing Revenue or other amounts payable pursuant to this Agreement to which such taxes relate. Purchaser will provide Seller with, at Seller’s expense (which shall be reasonable and
documented), reasonable assistance to enable Seller to recover any such Taxes or amounts otherwise withheld as permitted by Law. If applicable Law requires Purchaser to pay or withhold Taxes with respect to any payment to be made pursuant to this
Agreement, the Purchaser will make reasonable commercial efforts to notify the Seller in writing of such payment or withholding requirements at least [***] prior to paying or withholding such Taxes and provide such assistance to the Seller at the
Seller’s cost, including the provision of such documentation as may be required by a Taxing Authority, as may be reasonably requested by the Seller for purposes of claiming an exemption from or reduction of such Taxes. Seller (or its successor,
assignee or other transferee, if applicable) agrees to cooperate and produce on a timely basis any tax forms, reports, including an IRS Form W-9 or an IRS Form W-8BEN-E, or other documentation required or reasonably requested by the Purchaser in
order to reduce or exempt such payment from withholding Tax in advance of any payment made by Purchaser to Seller under this Agreement. 

Section 3.9. No Other Royalty Payments. For the avoidance of doubt, as of the date hereof, the Natural Product Royalties,
Sublicensee Natural Product Royalties, Cultured Product Royalties and Sublicensee Cultured Product Royalties are the only royalty payments (as distinct from milestone payments and other payments set forth in this Agreement) that are payable to
Seller by Purchaser, and the Parties hereby acknowledge and agree that there are no other royalty payments that are payable or potentially payable to Seller by Purchaser or its Affiliates in this Agreement or any other agreement. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF SELLER 

Seller hereby represents and warrants to Purchaser that, except as disclosed by Seller in the Seller’s Disclosure Schedules, the
following statements are true, complete and correct as of the date hereof and as of the Closing Date: 

  
 26 

 Section 4.1. Organization and Good Standing. Seller is a corporation duly
organized, validly existing and in good standing under the Laws of the Commonwealth of Massachusetts. Seller is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature or conduct of its business or
the ownership, leasing or operation of its properties or assets requires it to be so qualified, licensed or in good standing. 

Section 4.2. Authority. Seller has all requisite corporate power and authority to own and operate its respective properties and
assets, and to carry on its business as it is now being conducted. Seller has all requisite corporate power and authority to execute and deliver this Agreement and the Ancillary Agreements to which it is a party and to perform its respective
obligations hereunder and thereunder. The execution and delivery by Seller of this Agreement and the Ancillary Agreements to which it is a party and the performance by Seller of its respective obligations hereunder and thereunder have been duly
authorized by all requisite corporate action on the part of Seller. This Agreement, and each Ancillary Agreement executed on the date hereof or to be executed on the Closing Date, as applicable, has been or will be duly executed and delivered by
Seller, and, assuming the valid execution and delivery by Purchaser, constitute a legal, valid and binding obligation of Seller enforceable against Seller in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency,
reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). Seller does not have any
outstanding capital stock. 
 Section 4.3. No Conflict. The execution, delivery and performance by Seller of this Agreement and
each of the Ancillary Agreements to which it is a party and the consummation of the transactions contemplated hereby and thereby, do not and will not (a) violate any provision of the certificate of incorporation or the by-laws or similar
organizational documents of Seller; (b) require any action by (including any authorization, consent or approval) or in respect of (including notice to), any Person under any Purchased Asset; (c) violate or conflict with, or result in a
breach of, constitute a default under, or create rights of acceleration, termination or cancellation under any Purchased Asset, or (d) result in the creation or imposition of a material Encumbrance upon, or the forfeiture of, any Purchased
Asset; or (e) violate or result in a breach of, or constitute a default under any Law of any Governmental Entity to which Seller is subject. 

Section 4.4. Required Filings and Consents. 

(a) The execution and delivery of this Agreement by Seller, if any and as applicable, and the consummation of the transactions contemplated
hereby, do not require any consents, approvals, notices or filings with any Governmental Entities or other Third Parties other than as set forth on Schedule 4.4. 

(b) Other than the approval or non-objection to be obtained from the Massachusetts Attorney General pursuant to Section 7.1, no
consent, approval, qualification, order or authorization of, registration, declaration or filing with, or notice to, any Governmental Entity is necessary or required by or with respect to Seller in connection with the execution and delivery by
Seller of this Agreement, the consummation by Seller of the transactions contemplated by this Agreement or the compliance by Seller with the provisions of this Agreement, including the filing of a premerger notification and report form under the HSR
Act, and the receipt, termination or 

  
 27 

 
expiration, as applicable, of approvals or waiting periods required under the HSR Act or any other applicable competition, merger control, antitrust or similar Law. Seller, including its
“Ultimate Parent Entity” as that term is defined in 16 C.F.R. Part 801.1(a)(3), together with all entities its Ultimate Parent Entity controls pursuant to 16 C.F.R. Parts 801.1(a)(2) and (a)(3)(b)], does not have $18,800,000 of “total
assets” or more or in “annual net sales” as determined in accordance with 16 C.F.R. Part 801.11. 
 Section 4.5.
Solvency. Seller is, and will be immediately following the consummation of the transactions contemplated hereby (a) able to pay its debts as they become due, and (b) is solvent and will be solvent immediately following the Closing.
Seller is not engaged in any transaction, and it is not about to engage in any transaction, for which its remaining assets and capital are or will be insufficient. Seller has not entered into this Agreement for the purpose of hindering, delaying or
defrauding its creditors. 
 Section 4.6. Purchased Assets. 

(a) Seller has good and marketable title to, or valid contracts rights to, as applicable, all of the Purchased Assets free and clear of all
Encumbrances, other than Permitted Encumbrances. Seller has the power and right to sell, assign, transfer and deliver to Purchaser, the Purchased Assets and there are no adverse claims of ownership to the Purchased Assets and Seller has not received
notice that any Person has asserted a claim of ownership or right of possession or use in or to any of the Purchased Assets, nor are there, to the Knowledge of Seller, any facts, circumstances or conditions on which any such claim could be brought
in the future. At the Closing, Purchaser will acquire from Seller good and marketable title to, or valid contract rights to, as applicable, all of the Purchased Assets, free and clear of all Encumbrances, other than Permitted Encumbrances. 

(b) The Purchased Assets, together with the licenses set forth in Section 6.5 and excluding the Excluded Assets, comprise all
assets used or held for use by Seller and its Affiliates in connection with the Business. 
 Section 4.7. Contracts. 

(a) Schedule 4.7(a) lists all Contracts that are material to the Purchased Assets and the Business, and all such Contracts are in
writing, and none are oral Contracts. Seller has delivered or made available to Purchaser a true, correct and complete copy of each Assumed Contract, as amended. Each Assumed Contract is, in all material respects in full force and effect and is a
legal, valid and binding agreement of Seller and, to the Knowledge of Seller, is a legal, valid and binding agreement of each other party thereto, enforceable against Seller and each other party thereto in accordance with its terms, subject, as to
enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting the rights and remedies of creditors generally and subject to general principles of equity (regardless of whether such enforceability is
considered in a proceeding at law or in equity). Seller has performed or is performing all material obligations required to be performed by it under the Assumed Contracts and is not in material breach or default thereunder, and to the Knowledge of
Seller, no other party to any of the Assumed Contracts is in material breach or default thereunder, and no event has occurred which, with or without notice, lapse of time, or both, would constitute a material default under the provisions of such
Assumed 

  
 28 

 
Contract or would give to others any right of termination, amendment or cancellation of any Assumed Contract. Immediately following the Closing, each Assumed Contract will continue to be in full
force and effect, and be valid, binding and enforceable in accordance with its terms. 
 (b) No Assumed Contract (A) grants any
exclusive rights (including exclusive rights in Contract Services IP) to any Person, (B) limits the freedom of Seller or its Affiliates to compete with any Person or engage in any line of business or geographic area, (C) restricts the
research, development, manufacture, marketing, distribution, sale, supply, license or marketing of the products and services of Seller or any Affiliate or (D) limits the freedom of the freedom of Seller or any of its Affiliates to use any
Contract Services IP after the Closing Date. 
 (a) No Assumed Contract contains any restriction on Seller’s or its Affiliates’
solicitation, hiring or engagement of any Person or the solicitation of any customer. 
 (b) No Assumed Contract contains any option,
warrant, purchase right or other requirement that the Seller or any of its Affiliates sell, transfer or otherwise dispose of any of the Purchased Assets. 

(c) No Assumed Contract contains any right of first refusal, right of first negotiation, right of first offer or similar right in favor of any
party. 
 (d) No Assumed Contract grants an Encumbrance (other than Permitted Encumbrances) upon any Purchased Asset. 

(e) There are no Contracts of Seller or its Affiliates that involve any resolution or settlement of any Action relating to the Purchased
Assets. 
 Section 4.8. Intellectual Property. 

(a) To the Knowledge of Seller, the Contract Services IP does not include any registered Technology. Except as set forth on Schedule
4.8(a)(i), to the Knowledge of Seller, the Contract Services IP is free and clear of any Encumbrances, other than Permitted Encumbrances. On the Closing Date, Seller shall transfer to Purchaser all of its right, title, and interest in, under and
to all Contract Services IP. 
 (b) Seller owns or Controls and possesses the right to use and license the OpenBiome CMC Technology and such
other Technology subject to the licenses set forth in Section 6.5 (collectively, the “OpenBiome Technology”). 

(c) Schedule 4.8(c) lists (i) all Contracts that restrict Seller’s or its Affiliates’ use, transfer or license of any
Contract Services IP or OpenBiome Technology and (ii) all Contracts involving the licensing of any Contract Services IP or OpenBiome Technology to or from a Third Party (collectively, the “IP Contracts”). Neither Seller nor any
of its Affiliates has entered into any Contract with respect to the Contract Services IP or OpenBiome Technology requiring Seller or any of its Affiliates to indemnify any Person against infringement, misappropriation or violation of any Third Party
Technology. There are no outstanding or, to the Knowledge of Seller, threatened disputes with respect to any IP Contract. 

  
 29 

 (d) To the Knowledge of Seller, there have been no violations of any confidentiality or
assignment agreement relating to the Contract Services IP or any unauthorized disclosure of any material trade secrets that are included in the Contract Services IP. Seller has taken commercially reasonable measures to protect and safeguard and to
maintain in confidence all Confidential Information and Know-How that are included in the Contract Services IP. Seller has not disclosed any Confidential Information to any Third Party that is not subject to confidentiality obligations to Seller. To
the Knowledge of Seller, no party to a nondisclosure agreement with Seller with respect to Contract Services IP is in breach or default thereof. 

(e) (i) To the Knowledge of Seller, no Person has misappropriated or otherwise violated, either directly or indirectly, any Contract
Services IP or any OpenBiome Technology (ii) neither Seller nor any of its Affiliates has brought or threatened to bring any claim, suit or proceeding against any Person alleging any such misappropriation or violation, and (iii) neither of
the foregoing clauses (i) or (ii) have been asserted in any written notice. 
 (f) There has not been any third party claim, suit
or proceeding asserted or threatened in writing, including in the form of an offer or invitation to obtain a license, against Seller or any Affiliate relating to the Contract Services IP or any OpenBiome Technology (i) alleging misappropriation
or other violation of any Person’s Technology, (ii) challenging Seller’s or any Affiliate’s, as applicable, ownership of, right, title or interest in, under or to, use of, any Contract Services IP or any OpenBiome Technology,
(iii) adversely affecting the ownership rights of Seller or any Affiliate in, under or to any Contract Services IP or OpenBiome Technology, (iv) alleging that Seller or any Affiliate is in breach of any applicable grant, license,
agreement, instrument or other arrangement pursuant to which Seller or any Affiliate acquired the right to use such Contract Services IP or any OpenBiome Technology, or (vi) alleging misuse or antitrust violations arising from the use or other
Exploitation by Seller or any Affiliate of any Contract Services IP or OpenBiome Technology. 
 (g) Neither Seller nor any Affiliate has
granted any Person any right to bring, defend, or otherwise control any Action with respect to any Contract Services IP. Neither Seller nor any Affiliate has entered into, or is subject to, any third party consents, indemnifications, forbearances to
sue, licenses or other arrangements in connection with the resolution of any disputes or Action that (i) restrict Seller or an Affiliate with respect to the use of any Contract Services IP or (ii) permit any Person to use any Contract
Services IP. 
 (h) No current or former employee or consultant of Seller or its Affiliates owns any rights in or to any Contract Services IP
or, to the Knowledge of Seller, OpenBiome Technology. All current and former employees and consultants of Seller or its Affiliates who contributed to the discovery, creation or development of any Contract Services IP or, to the Knowledge of Seller,
OpenBiome Technology did so (i) within the scope of his or her employment such that it constituted a work made for hire and all Contract Services IP and OpenBiome Technology arising therefrom became the exclusive property of Seller or its
Affiliates or (ii) pursuant to a written agreement, assigned all of his or her Contract Services IP and OpenBiome Technology to Seller or its Affiliates and agreed to confidentiality restrictions restricting such Person’s right to use or
disclose proprietary information of the Seller or its Affiliates. To the Knowledge of Seller, no employees of the Seller or any of its Affiliates or personnel of a Third Party have any claim against the Seller or its Affiliates in connection with
such Person’s involvement in the conception and 

  
 30 

 
development of any Contract Services IP or OpenBiome Technology and no such claim has been asserted or threatened in writing. To the Knowledge of Seller, at no time during the conception of or
reduction to practice of any Contract Services IP or OpenBiome Technology owned by Seller or its Affiliates was any developer, inventor or other contributor to such Contract Services IP or OpenBiome Technology operating under any grants from any
Governmental Entity or private source, performing research sponsored by any Governmental Entity or private source or subject to any employment agreement or invention assignment or nondisclosure agreement or other obligation with any Third Party, in
each case that reasonably would be expected to impair or limit the Seller’s or its Affiliates’ rights in the Contract Services IP or OpenBiome Technology. 

(i) No current or former partner, director, stockholder, officer, contractor or employee of Seller or of any Affiliate will, after giving
effect to the transactions contemplated by this Agreement, own or retain any rights to use any of the Contract Services IP, and no royalty or other payment is payable, or will become payable, to any such person or to a Third Party for the use of any
of the Contract Services IP. 
 (j) The Contract Services IP has not been created pursuant to, and is not subject to, any funding agreement
with any government or government agency or any Third Party, and is not subject to the requirements of the Bayh-Dole Act or any similar provision of any applicable Law. 

Section 4.9. Compliance with Laws; Regulatory Compliance. 

(a) The Exploitation by Seller and its Affiliates of any Product and the ownership by Seller and its Affiliates of the Purchased Assets have
been, at all times, in material compliance with all applicable Law, including applicable Regulatory Laws. Except as set forth in Seller’s Disclosure Schedule, neither Seller nor any Affiliate has received any written communication from a
Governmental Entity that alleges that Seller or any Affiliate is not in compliance in any material respect with any Law or Order with respect to its Exploitation of any Product or with respect to ownership of the Purchased Assets, respectively and
as applicable. Seller and its Affiliates have, and have had, all Product Registrations necessary for its lawful Exploitation of any Product prior to the Closing Date, and each of such Product Registrations, if any, is valid and in full force and
effect. 
 (b) Except as set forth in the Seller Disclosure Schedule, there has not been any claim of which Seller or any Affiliate has
received notice of any Action pending or threatened against Seller or an Affiliate relating to any Product or the Purchased Assets. To the Knowledge of Seller, there is no fact or circumstance that would reasonably be expected to serve as a basis
for any Action against Seller or any Affiliate relating to any Product or any Purchased Assets or that, if successful, could reasonably be expected to result in restraining, enjoining or otherwise preventing the completion by Seller of the
transactions contemplated by this Agreement. There is no Action pending by Seller or any Affiliate, or which Seller intends to initiate against any Third Party relating to any Product or any Purchased Asset. There is no outstanding Order of any
Governmental Entity against Seller (i) that relates to the Business, a Product or any Purchased Asset, (ii) that could reasonably be expected to be materially adverse to the Business, any Product or any Purchased Asset, or (iii) that
could reasonably be expected to result in restraining, enjoining or otherwise preventing the completion by Seller of the transactions contemplated by this Agreement. 

  
 31 

 (c) There is no Action pending or, to the Knowledge of Seller, threatened against Seller by
any Governmental Entity, and there is no claim, investigation or administrative action of any Governmental Entity pending or, to the Knowledge of Seller, threatened, that affects or, if successful, could reasonably be expected to be materially
adverse to Seller, the Business, a Product, any Purchased Assets or the Assumed Liabilities or that, if successful, could reasonably be expected to result in restraining, enjoining or otherwise preventing the completion by Seller of the transactions
contemplated by this Agreement, nor are there, to the Knowledge of Seller, any facts, circumstances or conditions on which any such Action could be brought in the future. 

(d) Except as set forth in the Seller Disclosure Schedule, Seller and its Affiliates have timely filed all material reports, statements,
documents, registrations, filings, amendments, supplements and submissions required to be filed by it with respect to any Product and the Purchased Assets under applicable Regulatory Laws. Each such filing was, in all material respects, true,
complete and correct as of the date of submission, and any necessary or required updates, changes, corrections, amendments, supplements or modifications to such filings have been submitted to the applicable Governmental Entity. 

(e) Except for notice of the Clinical Hold, neither Seller nor any Affiliate has, with respect to any Product or any Purchased Asset,
(i) received or been subject to any action, notice, warning, administrative proceeding, review or investigation by a Regulatory Authority that alleges or asserts that Seller or any Affiliate has violated any applicable Regulatory Laws or
(ii) been subject to a corporate integrity agreement, deferred prosecution agreement, consent decree, monitoring agreement, settlement agreement or other similar agreement or Order mandating or prohibiting future or past activities. 

(f) Except as set forth on Schedule 4.9(f), the Manufacturing and servicing operations conducted by or on behalf of Seller and its
Affiliates with respect to any Product are conducted in material compliance with applicable Regulatory Laws, including applicable current good manufacturing practice regulations and similar federal, state, local or foreign requirements for the
Manufacture of any Product. 
 (g) Neither Seller, nor any Affiliate, nor any officer, employee or agent of Seller or of any Affiliate, in
each case who has been materially involved in the Exploitation of any Product (i) has been convicted of any crime or engaged in any conduct in the operation of Seller’s business for which debarment is mandated or authorized by 21 U.S.C.
§ 335a or any similar applicable Law, nor has any such Person been so debarred; (ii) has been convicted of any crime or engaged in any conduct which would reasonably be expected to cause Seller to be excluded from participating in federal
health care programs under Section 1128 of the Social Security Act of 1935, as amended, or any similar applicable Law, nor has any such Person been so excluded; or (iii) to the Knowledge of Seller, is subject to an investigation or
proceeding by any Regulatory Authority that could result in such a suspension, exclusion or debarment and there are no facts, to the Knowledge of Seller, that would reasonably be expected to give rise to such suspension, exclusion or debarment. 

(h) Neither Seller nor any Affiliate has, in connection with its Exploitation of a Product, conducted any business or engaged in any
transaction or dealing with any Person with whom transactions were, at the time of such transaction, prohibited as to U.S. Persons by any applicable sanctions Laws administered by the U.S. Treasury Department’s Office of Foreign Assets Control
(“OFAC”), including persons appearing on the List of Specially Designated Nationals and Blocked Persons published by OFAC. 

  
 32 

 Section 4.10. Taxes. 

(a) Seller has timely filed (or had timely filed on its behalf) all Tax Returns with respect to the Purchased Assets or the Business that they
were required to file and all such Tax Returns were true, correct and complete in all material respects. Seller has paid (or had paid on its behalf) all Taxes with respect to the Purchased Assets or the Business that are required to be paid by any
of it (whether or not shown on any Tax Return). 
 (b) There are no Encumbrances, other than for current Taxes not yet due and payable, for
Taxes upon any Purchased Asset. 
 (c) No extension of time within which to file any Tax Return with respect to the Purchased Assets or the
Business is in effect, and no waiver of any statute of limitations relating to Taxes payable with respect to the Business or the Purchased Assets has been granted. 

(d) To the Knowledge of Seller, there is no audit or administrative or judicial proceeding pending, being conducted, or claimed with respect to
the Tax status of the Seller or Tax Returns of, or Taxes payable with respect to the Business or the Purchased Assets. 
 (e) To the
Knowledge of Seller, there is no notice of proposed adjustment, deficiency, underpayment of Taxes or any other such notice from a Governmental Entity which has not been satisfied by payment or been withdrawn that has been received by Seller or any
of its Affiliates with respect to the Purchased Assets or the Business and no claim has been made by any Governmental Entity in a jurisdiction where Tax Returns are not filed with respect to the Purchased Assets or the Business that Taxes are
required to be paid in or Tax Returns are required to be filed in that jurisdiction by Seller or with respect to the Purchased Assets or the Business. 

(f) All material Taxes which were required by Law to be withheld, deducted, or to be collected for payment in connection with amounts paid or
owing to or allocable to any employee, independent contractor, creditor, stockholder, or other Person by Seller or with respect to the Purchased Assets or the Business, have been duly withheld, deducted and collected and have been paid to the
appropriate Governmental Entity or set aside or reserved on the Product Records, and all reporting and recordkeeping requirements related thereto have been complied with. 

(g) No Purchased Asset (including Assumed Contracts) will result in Purchaser or any of its Affiliates having any liability or obligation to
pay, reimburse, or indemnify any Person for Taxes of any other Person. 
 (h) Seller has not made any election to defer any payroll Taxes
under the CARES Act. 
 (i) Seller is a domestically organized corporation that qualifies as an organization described in
Section 501(c)(3) of the Code. 

  
 33 

 Section 4.11. Brokers. No broker, finder or investment banker is entitled to any
brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Seller. 

Section 4.12. No Other Representations and Warranties. SELLER ACKNOWLEDGES AND AGREES THAT EXCEPT FOR THE REPRESENTATIONS AND
WARRANTIES MADE BY PURCHASER IN THIS AGREEMENT OR IN ANY CERTIFICATE, ANY ANCILLARY AGREEMENT OR ANY OTHER DOCUMENT DELIVERED TO SELLER AT THE CLOSING PURSUANT TO THIS AGREEMENT, PURCHASER NOR ANY OTHER PERSON MAKES ANY EXPRESS OR IMPLIED
REPRESENTATION OR WARRANTY ON BEHALF OF PURCHASER IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF PURCHASER 

Purchaser hereby represents and warrants to Seller that the following statements are true, complete and correct as of the date hereof and as
of the Closing Date: 
 Section 5.1. Organization and Good Standing. Purchaser is a corporation duly organized, validly existing
and in good standing under the Laws of the State of Delaware. Purchaser is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature or conduct of its business or the ownership, leasing or operation
of its properties and other assets requires it to be so qualified, licensed or in good standing. 
 Section 5.2. Authority.
Purchaser has all requisite corporate power and authority to own and operate its properties and assets, to carry on its business as it is now being conducted and to execute and deliver this Agreement and the Ancillary Agreements and to perform its
obligations hereunder and thereunder. The execution and delivery by Purchaser of this Agreement and the Ancillary Agreements and the performance by Purchaser of its obligations hereunder and thereunder have been duly authorized by all requisite
corporate action on the part of Purchaser and no additional authorization on the part of Purchaser is necessary in connection with the execution, delivery and performance of this Agreement or of the Ancillary Agreements. This Agreement and each
Ancillary Agreement, to be executed on the date hereof and the Closing Date, as applicable, has been or will be duly executed and delivered by Purchaser and, assuming the valid execution and delivery by Seller, constitute a legal, valid and binding
obligation of Purchaser, enforceable against Purchaser in accordance with its terms, except as enforcement may be limited by bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or similar Laws affecting creditors’ rights
generally or by general principles of equity (regardless of whether enforcement is sought in a proceeding in equity or law). 

Section 5.3. No Conflict. The execution, delivery and performance of this Agreement and each of the Ancillary Agreements by
Purchaser and the consummation of the transactions contemplated hereby and thereby, do not and will not (a) violate any provision of the certificate of incorporation or by-laws of Purchaser, (b) violate or conflict with, or result in a
breach of, constitute a default under, or create rights of acceleration, termination or cancellation under, or to 

  
 34 

 
a loss of any benefit to which Purchaser or any of its Affiliates is entitled under, any agreement, to which Purchaser or any of its Affiliates is a party or to which its properties or assets are
subject or (c) violate or result in a breach of or constitute a default under any Law of any Governmental Entity to which Purchaser is subject, in the case of clauses (b) and (c) where any of the listed items, individually or in the
aggregate, would reasonably be expected to prevent or materially delay the consummation of the transactions contemplated by this Agreement. 

Section 5.4. Required Filings and Consents. The execution and delivery of this Agreement by Purchaser and the consummation of the
transactions contemplated hereby, do not require any consents, approvals, notices and filings other than the approval or non-objection of the Massachusetts AG pursuant to Section 7.1. 

Section 5.5. Action. There is no Action pending or threatened against Purchaser which, individually or in the aggregate, would
reasonably be expected to prevent or materially delay the consummation of the transactions contemplated by this Agreement. There are no Orders of any Governmental Entity or arbitrator outstanding against or investigation by any Governmental Entity
involving Purchaser or any of its assets which, individually or in the aggregate, would reasonably be expected to prevent or materially delay the consummation of the transactions contemplated by this Agreement. 

Section 5.6. Third Party License Fees for Natural Products. The amounts of the Third Party License Fees for Natural Products as of
the date hereof are set forth on Annex 5.6. Purchaser shall update Annex 5.6 at the Closing Date, but only if the amounts of the Third Party License Fees for Natural Products at the Closing Date are different than the amounts as of the
date hereof. 
 Section 5.7. Brokers. No broker, finder or investment banker is entitled to any brokerage, finders or other fee
or commission in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of Purchaser or any of its Affiliates. 

Section 5.8. Withholding. Based on the Seller’s representation in Section 4.10(i) of this Agreement, Purchaser does not
currently intend to withhold any U.S. Taxes from any payments to be made to the Seller pursuant to this Agreement, provided that the Seller (i) has delivered to Purchaser a valid and properly completed IRS Form W-9 and (ii) has not
assigned any right or obligation hereunder to another entity. 
 Section 5.9. No Other Representations and Warranties. PURCHASER
ACKNOWLEDGES AND AGREES THAT EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES MADE BY SELLER IN THIS AGREEMENT, ANY CERTIFICATE, ANY ANCILLARY AGREEMENT OR ANY OTHER DOCUMENT DELIVERED TO PURCASER AT THE CLOSING PURSUANT TO THIS AGREEMENT, SELLER NOR
ANY OTHER PERSON MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY ON BEHALF OF SELLER IN CONNECTION WITH THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

  
 35 

 ARTICLE VI 

INTELLECTUAL PROPERTY; KNOW-HOW TRANSFER 

Section 6.1. Defense of Claims Brought by Third Parties Against Seller or Purchaser. 

(a) If either Party becomes aware of any actual or potential claim that the Contract Services IP infringes the intellectual property rights of
any Third Party, then such Party shall promptly notify the other Party and shall share with the other Party all information available to it with respect to such alleged infringement; provided that prior to the Closing, Seller shall have the right,
in its discretion, to defend and dispose (including through settlement or license) such claim. 
 (b) Prior the Closing, the costs and
expenses incurred in connection with defense of any claim described in Section 6.1(a) shall be borne by Seller. Following the Closing, the costs and expenses incurred in connection with defense of any claim described in
Section 6.1(a) shall be borne by Purchaser; provided, that, for the avoidance of doubt, Purchaser shall not be responsible for any such costs incurred by Seller, including any out-of-pocket costs or attorneys’ fees, unless agreed to
in writing by Purchaser in advance of the incurrence of any such costs or fees. 
 Section 6.2. Settlement. Prior to the
Closing, any settlement, consent, judgement or other voluntary final disposition of a suit with respect to the Contract Services IP shall require the prior written consent of Purchaser. Following the Closing, Purchaser may, in its absolute
discretion, enter into any settlement, consent judgment or other voluntary final disposition of a suit with respect to the Contract Services IP provided that any such settlement, consent judgement or other voluntary final disposition does not impose
any financial obligation on Seller or its Affiliates, or create any adverse financial impact or hardship on Seller or its Affiliates. 

Section 6.3. Other Actions by Third Parties Not Involving Seller. 

(a) Notice. Seller shall promptly notify Purchaser in the event of any legal or administrative action by any Third Party involving any
Contract Services IP of which it becomes aware, including any nullity, revocation, interference, reexamination or compulsory license proceeding (“Contract Services IP Action”). 

(b) Contract Services IP. 

(i) From the date hereof until the Closing, Seller at Purchaser’s expense shall diligently defend in good faith against
any Contract Services IP Action involving any Product and shall (A) consult with Purchaser regarding such Contract Services IP Action, including timing and strategy, (B) keep Purchaser informed of all material developments,
(C) promptly provide Purchaser with copies of all papers received or filed in connection with such Contract Services IP Action, (D) provide Purchaser with an opportunity to review and provide input in connection with any filings, and
Seller shall implement all reasonable input provided by Purchaser, and (E) cooperate fully with Purchaser and provide Purchaser with all information and data, and execute any documents, reasonably necessary and requested by Purchaser related to
such Contract Services IP Action. 

  
 36 

 (ii) Following the Closing, Purchaser shall have the sole right, but not the
obligation, to defend against any Contract Services IP Action involving any Product, in its own name (to the extent permitted by applicable law), and any such defense will be at Purchaser’s expense. Following the Closing, Seller, upon
Purchaser’s written request, agrees to assist in any such Contract Services IP Action at Purchaser’s expense and in any event to cooperate with Purchaser at Purchaser’s expense. 

Section 6.4. Certain Costs. Notwithstanding anything to the contrary in this Agreement, each Party shall bear all of its own
internal costs incurred in connection with its activities under Section 6.1 to Section 6.3. 
 Section 6.5.
License Granted to Purchaser and its Affiliates. 
 (a) OpenBiome CMC Technology License. Seller, on behalf of itself and its
Affiliates, hereby grants, effective as of the date hereof, to Purchaser and its Affiliates an irrevocable and perpetual, royalty bearing (which royalty is fully paid-up as of the date of this Agreement), fully paid-up, non-transferable (except as
set forth herein in this Section 6.5(a)) sublicenseable (with the right to grant sublicenses through multiple tiers pursuant to Section 6.5(b)) worldwide license under (i) the OpenBiome CMC Technology, and (ii) any
improvements, modifications or enhancements to Finch Intellectual Property developed or made by or on behalf of and Controlled by Seller or its Affiliates, in each case of clause (i) and (ii), to Exploit products and services in the Territory.
Seller shall not license, assign, or otherwise transfer any rights to those aspects of OpenBiome CMC Technology that are not publicly available as of the date hereof to a Commercial Competitor of Purchaser and its Affiliates, except with respect to
[***]. Nothing in the foregoing shall restrict Seller from (y) publicly disclosing aspects of OpenBiome CMC Technology in connection with bona fide academic, scientific and medical publications or public presentations or (z) disclosing,
licensing, assigning, or otherwise transferring rights to aspects of the OpenBiome CMC Technology that (i) are publicly available as of the date hereof, (ii) that become publicly available through no action of Seller or its Affiliates, or
any of their respective officers, directors, employees, consultants, contractors or agents or (iii) that become publicly available through such academic, scientific and medical publications or public presentations. Such license is
non-transferable, except that Purchaser shall have the right to transfer the license to any of its Affiliates, or to an acquirer in connection with the sale, merger, exclusive license, transfer or consolidation of all or substantially all of the
business or assets of Purchaser to which this license relates. 
 (b) Sublicenses. The license provided for in
Section 6.5(a) will include the right to sublicense, through multiple tiers of sublicenses, any or all of the licensed rights to a Sublicensee. Any sublicenses granted pursuant to the foregoing are subject to the terms and conditions of
this Agreement, will be consistent with the terms of this Agreement. Purchaser shall use commercially reasonable efforts to enforce the terms of such sublicenses to the extent that any failure to so enforce the terms of such sublicense would
constitute a breach of this Agreement. Purchaser will provide Seller with a copy of any and all sublicenses (including any such sublicenses granted by any Sublicensees) but excluding any sublicenses granted to a Third Party performing activities on
behalf of Purchaser, within [***] of execution of each sublicense agreement and with a copy of any and all amendments to any such sublicense agreements within [***] of execution of each such amendment. 

  
 37 

 Section 6.6. Know-How Transfer. After the Closing Date, as reasonably requested
by Purchaser from time to time, qualified personnel from Seller or its Affiliates familiar with the Records will meet or participate in telephone conference calls with personnel from Purchaser or Purchaser’s designee at such times, and in the
case of in-person meetings, at such venues, to be agreed upon by the Parties as reasonably necessary to exchange knowledge necessary to fully transfer all of the Purchased Assets. Each of the Purchaser Manager and the Seller Manager shall serve as
each party’s manager of the know-how transfer pursuant to this Section 6.6. The activities
contemplated by this Section 6.6 shall continue through the [***] anniversary of the Closing Date. Seller
acknowledges that it shall receive no consideration from Purchaser or its Affiliates in respect of its obligations under this Section 6.6. 

Section 6.7. In-Licenses. 

(a) [***]. 
 (b) Seller shall
provide a quarterly report to Purchaser on a country-by-country basis of any amounts collected on all sales or transfers of value of OpenBiome FMT Products to its collaborators or other customers, and would reimburse Purchaser for any Third Party
License Fees for OpenBiome FMT Product that may arise under an Included New In-License resulting from such activities within [***] of receipt thereof. 

Section 6.8. Licenses Granted to Seller. 

(a) License Until the Closing Date. Beginning on the date hereof and ending on the earlier of the Closing Date or the termination of
this Agreement pursuant to Article X, Purchaser shall grant to Seller an irrevocable, non-exclusive, non-transferable, worldwide license under the Finch Intellectual Property to make, use, sell, offer for sale, import and export OpenBiome FMT
Products solely for: (i) the treatment of rCDI in the United States under enforcement discretion; and (ii) subject to Section 7.11, Clinical Research and Studies in all fields other than the Restricted Fields, provided
that, for purposes of the license under this clause (ii) “OpenBiome FMT Product” shall not include Enriched Products. For clarity, Purchaser shall retain all right, title and interest in and to such Finch Intellectual Property
that is the subject of the foregoing license, and Seller shall and hereby does assign to Purchaser all right, title and interest in and to any improvements (whether or not patentable) to such Finch Intellectual Property discovered, conceived, first
reduced to practice or otherwise made by Seller. 
 (b) License Following the Closing Date. Beginning on the Closing Date, Purchaser
shall grant to Seller an irrevocable, perpetual, royalty-bearing, non-exclusive, non-transferable, sublicensable (with the right to grant sublicenses through multiple tiers pursuant to this Section 6.8(b) and Section 6.8(c))
worldwide license under the Finch Intellectual Property solely: (i) to sell OpenBiome FMT Product that was manufactured prior to the Closing Date, for the treatment of rCDI in the United States under enforcement discretion; and
(ii) subject to Section 7.11, to make, use, sell, offer for sale, import and export OpenBiome 

  
 38 

 
FMT Products for Clinical Research and Studies in all fields other than the Restricted Fields, provided that, for purposes of the license under this clause (ii) “OpenBiome
FMT Product” shall not include Enriched Products. For clarity, Purchaser shall retain all right, title and interest in and to such Finch Intellectual Property that is the subject of the foregoing license, and Seller shall and hereby does assign
to Purchaser all right, title and interest in and to any improvements (whether or not patentable) to such Finch Intellectual Property discovered, conceived, first reduced to practice or otherwise made by Seller or any of Seller’s Affiliates or
sublicensees (and any such sublicense granted by Seller shall contain assignment provisions regarding any such improvement to enable such assignment of such improvements contemplated by this Agreement). Seller’s rights to use, sell, offer for
sale, import and export OpenBiome FMT Products shall be sublicensable through multiple tiers to its bona fide Third Party collaborators pursuant to Section 6.8(c). Seller shall have the right to sublicense the Manufacture of
OpenBiome FMT Products to Third Party contract manufacturers performing services on Seller’s behalf pursuant to Section 6.8(c). 

(c) Sublicenses. The licenses provided for in Section 6.8(b) will include the right to sublicense, through multiple tiers of
sublicenses, any or all of the licensed rights to a Sublicensee. Any sublicenses granted pursuant to the foregoing are subject to the terms and conditions of this Agreement, will be consistent with the terms of this Agreement. Seller shall use
commercially reasonable efforts to enforce the terms of such sublicenses to the extent that any failure to so enforce the terms of such sublicense would constitute a breach of this Agreement. Seller will provide Purchaser with a copy of any and all
sublicenses (including any such sublicenses granted by any Sublicensees) but excluding any sublicenses granted to a Third Party performing activities on behalf of Seller, within [***] of execution of each sublicense agreement and with a copy of any
and all amendments to any such sublicense agreements within [***] of execution of each such amendment. 
 (d) Royalty Payments. Seller
shall remain responsible for any Third Party License Fees for OpenBiome FMT Product resulting from Seller’s exercise of its rights under Section 6.8(a) and Section 6.8(b). 

(e) Elective Technology Transfer. 

(i) [***]. 
 (ii)
[***]. 
 (f) Limited License to Material from Finch Exclusive Donors. In addition to Seller’s rights under the permitted
activities set forth in Annex 6.8(f) and as set forth in this Agreement, Seller may request in writing an aliquot of stool material from a Finch Exclusive Donor (each, an “Aliquot”) to conduct an analysis of such material
related to historical activities whereby Seller used the material of such Finch Exclusive Donor prior to the date hereof (a “Follow-up Analysis”). If Purchaser agrees to provide any such Aliquot to Seller, then any such agreement
shall be set forth in a separate material transfer agreement between Seller and Purchaser. 

  
 39 

 ARTICLE VII 

CERTAIN COVENANTS 

Section 7.1. Solicitation of Non-Objection from the Massachusetts Attorney General. 

(a) Promptly, but in any event on or before the [***] after the date hereof, the Parties will submit this Agreement and the Ancillary
Agreements, other than the Subject Matter Agreement, to the Massachusetts Attorney General or her designee (the “Massachusetts AG”) to confirm that the Massachusetts AG will approve or not object to the Agreement, such Ancillary
Agreements and the transactions contemplated hereby and thereby (the “Massachusetts AG Approval”). Each Party shall use its commercially reasonable efforts to obtain prompt approval from the Massachusetts AG, including
(i) furnishing the other Party with such information and assistance as such Party may reasonably request in connection with such solicitation; (ii) complying in a timely manner with any request by the Massachusetts AG for additional
information, documents or other materials; and (iii) cooperating with the other Party in connection with resolving any questions or requests for additional information from the Massachusetts AG regarding such solicitation. Seller shall:
(A) inform Purchaser prior to delivering any material written communication to the Massachusetts AG and provide Purchaser a reasonable period of time to provide comments to Seller and consider any such comments in good faith, (B) inform
Purchaser promptly after receiving any material communication from the Massachusetts AG and (C) inform Purchaser before entering into any proposed understanding, undertaking or agreement with the Massachusetts AG. Seller shall notify Purchaser
of any scheduled meeting with the Massachusetts AG in respect of any such filings, investigation or other inquiry and, to the extent permitted by the Massachusetts AG and applicable Law, give Purchaser the opportunity to attend and participate in
such meeting. 
 (b) To the extent the Massachusetts AG requires any amendment or modification regarding the Agreement or any Ancillary
Agreement in connection with granting the Massachusetts AG Approval, the Parties agree to promptly negotiate in good faith to amend or modify the Agreement or any Ancillary Agreement to address any such issues; provided that, neither Party
shall be required to consent to any material amendment or modification to the Agreement or any Ancillary Agreement. 
 (c) The Parties agree
that, for purposes of this Agreement, the Massachusetts AG shall be deemed to have approved, and a “Massachusetts AG Approval” shall be deemed to have occurred, if the Massachusetts AG does not object to the Agreement, such Ancillary
Agreements, and the transactions contemplated hereby and thereby, or require an amendment or modification to the same, within [***] of receipt of the Agreement and such Ancillary Agreements. 

Section 7.2. Pre-Closing Actions. Subject to the terms and conditions contained herein, Seller shall, and shall cause its
Affiliates to, cooperate with Purchaser and use its commercially reasonable efforts to (a) take, or cause to be taken, all reasonable and appropriate action, and to make, or cause to be made, all filings reasonably necessary, proper or
advisable under applicable Laws, to consummate and make effective the transactions contemplated by this Agreement and (b) obtain prior to the Closing Date, all consents, approvals, authorizations, qualifications, opinions and orders of
Regulatory Authorities and other Persons as are necessary for consummation of the transactions contemplated hereby; provided, however, that no Contract shall be amended to obtain any such consent, approval or authorization, without first
obtaining the written approval of Purchaser. 

  
 40 

 Section 7.3. Purchaser’s Access and Inspection. 

(a) Seller shall, from and after the date hereof until the Closing, upon reasonable advance notice to Seller by Purchaser,
during regular business hours and subject in all cases to any quarantine or other restrictions imposed by Regulatory Authorities due to COVID-19, (i) make available for inspection by Purchaser or its Affiliates and their representatives all of
Seller’s properties, assets, books of accounts, records (including the work papers of Seller’s independent accountants), any and all data in the possession or under its control related to the Purchased Assets and any other materials
reasonably requested by them relating to the Purchased Assets or the licenses granted by Seller pursuant to Section 6.5, at such times as Purchaser may reasonably request, (ii) make available to Purchaser or its Affiliates or their
representatives the employees, officers and representatives of the Seller for interviews, at such times as Purchaser and its representatives may reasonably request, to verify and discuss information furnished to the Purchaser or its Affiliates and
their representatives and otherwise discuss the Purchased Assets or the licenses granted by Seller pursuant to Section 6.5; and (iii) authorize Seller’s lenders, creditors, lessors, lessees, licensors, licensees, employees,
developers, contractors, distributors, vendors, clients, customers, suppliers, Affiliates or other Persons having a material business relationship with Seller to respond to appropriate inquiries from Purchaser or its Affiliates regarding the
Purchased Assets or the licenses granted by Seller pursuant to Section 6.5. Any and all such inspections, interviews, and access for investigations shall be conducted during normal business hours and in a manner that does not
unreasonably interfere with the conduct of the business of Seller. 
 (b) Any information obtained by Purchaser pursuant to
this Section 7.3 shall be subject to Section 3 of the Amended and Restated Master Agreement. Effective upon, and only upon, the Closing, Purchaser’s confidentiality obligations under the Amended and Restated Master Agreement
shall terminate with respect to such information relating to the Purchased Assets obtained by Purchaser pursuant to this Section 7.3. 

Section 7.4. Notification of Certain Matters; Supplemental Schedules. 

(a) Seller shall give prompt notice to Purchaser of any of the following which occurs, or of which it becomes aware, following
the date hereof: (i) any notice of, or other communication relating to, a default or event that, with notice or lapse of time or both, is reasonably likely to become a material default under any Assumed Contract; and (ii) any notice or
other communication from any Third Party, including any Governmental Entity, alleging that the consent of such Third Party is or may be required in connection with the transactions contemplated by this Agreement, if such consent was not listed in
Schedule 4.4 on the date hereof. 

  
 41 

 (b) Seller shall deliver updated Seller’s Disclosure Schedules to the
Purchaser that shall include all disclosure necessary to make the representations and warranties of Seller set forth in this Agreement true and correct as though made as of the Closing Date. Any amendment or supplement included in any such updated
Seller’s Disclosure Schedules shall be ignored for purposes of, and shall not affect, Purchaser’s right to seek or obtain indemnification from the Seller in connection with breaches of the representations and warranties of Seller in this
Agreement unless such disclosures or exceptions relate to matters or actions specifically approved by Purchaser in writing. 

(c) If there is any amendment or supplement to the Seller’s Disclosure Schedules that adversely affects, or would
reasonably be expected to adversely affect, any Purchased Asset, then Purchaser may elect, at its sole discretion, to carve out any such equipment, Contract, Technology, systems, data, records or other asset from the Purchased Assets, and any such
asset will not be transferred to Purchaser pursuant to this Agreement. Purchaser shall provide written notice to Seller if it elects to carve out any such asset prior to the Closing, and any such asset will not be considered a “Purchased
Asset” under the Agreement. 
 (d) In the event that any updated Seller’s Disclosure Schedule that is delivered in
accordance with this Section 7.4 contains material information that has not previously been disclosed to Purchaser, Purchaser may cause the Closing to be delayed for a reasonable period of time not to exceed [***] and may request
reasonable additional diligence materials and information in Seller’s possession or control related to the information that was not previously disclosed to Purchaser and Seller shall use its reasonable best efforts to respond to any such
diligence request promptly by providing to the best of its ability the requested materials and information to Purchaser to the extent available within [***] of such request by Purchaser. Any failure to so provide such materials and information
reasonably requested in light of the new disclosure shall toll the time period referred to in the previous sentence until such materials and information are provided or Seller certifies to Purchaser in writing that no additional information is in
Seller’s possession or control. Any updated Seller’s Disclosure Schedules delivered by Seller in accordance with this Section 7.4 shall be prepared in a form and manner consistent with the Seller’s Disclosure Schedules
delivered to Purchaser on the date of this Agreement. 
 (e) Seller may continue to provide updated Seller’s Disclosure
Schedules in accordance with this Section 7.4 such that the most recently delivered Seller’s Disclosure Schedules is accurate as of the Closing Date, and with respect to any such updated Seller’s Disclosure Schedules, the
provisions of Section 7.4(b) and Section 7.4(d) shall apply again, and the Closing Date may be extended for additional periods of time in accordance therewith. 

(f) In connection with delivery of any updated Seller’s Disclosure Schedules, Seller shall simultaneously deliver to
Purchaser copies of all Contracts or other documents disclosed in the updated Seller’s Disclosure Schedules that have not been previously provided to Purchaser. 

  
 42 

 Section 7.5. Exclusive Dealing. 

(a) During the period from the date of this Agreement to the earlier of (i) the Closing Date and (ii) the date this
Agreement is terminated in accordance with Article X, Seller shall not take, and shall cause its Affiliates, officers, directors, employees, agents, representatives, consultants, financial advisors, attorneys, accountants and other agents to
refrain from taking, any action to, directly or indirectly, (A) encourage, initiate, solicit, any Person, other than Purchaser (and its Affiliates and representatives), concerning any merger, asset sale, license or similar transaction involving
Seller or its Affiliates and the Business or Purchased Assets other than sales of inventory or licenses entered into in the ordinary course of business (each, a “Transaction Proposal”) or (B) enter into, continue or otherwise
participate in any discussions or negotiations regarding, or furnish to any Person any information, or otherwise cooperate in any with, any Transaction Proposal. Without limiting the foregoing, it is agreed that any of the violation of the
restrictions set forth in the previous sentence by any representative or Affiliate of Seller shall be a breach of this Section 7.5(a) by Seller. Seller shall, and shall direct its representatives and Affiliates to, (i) immediately
cease and cause to be terminated all existing discussions or negotiations with any Person conducted heretofore with respect to any Transaction Proposal and (ii) promptly after the date hereof request the prompt return or destruction of all
confidential information previously furnished to such Person(s) for the purpose of evaluating a possible Transaction Proposal. 

(b) Seller will notify Purchaser within [***] if any Person makes any proposal, offer, inquiry to, or contact with, Seller with
respect to a Transaction Proposal and shall provide in reasonable detail the identity of any such Person and the material terms and conditions of any such Transaction Proposal (including any changes thereto) to Purchaser to the extent permitted
under any confidentiality agreements in place with such party as of the date hereof. 
 Section 7.6. Conduct of Business Pending
Closing. 
 (a) Prior to the Closing, Seller shall conduct the Business in the ordinary course of business and Seller
shall not engage in any transaction out of the ordinary course of business with respect to the Business without the written consent of Purchaser. Without limiting the foregoing, from the date of this Agreement until the Closing, Seller will: 

(i) maintain insurance for the Purchased Assets reasonably comparable to that in effect immediately prior to the date hereof or
that is otherwise consistent with businesses at a similar stage of development with a comparable risk profile; 
 (ii) comply
in all material respects with all applicable Laws and contractual obligations applicable to Seller regarding the Business and the Purchased Assets; 

(iii) continue to make all filings, pay any fee, or otherwise act to maintain the ownership, validity, and enforceability of
Contract Services IP; 
 (iv) use commercially reasonable efforts to preserve intact, in all material respects, (x) the
Business and (y) the relationships of Seller with employees and Third Parties having business relationships with Seller related to the Business; and 

  
 43 

 (v) keep the Purchaser apprised from time to time regarding material
developments at Seller regarding the Business or the Purchased Assets and consult with the Purchaser prior to making any decision or taking any action that would reasonably be expected to have strategic importance to Seller regarding the Business or
the Purchased Assets. 
 (b) Furthermore, except as is expressly permitted or required by this Agreement or consented to by
Purchaser in writing, from the date of this Agreement until the Closing, Seller will not, without the prior written consent of Purchaser, take or omit to take any of the following actions: 

(i) permit any Purchased Assets to become subject to any Encumbrance of any kind other than a Permitted Encumbrance; 

(ii) amend any provision of the certificate of incorporation or by-laws of Seller in a manner that is adverse to Purchaser or
inconsistent or otherwise has any adverse effect on the terms of this Agreement or the transactions contemplated hereby; 

(iii) enter into, materially amend, terminate or waive a material right under any Assumed Contract; 

(iv) cancel or waive any claims or rights of material value related to the Purchased Assets, 

(v) sell, lease, license, transfer, assign, distribute or otherwise dispose of any of any of the Purchased Assets other than
the sale of inventory in the ordinary course of business; 
 (vi) dispose or lapse of any rights in, or for the use of any of
the Contract Services IP; 
 (vii) cause or permit any damage, destruction or loss of any Purchased Asset; 

(viii) voluntarily incur any liability or other indebtedness which would cause Seller to become insolvent; or 

(ix) assign rights to Purchased Assets to creditors. 

(c) Nothing contained in this Agreement shall give Purchaser, directly or indirectly, the right to control or direct the
operations of Seller prior to the Closing, to the extent such right would violate any applicable Law. Prior to the Closing, Seller shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over its
operations and the Business. 
 Section 7.7. Grant of Licenses. All rights and licenses granted under or pursuant to any section
of this Agreement are for purposes of 11 U.S.C. § 365(n) or any analogous provisions in any other country or jurisdiction (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined in
Section 101(56) of the Bankruptcy Code (and any equivalent provisions 

  
 44 

 
under the bankruptcy or insolvency laws of any other relevant jurisdiction). The Parties shall retain and may fully exercise all of their respective rights and elections under the Bankruptcy
Code. The non-bankrupt Party shall further be entitled to a complete duplicate of, or complete access to, any such intellectual property and all embodiments of such intellectual property, which, if not already in its possession, shall be promptly
delivered to the non-bankrupt Party (a) upon the commencement of a bankruptcy proceeding upon the non-bankrupt Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its
obligations under this Agreement or (b) if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-bankrupt Party.

 Section 7.8. Intentionally omitted. 

Section 7.9. Termination of Contracts. 

(a) Pursuant to the terms and subject to the conditions of this Agreement, on the date hereof, the Parties hereby terminate
each of the Contracts listed on Annex 7.9(a) and any and all rights, obligations or duties created thereunder; provided that any Liabilities arising prior to the date of termination shall survive, along with any other provisions of
such Contracts that expressly survive termination (as set forth in such Contracts), unless such provisions or terms conflict with the terms or conditions of this Agreement, in which such case, the terms or conditions of this Agreement shall control;
provided further that, notwithstanding the foregoing, the Parties hereby acknowledge and agree that any and all license grants in such agreements (even if they are irrevocable and/or perpetual) shall not survive and shall be terminated in all
respects. 
 (b) Pursuant to the terms and subject to the conditions of this Agreement, at the Closing Date, the Parties
hereby terminate each of the Contracts listed on Annex 7.9(b) and any and all rights, obligations or duties created thereunder; provided that any Liabilities arising prior to the date of termination shall survive, along with any other
provisions of such Contracts that expressly survive termination (as set forth in such Contracts), unless such provisions or terms conflict with the terms or conditions of this Agreement, in which such case, the terms or conditions of this Agreement
shall control; provided further that, notwithstanding the foregoing, the Parties hereby acknowledge and agree that any and all license grants in such agreements (even if they are irrevocable and/or perpetual) shall not survive and shall be
terminated in all respects. 
 Section 7.10. [***]. 

Section 7.11. [***]. 

Section 7.12. Subject Matter Agreement. Purchaser and Seller will use commercially reasonable efforts to negotiate and finalize
the Subject Matter Agreement within [***] of the date hereof. 
 Section 7.13. Seller’s Disclosure Schedules. To the extent
Purchaser has an Initial Public Offering it will use commercially reasonable efforts to redact Seller’s Disclosure Schedules in any filing of this Agreement in compliance with the rules of any nationally recognized stock exchange. 

Section 7.14. [***]. 

  
 45 

 Section 7.15. Notice to Commissioner and Payment of Taxes. No later than [***]
before the Closing Date, Seller shall provide written notice to the Commissioner of the Massachusetts Department of Revenue (the “Commissioner”), regarding the transactions contemplated by this Agreement, in accordance with
Massachusetts General Laws, Part 1, Title IX, Chapter 62C, Section 51, in a form reasonably acceptable to Purchaser (the “Commissioner Notice”). Seller shall pay any Taxes assessed by the Commissioner, or otherwise due to
be paid to the Massachusetts Department of Revenue, in connection with such notice prior to the Closing (the “Seller Massachusetts Taxes”). 

ARTICLE VIII 
 CLOSING
CONDITIONS 
 Section 8.1. Conditions to the Obligation of each Party to Effect the Closing. The obligation of each Party to
effect the Closing is subject to the satisfaction or waiver by each Party on or prior to the Closing Date of the following conditions: 
 (a)
The Massachusetts AG shall have provided the Massachusetts AG Approval, subject to any necessary amendments or modifications to this Agreement or any Ancillary Agreement in accordance with Section 7.1(b). 

Section 8.2. Additional Conditions to Purchaser’s Obligation. The obligation of Purchaser to effect the Closing is subject to
the satisfaction or waiver on or prior to the Closing Date of the following conditions: 
 (a) The representations and warranties of Seller
set forth in this Agreement that are qualified as to materiality or that are Fundamental Representations shall be true and correct in all respects, and all other representations and warranties of Seller set forth in this Agreement that are not so
qualified or are not Fundamental Representations shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing Date with same effect as though made as of the Closing Date, except that the
accuracy of representations and warranties that by terms speak as of a specified date will be determined as of such date. 
 (b) Seller shall
have performed or complied in all material respects with each obligation, agreement and covenant to be performed or complied by it under this Agreement at or before the Closing. 

(c) Since the date hereof, there shall have been no Material Adverse Effect. 

(d) Seller shall have signed and delivered the instruments and documents set forth in Section 2.6(a). 

(e) The assignments, consents, waivers, approvals and authorizations, in form and substance reasonably satisfactory to Purchaser, relating to
those items set forth on Annex 8.2(e) have been delivered by Seller to Purchaser. 
 (f) There shall not be pending, or threatened, by
any Governmental Entity any Action (or by any other Person any Action which has a reasonable likelihood of success), (i) seeking to 

  
 46 

 
prohibit or limit in any respect, or place any conditions on, the ownership or operation by Purchaser, or its Affiliates of any material portion of the business or assets of Purchaser or its
Affiliates, or to compel Purchaser or its Affiliates to dispose of or hold separate any material portion of the business or assets of Purchaser or its Affiliates, in each case as a result of the transactions contemplated by this Agreement or
(ii) seeking to impose limitations on the ability of Purchaser or any of its Affiliates to acquire or hold, or exercise full rights of ownership of, the Purchased Assets. No order, injunction or decree that could reasonably be expected to
result, directly or indirectly, in any of the effects referred to in clauses (i) and (ii) of this Section 8.2(f) shall be in effect. 

(g) Seller shall have provided the Commissioner Notice to the Commissioner at least [***] before the Closing Date and shall have paid all
Seller Massachusetts Taxes. 
 Section 8.3. Additional Conditions to Seller’s Obligation. The obligation of Seller to
effect the Closing is subject to the satisfaction or waiver on or prior to the Closing Date of the following conditions: 
 (a) The
representations and warranties of Purchaser set forth in this Agreement that are qualified as to materiality or that are Fundamental Representations shall be true and correct in all respects, and all other representations and warranties of Purchaser
set forth in this Agreement that are not so qualified shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing Date with same effect as though made as of the Closing Date, except that
the accuracy of representations and warranties that by their respective terms speak as of a specified date will be determined as of such date. 

(b) Purchaser shall have performed or complied in all material respects with each obligation, agreement and covenant to be performed or
complied by it under this Agreement at or before the Closing. 
 (c) Purchaser shall have signed and delivered the instruments and documents
set forth in Section 2.6(b). 
 ARTICLE IX 

INDEMNIFICATION 

Section 9.1. Indemnification by Seller. 

(a) Following the Closing, Seller shall defend, indemnify and hold harmless Purchaser and its Affiliates and, if applicable, their respective
directors, officers, agents, employees, representatives, successors and assignees (a “Purchaser Indemnified Party”), from and against any and all damages, liabilities obligations, losses, Taxes, fines, penalties, fees, costs
(including costs of investigation, defense and enforcement of this Agreement), expenses or amounts paid in settlement (in each case, including reasonable attorney’s and experts’ fees and expenses) (collectively, the
“Losses”) whether or not involving a Third-Party Claim incurred by such Purchaser Indemnified Party to the extent arising from or relating to: 

  
 47 

 (i) any breach of or inaccuracy in any representation or warranty of Seller
set forth in this Agreement (ignoring for this purpose any materiality qualifiers set forth in such representation or warranty for determining (A) whether there has been a breach of or inaccuracy in any representations or warranty set forth in
this Agreement; and (B) the amount of Losses with respect to any such breach of or inaccuracy in any such representation or warranty set forth in this Agreement); 

(ii) any claim for fraud or intentional misrepresentation; 

(iii) any nonfulfillment or breach of any covenant or agreement on the part of Seller set forth in this Agreement; 

(iv) any Taxes (A) that are the responsibility of Seller, (B) attributable to a Pre-Closing Tax Period, or
(C) required to be withheld by Purchaser with respect to any payment made under this Agreement that were not withheld pursuant to Section 3.8; 

(v) any Excluded Liability or Excluded Asset; and 

(vi) any of the items listed on Exhibit E. 

(b) Monetary Limitations. 

(i) Seller will have no obligation to indemnify Purchaser Indemnified Parties pursuant to Section 9.1(a)(i) in
respect of Losses, nor shall such Losses be included in calculating the aggregate Losses pursuant to Section 9.1(b)(ii), other than Losses in excess of [***] resulting from any single claim or aggregated claims arising out of the same
facts, events or circumstances; provided, that the foregoing limitation will not apply to (a) claims for indemnification pursuant to Section 9.1(a)(i) in respect of breaches of, or inaccuracies in any Fundamental
Representation or (b) claims based upon fraud or intentional misrepresentation; 
 (ii) Seller will have no obligation
to indemnify Purchaser Indemnified Parties pursuant to Section 9.1(a)(i) in respect of Losses arising from the breach of, or inaccuracy in, any representation or warranty described therein unless and until the aggregate amount of all
such Losses incurred or suffered by Purchaser Indemnified Parties [***]; provided, that the foregoing limitations will not apply to (a) claims for indemnification pursuant to Section 9.1(a)(i) in respect of breaches of, or
inaccuracies in any Fundamental Representation or (b) claims based upon fraud or intentional misrepresentation; 
 (iii)
Seller’s aggregate liability in respect of claims for indemnification pursuant to Section 9.1(a)(i) will not exceed an aggregate amount equal to [***]; provided, that the foregoing limitations will not apply to
(a) claims for indemnification pursuant to Section 9.1(a)(i) in respect of breaches of, or inaccuracies in any Fundamental Representation or (b) claims based upon fraud or intentional misrepresentation; provided, further
that for claims for indemnification pursuant to breaches of or inaccuracies of Fundamental Representations (except with respect to claims based upon fraud) or claims for indemnification pursuant to Section 9.1(a)(iii), Seller’s
aggregate liability will not exceed amounts paid by Purchaser to Seller under this Agreement pursuant to Section 2.1(b) and Section 2.5(a). 

  
 48 

 Section 9.2. Indemnification by Purchaser. 

(a) Following the Closing, Purchaser shall defend, indemnify and hold harmless Seller and its Affiliates and, if applicable, their respective
directors, officers, agents, employees, representatives, successors and assignees (a “Seller Indemnified Party”), from and against any and all Losses, whether or not involving a Third Party Claim, incurred by such Seller Indemnified
Party to the extent arising from or relating to: 
 (i) any breach of or inaccuracy in any representation or warranty of
Purchaser set forth in this Agreement (ignoring for this purpose any materiality qualifiers set forth in such representation or warranty for determining (A) whether there has been a breach of or inaccuracy in any representations or warranty set
forth in this Agreement; and (B) the amount of Losses with respect to any such breach of or inaccuracy in any such representation or warranty set forth in this Agreement); 

(ii) any claim for fraud or intentional misrepresentation; 

(iii) any nonfulfillment or breach of any covenant or agreement on the part of Purchaser set forth in this Agreement; and 

(iv) any Assumed Liability. 

(b) Monetary Limitations. 

(i) Purchaser will have no obligation to indemnify Seller Indemnified Parties pursuant to Section 9.2(a)(i) in
respect of Losses, nor shall such Losses be included in calculating the aggregate Losses pursuant to Section 9.2(b)(ii), other than Losses in excess of [***] resulting from any single claim or aggregated claims arising out of the same
facts, events or circumstances; provided, that the foregoing limitation will not apply to (a) claims for indemnification pursuant to Section 9.2(a)(i) in respect of breaches of, or inaccuracies in any Fundamental
Representation or (b) claims based upon fraud or intentional misrepresentation; 
 (ii) Purchaser will have no
obligation to indemnify Seller Indemnified Parties pursuant to Section 9.2(a)(i) in respect of Losses arising from the breach of, or inaccuracy in, any representation or warranty described therein unless and until the aggregate amount of
all such Losses incurred or suffered by Seller Indemnified Parties exceeds [***] (at which point Purchaser will indemnify Seller Indemnified Parties for all such Losses in excess of such amount); provided, that the foregoing limitations will
not apply to (a) claims for indemnification pursuant to Section 9.2(a)(i) in respect of breaches of, or inaccuracies in any Fundamental Representation or (b) claims based upon fraud or intentional misrepresentation; 

  
 49 

 (iii) Purchaser’s aggregate liability in respect of claims for
indemnification pursuant to Section 9.2(a)(i) will not exceed an aggregate amount equal to [***]; provided, that the foregoing limitations will not apply to (a) claims for indemnification pursuant to
Section 9.2(a)(i) in respect of breaches of, or inaccuracies in any Fundamental Representation or (b) claims based upon fraud or intentional misrepresentation; provided, further that for claims for indemnification pursuant to
breaches of or inaccuracies of Fundamental Representations (except with respect to claims based upon fraud) or claims for indemnification pursuant to Section 9.2(a)(iii), Purchaser’s aggregate liability will not exceed amounts paid
by Purchaser to Seller under this Agreement pursuant to Section 2.1(b) and Section 2.5(a). 
 Section 9.3.
Time for Claims. No claim may be made or suit instituted seeking indemnification pursuant to Section 9.1(a)(i) or Section 9.2(a)(i) for any breach of, or inaccuracy in, any representation or warranty unless a written
notice is provided to the Indemnifying Party: 
 (a) at any time prior to the expiration of the applicable statute of limitations, in the
case of any breach of, or inaccuracy in a Fundamental Representation; 
 (b) at any time in the case of any claim or suit based upon fraud or
intentional misrepresentation; or 
 (c) at any time prior to the [***] anniversary of the Closing, in the case of any breach of, or
inaccuracy in, any other representation or warranty in this Agreement or in any certificate delivered pursuant to this Agreement. 

Section 9.4. Notice of Claims. If any Action (in equity or at law) is instituted by a Third Party (a “Third-Party
Claim”) with respect to which any of the Persons to be indemnified under this Article IX (the “Indemnified Party”) intends to claim any Loss under this Article IX, the Indemnified Party shall promptly notify
the Party from whom indemnification is sought (the “Indemnifying Party”) of such Third-Party Claim (the “Third-Party Claim Notice”). A failure by the Indemnified Party to give notice of any Third-Party Claim in a
timely manner pursuant to this Section 9.4 shall not limit the obligation of the Indemnifying Party under this Article IX, except to the extent such Indemnifying Party is actually materially prejudiced thereby. 

Section 9.5. Indemnification Procedures. 

(a) The Indemnifying Party under this Article IX shall have the right, but not the obligation, exercisable by written notice to the Indemnified
Party, to assume the conduct and control, at the expense of the Indemnifying Party and through counsel of its choosing that is reasonably acceptable to the Indemnified Party, any Third-Party Claim so long as (i) the Indemnifying Party gives
written notice to the Indemnified Party within [***] after the Indemnified Party has given notice of the Third-Party Claim stating that the Indemnifying Party will, and thereby covenants to, indemnify, defend and hold harmless the Indemnified Party
from and against the entirety of any and all Losses the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third-Party Claim to the extent provided in this Article IX, subject to the
limitations set forth in this Article IX, (ii) the Third-Party Claim involves only money damages and does not seek an injunction or other equitable relief against the Indemnified Party, (iii) the Indemnified Party has not been
advised by counsel that an actual or potential conflict exists between the Indemnified Party and the Indemnifying Party in 

  
 50 

 
connection with the defense of the Third-Party Claim, (iv) the Third-Party Claim does not relate to or otherwise arise in connection with any Taxes or any criminal or regulatory enforcement
Action and (v) the Indemnifying Party conducts the defense of the Third-Party Claim actively and diligently. The Indemnifying Party will not consent to the entry of any judgment or enter into any compromise or settlement with respect to the
Third-Party Claim without the prior written consent of the Indemnified Party unless such judgment, compromise or settlement (i) provides for the payment of the Indemnifying Party of money as the sole relief for the claimant, (ii) results
in the full and general release of the Indemnified Party from all liabilities arising or relating to, or in connection with, the Third-Party Claim, and (iii) involves no finding or admission of any violation of Laws or the rights of any Person
and will have no adverse effect on any other claims that may be made against the Indemnified Party. In the event the Indemnifying Party is entitled to control and conduct the defense of such Third-Party Claim pursuant to this
Section 9.5(a), the Indemnifying Party shall permit the Indemnified Party to participate in, but not control, the defense of any such Third-Party Claim through counsel chosen by the Indemnified Party; provided, that the fees and expenses
of such counsel shall be borne by the Indemnified Party. 
 (b) If the Indemnifying Party elects not to control or conduct the defense of a
Third-Party Claim or is not otherwise entitled to control or conduct such defense pursuant to Section 9.5(a), the Indemnified Party may control and conduct the defense of a Third-Party Claim and consent to the entry of any judgement or
enter into any compromise or settlement with respect to, the Third-Party Claim; provided that the Indemnifying Party will not be bound by the entry of any such judgment consented to, or any such compromise or settlement effected, without its
prior written consent (which consent may not be unreasonably withheld, conditioned or delayed). In the event that the Indemnified Party conducts the defense of the Third-Party Claim pursuant to this Section 9.5(b), (i) the
Indemnifying Party will remain responsible for any and all Losses that the Indemnified Party may incur or suffer resulting from or arising out of the Third-Party Claim to the fullest extent provided in this Article IX, subject to the
limitations set forth in this Article IX and (ii) the Indemnifying Party nevertheless shall have the right to participate in the defense of any Third-Party Claim and, at its own expense, to employ counsel of its own choosing for such
purpose. 
 (c) The Parties shall cooperate in the defense of any Third-Party Claim, with such cooperation to include (i) the retention
and the provision to the Indemnifying Party of records and information that are reasonably relevant to such Third-Party Claim and (ii) reasonable access to employees on a mutually convenient basis for providing additional information and
explanation of any material provided hereunder. 
 Section 9.6. Set-Off. In addition to all other remedies contemplated by this
Agreement, Purchaser may set off, deduct or retain any amount due to Purchaser in respect of any claim for indemnification pursuant to this Article IX against any payment due to Seller under this Agreement, including the payments set forth in
Article III; provided, for clarity, that the foregoing is not intended in any way to affect the limitations set forth in Section 9.1(b) 

Section 9.7. Exclusive Remedy. From and after the Closing, except as expressly provided herein, the sole and exclusive remedy of
any Indemnified Party for any and all claims (other than claims for fraud or intentional misrepresentation) arising under this Agreement shall be pursuant to the indemnification provisions set forth in this Article IX. Notwithstanding the
foregoing, this Section 9.7 shall not operate to limit the rights of a party to seek equitable remedies (including specific performance or injunctive relief) or, in the case of fraud or intentional misrepresentation, any remedies
available to it under applicable Law. 

  
 51 

 ARTICLE X 

TERMINATION 

Section 10.1. Termination. This Agreement may be terminated at any time prior to the Closing: 

(a) by mutual written consent of Purchaser, on one hand, and Seller, on the other hand; 

(b) by Seller or Purchaser, by giving written notice of such termination to the other Party, if any order, injunction or decree
by a Governmental Entity that has the effect of preventing the consummation of the transactions contemplated by this Agreement is in effect and has become final and nonappealable; 

(c) by Purchaser by giving written notice of such termination to Seller if (i) any of the representations and warranties
of Seller contained in this Agreement fail to be true and correct such that the condition set forth in Section 8.2(a) would not be satisfied, or (ii) Seller shall have breached or failed to comply with any of its obligations under
this Agreement such that the condition set forth in Section 8.2(b) would not be satisfied (in either case, other than as a result of a material breach by Purchaser of any of its obligations under this Agreement) and such failure or
breach with respect to any such representation, warranty or obligation cannot be cured or, if curable, shall continue unremedied for a period of [***] after Seller has received written notice from Purchaser of the occurrence of such failure or
breach (provided that in no event shall such [***] period extend beyond the Termination Date); 
 (d) by Seller by giving
written notice of such termination to Purchaser if (i) any of the representations and warranties of Purchaser contained in this Agreement fail to be true and correct such that the condition set forth in Section 8.3(a) would not be
satisfied, or (ii) Purchaser shall have breached or failed to comply with any of its obligations under this Agreement such that the condition set forth in Section 8.3(b) would not be satisfied (in either case, other than as a result
of a material breach by Seller of any of its obligations under this Agreement) and such failure or breach with respect to any such representation, warranty or obligation cannot be cured or, if curable, shall continue unremedied for a period of [***]
after Purchaser has received written notice from Seller of the occurrence of such failure or breach (provided that in no event shall such [***] period extend beyond the Termination Date); or 

(e) by either Party, by giving written notice of such termination to the other Party, if the Closing has not occurred (other
than through the failure of Seller to comply fully with its obligations under this Agreement or a breach by Seller of any obligation under this Agreement and such failure or breach has been the cause of, or resulted in, the failure

  
 52 

 
of the Closing to occur on or before such date) by March 1, 2021, or any later date agreed to by the parties in writing (such date, (the “Termination Date”); provided
that if the failure to affect the Closing by the Termination Date is due to (i) a delay in obtaining the approval or non-objection from the Massachusetts AG pursuant to Section 7.1, or (ii) a delay in obtaining any assignment,
consent, waiver, approval or authorization, set forth on Annex 8.2(e), in either case, the Termination Date shall be [***] after the satisfaction of the conditions set forth in Section 7.1 or Section 8.2(e), as
applicable. 
 Section 10.2. Effect of Termination. In the event of the termination of this Agreement in accordance with
Section 10.1 (Termination), this Agreement shall thereafter become void and have no effect, except for the obligations of the Parties contained in this Section 10.2 (Effect of Termination), Article III (Milestones and
Other Financial Obligations), Section 6.5 (Licenses Granted to Purchaser and its Affiliates), Section 7.7 (Grant of Licenses), Section 7.9(a) (Termination of Contracts),
Section 7.10 ([***]), Section 11.7 (Public Disclosure), Section 11.9 (Confidentiality; Return of Information) and Section 11.12 (Governing Law;
Jurisdiction; Venue and Service). 
 ARTICLE XI 

MISCELLANEOUS 

Section 11.1. Further Assurances and Post-Closing Covenants. From time to time after the Closing, and for no further
consideration, each of the Parties shall, and shall cause its Affiliates to, execute, acknowledge and deliver such assignments, transfers, consents, assumptions and other documents and instruments and take such other commercially reasonable actions
as may reasonably be requested to more effectively assign, convey or transfer to or vest in Purchaser the Purchased Assets and the Assumed Liabilities contemplated by this Agreement to be transferred or assumed at the Closing (including
transferring, at no additional cost to Purchaser, any Purchased Asset contemplated by this Agreement to be transferred to Purchaser at the Closing and that was not so transferred at the Closing). 

Section 11.2. Notices. All notices or other communications hereunder shall be deemed to have been duly given and made if in
writing and if served by personal delivery upon the Party for whom it is intended, delivered by registered or certified mail, return receipt requested, or by a national overnight courier service, or sent by electronic mail (with confirmation of
delivery), to the Person at the address or email address set forth below, or such other address as may be designated in writing hereafter, in accordance with this Section 11.2, by such Person: 

(a) If to Seller, to: 

Microbiome Health Research Institute, Inc. d/b/a OpenBiome 

2147 Massachusetts Ave. 

Cambridge, MA, 02140 

Email: [***] 

Attention: [***] 

  
 53 

 with a copy to: 

[***] 

(b) If to Purchaser, to: 

Finch Therapeutics, Inc. 

200 Inner Belt Road 

Somerville, MA 02143 

Email: [***] 

Attention: [***] 

with a copy to: 

[***] 
 All notices and other
communications under this Agreement shall be deemed to have been received (i) when delivered by hand, if personally delivered, (ii) three (3) Business Days after the date of mailing, if mailed by registered or certified mail, return
receipt requested and first class postage prepaid, (iii) one (1) Business Day after the date of mailing with a national overnight courier service or (iv) on the date of receipt, if sent by electronic mail prior to 5:00 p.m. (Eastern
time) on any Business Day or the next succeeding Business Day if sent after 5:00 p.m. (Eastern time) on any Business Day or on any day other than a Business Day. 

Section 11.3. Amendment; Waiver. Any provision of this Agreement may be amended or waived if, and only if, such amendment or
waiver is in writing and signed (a) in the case of an amendment, by Purchaser and Seller and (b) in the case of a waiver, by the Party against whom the waiver is to be effective. No failure or delay by any Party in exercising any right,
power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

Section 11.4. Assignment. Neither Party may assign or transfer (whether by operation of law or otherwise) this Agreement or any
rights (including any rights to payments) or obligations hereunder without the prior written consent of the other Party except that (i) Seller may make such an assignment, in whole or in part, without Purchaser’s consent to an Affiliate,
and (ii) Purchaser may make such an assignment, in whole or in part, on a Product-by-Product, country-by-country basis without Seller’s consent to an Affiliate or to a successor to substantially all of the business to which this Agreement
relates, whether in a merger, sale of stock, sale of assets, license, reorganization or other transaction. Any permitted successor or assignee of obligations hereunder will expressly assume performance of such obligations (and in any event, any
Party assigning this Agreement to an Affiliate will remain bound by the terms and conditions hereof). Any permitted assignment will be binding on and inure to the benefit of the successors of the assigning Party. Any assignment or attempted
assignment by either Party in violation of the terms of this Section 11.4 will be null, void and of no legal effect. 

Section 11.5. Entire Agreement. This Agreement, together with the Ancillary Agreements, contains the entire agreement among the
Parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral or written, with respect to such matters. 

  
 54 

 Section 11.6. No Third-Party Beneficiaries. This Agreement shall inure to the
benefit of and be binding upon the Parties and their respective successors and permitted assignees. Nothing in this Agreement, express or implied, is intended to confer upon any Person other than Purchaser, Seller or their successors or permitted
assignees, any rights or remedies under or by reason of this Agreement. For the avoidance of doubt, it is hereby acknowledged and agreed by the Parties hereto that an Indemnified Party that is not a Party hereto is intended to be a third party
beneficiary of this Agreement. 
 Section 11.7. Public Disclosure. No Party shall, and each Party shall cause its Affiliates
officers, directors, employees, advisors and other representatives not to, issue a press release or public announcement or otherwise make any public disclosure concerning the subject matter of this Agreement without the prior written approval of the
other Party; provided, however the provisions of this Section 11.7 shall not prohibit (i) any disclosure required to comply with the requirements of the rules of any nationally recognized stock exchange (in which case such Party
shall notify the other Party promptly and shall use commercially reasonable efforts to provide the other Party with a copy of the contemplated disclosure prior to submission or release, as the case may be), (ii) any disclosure required to
comply with the requirements of any court order or applicable Law (in which case such Party will notify the other Party promptly of such requirement (unless such notification would be unlawful), reasonably cooperate with the other Party in seeking a
protective order or similar relief to protect the confidentiality of the information to be disclosed (at the expense of the other Party) and limit the disclosure to what is requested by the requirement) or (iii) any disclosure made in
connection with the enforcement of any right or remedy relating to this Agreement or the transactions contemplated by this Agreement. 

Section 11.8. Publishing and Use of Trademarks. Neither Party (nor any of its Affiliates, agents or representatives) shall use the
registered or unregistered trademarks, service marks, trade dress, trade names, logos, insignia, domain names, symbols or designs of the other Party or its Affiliates in any press release, publication or other form of promotional disclosure without
the prior written consent of the other Party in each instance. 
 Section 11.9. Confidentiality. 

(a) Each of Purchaser and Seller acknowledges that the information provided to them in connection with this Agreement and the consummation of
the transactions contemplated by this Agreement is subject to Section 3 of the Amended and Restated Master Agreement; provided that effective upon the Closing, such terms shall terminate with respect to information included in or related
to the Purchased Assets and the Assumed Liabilities. 
 (b) Seller recognizes that it possesses information of a confidential or secret
nature in both written and unwritten form regarding the Purchased Assets and the Assumed Liabilities, which has unique commercial value to the Purchased Assets and the Assumed Liabilities (and which is existing as of the Closing Date) and which is
not used primarily in the ownership and operation of the Excluded Assets (hereinafter referred to as “Confidential Information”). For purposes of this Agreement, the foregoing “Confidential Information” shall not include
any 

  
 55 

 
information which (1) as of the Closing Date, is generally available to and known by the general public (other than as a result of a disclosure through the actions of Seller or any of its
Affiliates, or any of its or their employees, officers, directors, agents or representatives), (2) is independently developed by Seller after the Closing without reference to the Confidential Information or any Purchased Assets or (3) any
information used primarily in the ownership and operation of the Excluded Assets. 
 (c) Seller agrees that, following the Closing, all
Confidential Information shall be the sole property of Purchaser and its assigns. Seller will promptly disclose all Confidential Information to Purchaser upon request, and assign to Purchaser any rights which Seller may have or which Seller may
acquire in any Confidential Information. 
 (d) Subject to Section 11.9(e), Seller will, and will cause its Affiliates, and its
and their employees, officers, directors, agents and representatives to, keep in strict confidence all Confidential Information and will not use or disclose any Confidential Information or anything relating to it, in whole or in part, nor permit
others to use or disclose it in any way, without the prior written consent of Purchaser. Seller further agrees to inform Purchaser immediately in writing in the event of any breach of this obligation of confidentiality that becomes known to Seller.

 (e) Notwithstanding anything contained in this Agreement to the contrary, Seller is permitted to disclose the Confidential Information
(i) pursuant to a court order or other requirement of a judicial, administrative or governmental proceeding, or otherwise to the extent required for Seller to comply with applicable Law, provided that, in each instance, Seller (A) notifies
Purchaser of the court order or other requirement promptly after Seller becomes aware of the court order or other requirement (unless such notification would be unlawful); (B) reasonably cooperates with Purchaser in seeking a protective order
or similar relief to protect the confidentiality of the information to be disclosed (in each case at the expense of Purchaser); and (C) limits the disclosure to what is requested by the court order or other requirement, or (ii) to the
extent necessary to enforce its rights or remedies under this Agreement. 
 Section 11.10. Equitable Relief. The Parties agree
that irreparable damage would occur in the event that any of the provisions of this Agreement is not performed in accordance with its specific terms or is otherwise breached. It is accordingly agreed that each Party shall be entitled to an
injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement in any court of the United States or any state having jurisdiction, this being in addition to any other remedy to
which such Party is entitled at law or in equity. Each Party hereby waives (i) any requirement that the other Party post a bond or other security as a condition for obtaining any such relief and (ii) any defenses in any action for specific
performance, including the defense that a remedy at Law would be adequate. 
 Section 11.11. Expenses. Except for the
Seller’s Legal Fees as set forth in Section 2.1(b), whether or not the Closing takes place, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party
incurring such costs and expenses. 

  
 56 

 Section 11.12. Governing Law; Dispute Resolution. 

(a) Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, excluding any
conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

(b) Dispute Resolution. 

(i) Initial Negotiation. Any dispute arising out of or relating to the Agreement will be resolved by having individuals
authorized by each Party make a good faith effort to negotiate an amical resolution to the dispute. All negotiations pursuant to this Section 11.12 will be subject to the covenants regarding confidentiality set forth in
Section 11.9. If the initial negotiations described above do not resolve the issue, binding arbitration as provided in Section 11.12(b)(ii) will be the sole and exclusive procedure for the resolution of any such dispute. 

(ii) Invoking Arbitration and Selecting an Arbitrator. If the Parties fail to agree with respect to any dispute subject
to this Section 11.12(b) within [***] following commencement of the negotiations provided for in Section 11.12(b)(i), at the written request of either Party, the matter in dispute will be submitted for binding arbitration in
the Commonwealth of Massachusetts. One arbitrator will be mutually selected by both Parties. All expenses (legal, incidental, etc.), including the costs of the arbitrator, will be borne by the losing Party or, if both Parties prevail in part, be
apportioned by the arbitrator between the Parties. Arbitration proceedings will be governed by the Rules of the American Arbitration Association then in effect. All aspects of the arbitration shall be treated as confidential; provided that, nothing
in this Section 11.12(b) is intended to, or shall, preclude a Party to the arbitration from communicating with, or making disclosures to its lawyers, tax advisors, auditors and insurers, as necessary and appropriate or from making such
other disclosures as maybe required by any applicable Law. To the maximum extent permitted by applicable Law, the decision of the arbitrator shall be final and binding and not be subject to appeal. If a Party against whom the arbitrator renders an
award fails to abide by such award, the other party may seek to enforce such award in any court of competent jurisdiction. The final decision of the arbitrator shall be rendered within [***] of the commencement of the arbitration. 

Section 11.13. Counterparts. This Agreement may be executed in counterparts, and by the Parties hereto in separate counterparts,
each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement by e-mail of a .pdf attachment or
other electronic means shall be effective as delivery of a manually executed counterpart of this Agreement. 
 Section 11.14.
Headings. The heading references herein and the table of contents hereto are for convenience purposes only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

  
 57 

 Section 11.15. Severability. The provisions of this Agreement shall be deemed
severable and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any term or other provision of this Agreement, or the application thereof to any Person or any
circumstance, is invalid, illegal or unenforceable, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable
provision and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity, illegality or unenforceability, nor shall such invalidity, illegality or
unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction. 

Section 11.16. Force Majeure. Neither Party shall be liable to the other for failure or delay in the performance of any of its
obligations under this Agreement for the time and to the extent such failure or delay is caused by a Force Majeure. The Party affected by the Force Majeure shall provide the other Party in writing with prompt notice and a description of such Force
Majeure thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use commercially reasonable efforts to overcome the difficulties created
thereby and to resume performance of its obligations as soon as practicable. 
 Section 11.17. Payments under Clinical Supply and
Services Agreement. Purchaser acknowledges and agrees that it is not entitled to any recovery or refund of payments previously made by it pursuant to that certain Clinical Supply and Services Agreement dated February 10, 2020 between
Purchaser and Seller for any losses incurred by Purchaser directly as a result of the Clinical Hold. 
 [REMAINDER OF PAGE LEFT BLANK
INTENTIONALLY] 

  
 58 

 IN WITNESS WHEREOF, each of the undersigned have executed or caused this Agreement to be
executed as of the date first written above. 
  

			
	PURCHASER:
	
	FINCH THERAPEUTICS, INC.
		
	By:	 	 /s/ Gregory Perry

		 	Name: Gregory Perry
		 	Title: Chief Financial Officer

  
 [Signature Page to Asset
Purchase Agreement] 

 IN WITNESS WHEREOF, each of the undersigned have executed or caused this Agreement to be
executed as of the date first written above. 
  

			
	SELLER:
	
	MICROBIOME HEALTH RESEARCH INSTITUTE, INC. D/B/A OPENBIOME
		
	By:	 	 /s/ Jim Bildner

		 	Name: Jim Bildner
		 	Title: Chair of the Indpendent Special Committee

  
 [Signature Page to Asset
Purchase Agreement] 

 EXHIBIT A 

AMENDED AND RESTATED MASTER AGREEMENT 

[See attached] 

 EXHIBIT B 

FORM OF BILL OF SALE AND 

ASSIGNMENT AND ASSUMPTION AGREEMENT 

This BILL OF SALE AND ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) is made and entered into as of [__], by and between
Microbiome Health Research Institute, Inc. d/b/a OpenBiome, a Massachusetts nonprofit corporation (“Seller”) and Finch Therapeutics, Inc., a Delaware corporation (“Purchaser”). Seller and Purchaser are sometimes referred to
herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 

WHEREAS, Seller and Purchaser have entered into that certain Asset Purchase Agreement, dated as of November 19, 2020 (the
“Asset Purchase Agreement”); and 
 WHEREAS, pursuant to the Asset Purchase Agreement, Seller has agreed to sell,
convey, assign and transfer the Purchased Assets and transfer the Assumed Liabilities to Purchaser, and Purchaser has agreed to purchase, acquire and accept the Purchased Assets and assume the Assumed Liabilities from Seller. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the mutual benefits to be derived from this Agreement and of the representations, warranties, conditions, agreements and covenants contained in the Asset Purchase Agreement, this Agreement and the other Ancillary
Agreements, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows: 

 

	 	1.	 Definitions. Capitalized terms used in this Agreement and not otherwise defined herein shall have the
respective meanings ascribed thereto in the Asset Purchase Agreement. 

  

	 	2.	 Conveyance and Acceptance. In accordance with the provisions of the Asset Purchase Agreement, Seller
hereby sells, conveys, assigns and transfers to Purchaser, its successors, legal representatives, and assigns, all of Seller’s right, title and interest in and to the Purchased Assets, and Purchaser hereby purchases, acquires and accepts the
Purchased Assets, in each case, free and clear of any Encumbrances other than Permitted Encumbrances. For the avoidance of doubt, Seller does not sell, convey, assign or transfer to Purchaser, and Purchaser does not purchase, acquire or accept from
Seller, any Excluded Assets. 

  

	 	3.	 Assumption of Assumed Liabilities. Seller hereby assigns to Purchaser the Assumed Liabilities, and
Purchaser hereby assumes and agrees to pay and discharge when due the Assumed Liabilities. For the avoidance of doubt, Seller does not assign to Purchaser, and Purchaser does not assume from Seller, any Excluded Liabilities. 

	 	4.	 Asset Purchase Agreement Controls. Notwithstanding any other provision of this Agreement to the
contrary, nothing contained herein shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations or,
in general any of the rights and remedies, or any of the obligations of Purchaser or Seller set forth in the Asset Purchase Agreement. This Agreement is subject to and governed entirely in accordance with the terms and conditions of the Asset
Purchase Agreement. 

  

	 	5.	 Governing Law. The interpretation, construction and enforcement of this Agreement, and all matters
relating to it, will be governed by the laws of the State of Delaware, without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction. 

 

	 	6.	 Severability. In the event that any provision in this Agreement will be held invalid, illegal or
unenforceable, the validity, legality and enforceability of the remaining provisions hereof or thereof will not in any way be affected or impaired thereby. In the event that any provision in this Agreement would, under applicable Law, be invalid or
unenforceable in any respect, each party hereto intends that such provision will be construed by modifying or limiting it so as to be valid and enforceable to the maximum extent allowable under applicable Law. 

 

	 	7.	 Successors and Assigns. The assignments and rights pursuant hereto shall inure to the benefit of
Purchaser and its successors, assigns, and other legal representatives and is binding upon Seller and its successors, assigns, and other legal representatives. 

 

	 	8.	 Counterparts. This Agreement may be signed in counterparts, including by e-mail of a .pdf attachment or
other electronic means, each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 

*** 
 [Signature page
follows.] 

  
 2 

 IN WITNESS WHEREOF, the Parties have each caused this Agreement to be duly executed
as of the date first written above. 
  

			
	SELLER:
	
	 MICROBIOME HEALTH RESEARCH

INSTITUTE, INC. D/B/A OPENBIOME

		
	By:	 	     

		 	Name: Jim Bildner
		 	 Title: Chair of the Indpendent Special

Committee

	
	PURCHASER:
	
	FINCH THERAPEUTICS, INC.
		
	By:	 	     

		 	Name:
		 	Title:

 EXHIBIT C 

LICENSE AGREEMENT 
 [See
attached] 

 EXHIBIT D 

Services 
 [***] 

 EXHIBIT E 

EXPRESS INDEMNITIES 
 [***]

 Annex 1.1(a)(i)(A) 

STOOL DONORS 
 [***]

 Annex 1.1(a)(i)(B) 

FINCH EXCLUSIVE MALA DONORS 

[***] 

 Annex 1.1(a)(i)(C) 

FINCH PROPRIETARY METHOD 

[***] 

 Annex 1.1(a)(ii) 

CP101 TECHNOLOGY 

[***] 

 Annex 1.1(b) 

QSL LICENSED TECHNOLOGY 

[***] 

 Annex 2.1(c) 

EXCLUSIVE DONOR MATERIALS IN PURCHASER’S POSSESSION 

[***] 

 Annex 2.1(d)(i)(A) 

CAPITAL EQUIPMENT 

[***] 

 Annex 2.1(d)(i)(B) 

ASSUMED CONTRACTS 

[***] 

 Annex 2.1(d)(i)(C) 

CONTRACT SERVICES IP 

[***] 

 Annex 2.2 

EXCLUDED ASSETS 

[***] 

 Annex 5.6 

THIRD PARTY LICENSE FEES FOR NATURAL PRODUCTS 

[***] 

 Annex 6.8(e) 

ELECTIVE TECHNOLOGY TRANSFER RAW MATERIALS, CONSUMABLES AND EQUIPMENT 

[***] 

 Annex 6.8(f) 

PERMITTED ACTIVITIES 

[***] 

 Annex 7.9(a) 

TERMINATED CONTRACTS ON THE DATE HEREOF 

[***] 

 Annex 7.9(b) 

TERMINATED CONTRACTS ON THE CLOSING DATE 

[***] 

 Annex 8.2(e) 

SELLER CONSENTS 

[***]EX-10.7

 Exhibit 10.7 

Execution Version 

LMIC LICENSE AGREEMENT 
 by
and between 
 MICROBIOME HEALTH RESEARCH INSTITUTE, INC. 

and 
 FINCH THERAPEUTICS, INC.

 November 19, 2020 

 TABLE OF CONTENTS 

 

							
		
	 1.  DEFINITIONS
	  	 	3	 
		
	 2.  LICENSE GRANTS AND TECHNOLOGY TRANSFER
	  	 	10	 
			
	 2.1.
	 	License from Finch to OpenBiome	  	 	10	 
			
	 2.2.
	 	New In-Licenses	  	 	11	 
			
	 2.3.
	 	Independent and Competitive Activities	  	 	11	 
			
	 2.4.
	 	OpenBiome Sublicensees	  	 	11	 
			
	 2.5.
	 	No Implied Rights	  	 	12	 
			
	 2.6.
	 	Data Transfer	  	 	12	 
		
	 3.  PAYMENTS.
	  	 	12	 
			
	 3.1.
	 	Royalty Payments	  	 	12	 
			
	 3.2.
	 	Reports and Payments	  	 	13	 
			
	 3.3.
	 	No Deductions or Offsets	  	 	14	 
			
	 3.4.
	 	Expenses	  	 	15	 
		
	 4.  DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION
	  	 	15	 
			
	 4.1.
	 	Development	  	 	15	 
			
	 4.2.
	 	Regulatory Matters	  	 	15	 
			
	 4.3.
	 	Manufacturing	  	 	15	 
			
	 4.4.
	 	Commercialization	  	 	15	 
			
	 4.5.
	 	Activities by Others	  	 	16	 
		
	 5.  INTELLECTUAL PROPERTY
	  	 	16	 
			
	 5.1.
	 	Ownership	  	 	16	 
			
	 5.2.
	 	Prosecution of Finch Patents	  	 	16	 
			
	 5.3.
	 	Enforcement of Finch Patents	  	 	17	 
		
	 6.  CONFIDENTIALITY
	  	 	17	 
			
	 6.1.
	 	Confidentiality	  	 	17	 
			
	 6.2.
	 	Authorized Disclosure	  	 	17	 
			
	 6.3.
	 	SEC Filings and Other Disclosures	  	 	18	 
			
	 6.4.
	 	Public Announcements; Publications	  	 	19	 
		
	 7.  REPRESENTATIONS AND WARRANTIES
	  	 	20	 
			
	 7.1.
	 	Finch Representations and Warranties	  	 	20	 
			
	 7.2.
	 	Mutual Representations and Warranties	  	 	20	 
			
	 7.3.
	 	Covenants of each Party	  	 	21	 

  
 1 

							
	 7.4.
	 	Covenant of OpenBiome	  	 	21	 
			
	 7.5.
	 	Disclaimer	  	 	21	 
		
	 8.  TERM AND TERMINATION
	  	    	21   	   
			
	 8.1.
	 	Term	  	 	21	 
			
	 8.2.
	 	Termination for Convenience by OpenBiome	  	 	21	 
			
	 8.3.
	 	Termination for Default	  	 	22	 
			
	 8.4.
	 	Patent Challenge	  	 	22	 
			
	 8.5.
	 	Insolvency	  	 	22	 
			
	 8.6.
	 	Effects of Termination	  	 	22	 
		
	 9.  LIMITATION OF LIABILITY, INDEMNIFICATION AND INSURANCE
	  	    	24   	   
			
	 9.1.
	 	Limitation of Liability	  	 	24	 
			
	 9.2.
	 	Indemnification by OpenBiome	  	 	24	 
			
	 9.3.
	 	Indemnification by Finch	  	 	24	 
			
	 9.4.
	 	Procedure	  	 	24	 
			
	 9.5.
	 	Insurance	  	 	25	 
		
	 10.  MISCELLANEOUS
	  	    	25   	   
			
	 10.1.
	 	Disputes	  	 	25	 
			
	 10.2.
	 	Assignment	  	 	26	 
			
	 10.3.
	 	Further Actions	  	 	26	 
			
	 10.4.
	 	Interpretation	  	 	26	 
			
	 10.5.
	 	Notices	  	 	27	 
			
	 10.6.
	 	Amendment	  	 	27	 
			
	 10.7.
	 	Waiver and Non-Exclusion of Remedies	  	 	27	 
			
	 10.8.
	 	Severability	  	 	28	 
			
	 10.9.
	 	Descriptive Headings	  	 	28	 
			
	 10.10.
	 	Governing Law	  	 	28	 
			
	 10.11.
	 	Use of Names	  	 	28	 
			
	 10.12.
	 	Entire Agreement	  	 	28	 
			
	 10.13.
	 	Independent Contractors	  	 	28	 
			
	 10.14.
	 	Counterparts	  	 	28	 
			
	 10.15.
	 	No Third Party Rights or Obligations	  	 	29	 

 Schedules 
 Schedule
1 – LMIC Territory 

  
 2 

 LMIC LICENSE AGREEMENT 

This LMIC License Agreement (the “Agreement”) is entered into as November 19, 2020 (the “Effective
Date”), by and between Microbiome Health Research Institute, Inc. d/b/a OpenBiome, a Massachusetts nonprofit corporation, having an address of 2067 Massachusetts Ave, Cambridge, MA 02140 (“OpenBiome”), and Finch
Therapeutics, Inc., a corporation organized under the laws of Delaware, having an address of 200 Inner Belt Road, Somerville, MA 02143 (“Finch”). OpenBiome and Finch may each be referred to herein individually as a
“Party” and collectively as the “Parties.” 
 WHEREAS, the Parties are simultaneously entering into
that certain Asset Purchase Agreement pursuant to which Finch is purchasing from OpenBiome the Option (as defined in the Asset Purchase Agreement) and OpenBiome is granting certain licenses to Finch upon the terms and conditions provided therein;
and 
 WHEREAS, Finch wishes to grant to OpenBiome, and OpenBiome wishes to receive from Finch, a
non-exclusive license under the Finch Intellectual Property in the LMIC Field in the LMIC Territory in accordance with the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 
  

	1.	 DEFINITIONS 

As used in this Agreement, the following terms will have the meanings set forth below: 

1.1. “Additional Technology” has the meaning set forth in Section 2.3. 

1.2. “Affiliate” means, with respect to any Person, any other Person that directly, or indirectly through one or more
intermediaries, controls, is under common control with, or is controlled by such Party or party. For the purpose of this definition only, “control” means the actual power, either directly or indirectly through one (1) or more
intermediaries, to direct or cause the direction of the management and policies of a Person, whether by the ownership of more than fifty percent (50%) of the voting equity of such Person, by contract or otherwise. 

1.3. “Agreement” has the meaning set forth in the Preamble. 

1.4. “Amended and Restated Master Agreement” means that certain Amended and Restated Master Agreement by and between the
Parties dated as of the date hereof. 
 1.5. “Applicable Law” means collectively all laws, regulations,
ordinances, decrees, judicial and administrative orders (and any license, franchise, permit, or similar right granted under any of the foregoing), and any policies and other requirements of any applicable Governmental Authority that govern or
otherwise apply to a Party’s activities in connection with this Agreement. 

  
 3 

 1.6. “Asset Purchase Agreement” means that certain Asset Purchase Agreement
by and between the Parties dated as of the date hereof. 
 1.7. “Bankruptcy Code” means Section 101(35A)
of Title 11 of the United States Code, as amended. 
 1.8. “Business Day” means a day other than a Saturday,
Sunday or a day that is a statutory holiday in Japan or a bank or other public holiday in New York, New York, USA. 
 1.9.
“Calendar Quarter” means the respective periods of three consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided that the first Calendar Quarter of the Term
shall begin on the Effective Date and end on the first to occur of March 31, June 30, September 30 and December 31 and the last Calendar Quarter shall end on the last day of the Term. 

1.10. “Calendar Year” means any twelve (12) month period beginning on January 1 and ending on the next
subsequent December 31; provided that the first Calendar Year of the Term shall begin on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on
January 1 of the year in which the Term ends and end on the last day of the Term. 
 1.11. “Clinical
Trial” means a human clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a product is reasonably safe for continued testing, (b) investigate the safety and efficacy of a
product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with a product in the dosage range to be prescribed or (c) support or maintain Regulatory Approval of such product or label expansion
of such product. 
 1.12. “Commercialization” means any and all activities directed to the marketing, promotion,
distribution, pricing, reimbursement, offering for sale, and sale of a product and interacting with Regulatory Authorities following receipt of Regulatory Approval in the applicable country or region for such product regarding the foregoing, but
excluding activities directed to Manufacturing or Development. “Commercialize,” “Commercializing,” and “Commercialized” will be construed accordingly. 

1.13. “Confidential Information” means, with respect to each Party, all
Know-How or other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s or its Representatives’ technology, products, business
information or objectives or plans or results, that is communicated by or on behalf of the Disclosing Party to the Receiving Party or its permitted recipients before, on or after the Effective Date, including any such information that was disclosed
by a Party or any of its Affiliates under the MSAA. Confidential Information does not include any Know-How or other information that, to the extent shown by reasonable documentary evidence, (a) was
already known by the Receiving Party (other than under an obligation of confidentiality, including to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party, (b) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became generally available to the public or otherwise part of the public domain after its disclosure

  
 4 

 
to the Receiving Party, other than through any act or omission of the Receiving Party in breach of its obligations to the Disclosing Party or any of its Affiliates, including under the MSAA or
under this Agreement, (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party or any of its Affiliates not to disclose such information to the
Receiving Party or (e) was independently discovered or developed by or on behalf of the Receiving Party without use of or reference to any Confidential Information belonging to the Disclosing Party. The terms and conditions of this Agreement
will be considered Confidential Information of both Parties. 
 1.14. “Control” or
“Controlled” means, with respect to any know-how or patent, the possession, whether by ownership or (sub)license, of the right to assign, or grant a license, sublicense or other right to or
under such patent or know-how as provided for herein. 
 1.15. “Cover”
means, with respect to an OpenBiome Royalty Product and the Finch Intellectual Property, that (a) the Manufacture, use, sale, offer for sale, import, or export of the OpenBiome Royalty Product would, but for a license or a statutory exemption
such as, but not limited to, that provided by 35 U.S.C. § 271(e)(1), infringe an unexpired and Valid Claim of an issued patent within the Finch Patents that is enforceable in the country where the infringing activity has occurred; or
(b) the Development, Manufacture, use, sale or importation of the OpenBiome Royalty Product incorporates, uses or is derived from the Finch Know-How. 

1.16. “Development” means all internal and external research, development, and regulatory activities related to
products, including (a) research, non-clinical testing, toxicology, testing and studies, non-clinical and preclinical activities, and Clinical Trials, and
(b) preparation, submission, review, and development of data or information for the purpose of submission to a Regulatory Authority to obtain authorization to conduct Clinical Trials and to obtain, support, or maintain Regulatory Approval of a
product, but excluding activities directed to Manufacturing or Commercialization. Development will include development and regulatory activities for additional forms, formulations, or indications for a product after receipt of Regulatory Approval of
such product (including label expansion), including Clinical Trials initiated following receipt of Regulatory Approval or any Clinical Trial to be conducted after receipt of Regulatory Approval that was mandated by the applicable Regulatory
Authority as a condition of such Regulatory Approval with respect to an approved formulation or indication (such as post-marketing studies and observational studies, if required by any Regulatory Authority in any region in the LMIC Territory to
support or maintain Regulatory Approval for a product in such region). “Develop,” “Developing,” and “Developed” will be construed accordingly. 

1.17. “Disclosing Party” means the Party disclosing Confidential Information to the other Party. 

1.18. “Dollar” means the U.S. dollar, and “$” will be interpreted accordingly. 

1.19. “Effective Date” has the meaning set forth in the Preamble. 

1.20. “European Union” or “EU” means, with respect to any given time, all countries who
are members of the European Union as of the Effective Date; provided that, notwithstanding anything to the contrary in this Agreement, the United Kingdom will be deemed a part of the European Union for the purposes of this Agreement. 

  
 5 

 1.21. “Exploit” or
“Exploiting” means to make, have made, import, use, sell or offer for sale including to discover, research, develop, modify, enhance, improve, manufacture, have manufactured, hold or keep (whether for disposal or
otherwise) store, formulate, optimize, have used, export, transport, distribute, promote and market or have sold or otherwise dispose or offer to dispose of, a product or process. “Exploitation” means the act of Exploiting a product or
process. 
 1.22. “FDA” means the United States Food and Drug Administration or any successor agency thereto.

 1.23. “Finch” has the meaning set forth in the Preamble. 

1.24. “Finch Indemnified Party” has the meaning set forth in Section 9.1. 

1.25. “Finch Intellectual Property” means the Finch Patents and the Finch
Know-How, excluding any Technology that is the subject of a New In-License that is not an Included New In-License. 

1.26. “Finch Know-How” means all information (including regulatory data)
and other know-how owned or Controlled by Finch and its Affiliates [***], and that is not generally known and is reasonably necessary or useful for the Exploitation of Natural Products, and any improvements,
modifications or enhancements thereto. “Finch Know-How” excludes information and other know-how that is solely related to its product referred to as
“CP101” and other Lyophilized Products of Finch and its Affiliates, but that is not related to other Natural Products that are not Lyophilized Products. 

1.27. “Finch Patents” means all patent applications and issued patents (including all continuations, CIPs,
continued prosecution and divisions thereof, reissues, renewals, extensions, substitutions, reexaminations, supplementary protection certificates, pediatric exclusivity periods and the like, of any such patents and patent applications, and foreign
equivalents thereof) owned or Controlled by Finch and its Affiliates [***], that are reasonably necessary or useful for the Exploitation of Natural Products. 

1.28. “First Commercial Sale” means, with respect to any OpenBiome Royalty Product in any country or region, the
first sale of such OpenBiome Royalty Product, by or on behalf of OpenBiome (including by any of its Affiliates or Sublicensees), in an arms-length transaction to a Third Party (other than a Sublicensee) for distribution, use, or consumption in such
country or region after receipt of Regulatory Approval for such OpenBiome Royalty Product in such country or region. For the avoidance of doubt, “First Commercial Sale” excludes any transfers of OpenBiome Royalty Product to Third Parties
(a) for testing purposes, (b) at no consideration for promotional purposes, (c) for any expanded access program, (d) for any compassionate sales or use program (including named patient program or single patient program), (e) for
any indigent program; provided that, in each case of clauses (b) through (e), such OpenBiome Royalty Product is (i) provided at no charge and (ii) not sold in connection (e.g., as a bundle or another type of direct or indirect
bundling arrangement) with any other product of OpenBiome, its Affiliates or Sublicensees in which consideration is charged for such OpenBiome Royalty Product. 

  
 6 

 1.29. “Governmental Authority” means any federal, state,
national, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, or any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body). Governmental Authorities include all Regulatory Authorities. 

1.30. “Included New In-License” has the meaning set forth in
Section 2.2. 
 1.31. “IND” means (a) an Investigational New Drug Application
as defined in the United States Federal Food, Drug and Cosmetics Act, as amended, and all regulations promulgated thereunder, or (b) an analogous application, filing or submission to the analogous Regulatory Authority in a regulatory
jurisdiction outside the United States, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 

1.32. “Indemnified Party” has the meaning set forth in Section 9.3. 

1.33. “Indication” shall mean a separate and distinct disease or medical condition in humans or animals
that a product is intended to treat, prevent, diagnose, monitor or ameliorate, as set forth in the IND or label for such product, as applicable, as approved by the applicable Regulatory Authority. The Parties agree and acknowledge that [***]. 

1.34. “Know-How” means any proprietary information and materials,
including records, discoveries, improvements, modifications, processes, techniques, methods, assays, chemical or biological materials, designs, protocols, formulas, data (including physical data, chemical data, toxicology data, animal data, raw
data, clinical data, and analytical and quality control data), dosage regimens, control assays, product specifications, marketing, pricing and distribution costs, inventions, algorithms, technology, forecasts, profiles, strategies, plans, results in
any form whatsoever, know-how and trade secrets (in each case, whether or not patentable or copyrightable). 

1.35. “Liabilities” has the meaning set forth in Section 9.1. 

1.36. “LMIC Field” means the treatment in humans of (a) Malnutrition and (b) Neglected Tropical
Diseases. 
 1.37. “LMIC Territory” means the countries listed on Schedule 1 hereto. 

1.38. “Lyophilized Product” means a Natural Product wherein processed stool is lyophilized. As a non-limiting example, Finch’s CP101 is a “Lyophilized Product.” 
 1.39.
“Malnutrition” means moderate acute malnutrition, severe acute malnutrition, stunting and environmental enteric dysfunction. 

  
 7 

 1.40. “Manufacture” means any and all activities directed to manufacturing,
processing, packaging, labeling, filling, finishing, assembly, quality assurance, quality control, testing, and release, shipping, or storage of any product (or any components or process steps involving any product), placebo, or comparator agent, as
the case may be, including process development, qualification, and validation, scale-up, pre-clinical, clinical, and commercial manufacture and analytic development,
product characterization, and stability testing, but excluding activities directed to Development or Commercialization. “Manufacturing” and “Manufactured” will be construed accordingly. 

1.41. “Natural Product” means any Product manufactured directly from stool from a stool donor source without the use of
culturing or replication. As a non-limiting example, Finch’s CP101 is a “Natural Product.” 

1.42. “Natural Product Drug Substance” means a formulated liquid suspension derived from the stool of a stool donor source
that may be incorporated into a Natural Product. 
 1.43. “Neglected Tropical Diseases” means tuberculosis,
malaria, cholera, cryptosporidium, shigella, typhoid and non-typhoid salmonella and any neglected tropical disease as designated by the World Health Organization. 

1.44. “Net Sales” means [***]. 

1.45. “New In-License” means a license entered into by Finch or
its Affiliates after the Effective Date concerning Technology of a Third Party that would be reasonably useful or necessary for OpenBiome in the Exploitation of OpenBiome Licensed Natural Product, OpenBiome Licensed Drug Substance and OpenBiome
Royalty Product that may require payments to such Third Party (e.g., royalties, milestones and maintenance fees). 
 1.46.
“OpenBiome” has the meaning set forth in the Preamble. 
 1.47. “OpenBiome Licensed Drug
Substance” means any Natural Product Drug Substance manufactured by OpenBiome or its Affiliates or Sublicensees. 
 1.48.
“OpenBiome Licensed Natural Product” means any Natural Product made, sold, or distributed by OpenBiome or its Affiliates or Sublicensees. 

1.49. “OpenBiome Royalty Product” means (a) any OpenBiome Licensed Natural Product and (b) any Product made, used,
sold or distributed by OpenBiome or its Affiliates or Sublicensees that incorporates OpenBiome Licensed Drug Substance. 
 1.50.
“Option” has the meaning set forth in the Asset Purchase Agreement. 
 1.51. “Party” or
“Parties” has the meaning set forth in the Preamble. 
 1.52. “Patent Challenge” means any
direct challenge to the validity, patentability, scope, construction, inventorship, ownership, enforceability or non-infringement of any Finch Patent or otherwise opposing any Finch Patent through a legal or
administrative proceeding. 

  
 8 

 1.53. “Patents” means (a) all patents and patent
applications in any country or region, (b) all patent applications filed either from such patents or patent applications or from an application claiming priority from any of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals, and continued prosecution applications, (c) any and all patents that have issued or in the future issue from
the foregoing patent applications, and (d) any and all substitutions, renewals, registrations, confirmations, extensions, or restorations, including revalidations, reissues, and re-examinations (including
any supplementary protection certificates and the like) of the foregoing patents or patent applications. 
 1.54.
“Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated
association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government. 

1.55. “Product” means any product developed or made from an isolated set of bacterial strains or a natural composition of
bacterial strains. 
 1.56. “Prosecution” means the preparation, filing, prosecution, protection, defense, issuance and
maintenance of all Patents, including oppositions, inter partes reviews, interferences, declaratory judgment actions, post-grant reviews and similar proceedings before any patent office or court of competent jurisdiction (or appeals therefrom). 

1.57. “Receiving Party” means the Party receiving Confidential Information of the other Party. 

1.58. “Regulatory Approval” means all approvals necessary for the Manufacture, marketing, importation and sale
of a Product for one or more Indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, including (where required for sale) any pricing and reimbursement approvals.
Regulatory Approvals include approvals by Regulatory Authorities of INDs. 
 1.59. “Regulatory Authority”
shall mean the FDA, the Federal Trade Commission, the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services or any other federal, state, local or foreign Governmental Authority that is concerned with or
regulates the Development, testing, packaging, labeling, storage, sale, quality, safety, efficacy, reliability or Manufacturing and servicing of medical devices, federal or state health care programs, or the provision of health care or similar
services. 
 1.60. “Regulatory Filings and Approvals” means, with respect to any OpenBiome Royalty Product in
any jurisdiction, any and all regulatory applications, filings, approvals, and associated correspondence reasonably required to Develop, Manufacture, market, sell, import, otherwise Commercialize, and exploit such OpenBiome Royalty Product in, or
into, any jurisdiction, including, for clarity, all Regulatory Approvals necessary for the sale of such OpenBiome Royalty Product in a given jurisdiction in accordance with all Applicable Laws. 

1.61. “Representatives” means (a) with respect to OpenBiome, OpenBiome, its Affiliates, its Sublicensees
and each of their respective officers, directors, employees, consultants, contractors and agents and (b) with respect to Finch, its Affiliates and each of their respective officers, directors, employees, consultants, contractors and agents.

  
 9 

 1.62. “Review Period” has the meaning set forth in
Section 6.4.2. 
 1.63. “Royalty Payments” has the meaning set forth in
Section 3.1.1. 
 1.64. “Royalty Term” means, with respect to a OpenBiome Royalty Product within a
country in the LMIC Territory, the period beginning on the First Commercial Sale of such OpenBiome Royalty Product in such country and ending on the later of (a) the expiration of the last to expire Valid Claim from a Patent within the Finch
Intellectual Property that Covers such OpenBiome Royalty Product; or (b) ten (10) years from the Effective Date. 
 1.65.
“Sublicensee” means any Person other than an Affiliate of OpenBiome to whom OpenBiome grants or has granted, directly or indirectly (e.g. a sublicensee of a sublicensee of OpenBiome), a permitted sublicense of
rights licensed by Finch to OpenBiome under this Agreement, [***]. 
 1.66. “Technology” means all
patents, patent applications, trade secrets, copyrights, know-how, methods, processes, techniques, data, technical documentation, manuals, regulatory submissions, specifications, SOPs, instructions, and other
intellectual property of any kind (whether or not protected or protectable under patent, trademark, copyright or similar laws). 
 1.67.
“Term” has the meaning set forth in Section 8.1. 
 1.68. “Third
Party” means any Person other than OpenBiome, Finch or their respective Affiliates. 
 1.69. “Third Party License
Fees” means any payments or fees (including royalties, milestones and maintenance fees) owed by Finch to Third Parties as a result of the practice of intellectual property licensed from such Third Parties in the Exploitation of Natural
Products. For the avoidance of doubt, the Third Party License Fees include any royalties, milestones and other payments due by Finch to the Regents of the University of Minnesota under the UMN Agreement. 

1.70. “UMN Agreement” means that certain Exclusive License Agreement between Finch and the Regents of the
University of Minnesota, dated March 26, 2012, as amended. 
 1.71. “Valid Claim” means a claim of any issued,
unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time
allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 
  

	2.	 LICENSE GRANTS AND TECHNOLOGY TRANSFER 

2.1. License from Finch to OpenBiome. 

2.1.1. Non-Exclusive License to OpenBiome. Subject to the terms and
conditions of this Agreement, Finch hereby grants to OpenBiome an irrevocable (subject to Article 8), perpetual (subject to Article 8), royalty-bearing, non-exclusive, sublicensable (through
multiple tiers) license during the Term under the Finch Intellectual Property to 

  
 10 

 
make, use, sell, have sold, offer for sale and import (a) OpenBiome Natural Licensed Products and (b) OpenBiome Licensed Drug Substance, in each case, (a) and (b), for Exploiting
OpenBiome Royalty Products in the LMIC Field in the LMIC Territory; provided that, the foregoing license grant shall not include a license under the Finch Intellectual Property to Exploit a Lyophilized Product, or to otherwise use the Finch
Intellectual Property to lyophilize a product (including an OpenBiome Royalty Product). 
 2.1.2. Additional
Indications. During the Term, OpenBiome may request that the definition of the LMIC Field be amended to include additional Indications and Finch shall consider such request(s) in good faith; provided that, Finch shall have no obligation
to amend the LMIC Field to include such additional Indications. 
 2.2. New In-Licenses.
[***]. 
 2.3. Independent and Competitive Activities. The Parties acknowledge that, notwithstanding anything in this Agreement
to the contrary (including the license grant in Section 2.1.1), OpenBiome may independently develop its own Technology and/or Exploit a Third Party’s Technology for use with OpenBiome Licensed Natural Products or
OpenBiome Licensed Drug Substance, including for processing, lyophilizing and/or encapsulating OpenBiome Licensed Drug Substance (“Additional Technology”), provided that, for clarity, such activities shall not be within the
scope of the license grant of Section 2.1.1, and that OpenBiome may not utilize the Finch Intellectual Property or any Confidential Information of Finch in connection with such development or Exploitation of Additional
Technology. 
 2.4. OpenBiome Sublicensees. OpenBiome may grant sublicenses (through multiple tiers) of the rights granted under
Section 2.1, in whole or in part, to any of its Affiliates and Third Parties, provided that: 

2.4.1. no such sublicense shall diminish OpenBiome’s duties or obligations under the Agreement, and OpenBiome shall remain
liable and responsible for such duties and obligations; 
 2.4.2. any act or omission of a Sublicensee (at any tier) which
would be a breach of this Agreement if performed by OpenBiome shall be deemed a breach by OpenBiome of this Agreement; 

2.4.3. OpenBiome shall provide Finch with fully executed copies of all sublicense agreements (at all tiers) and any amendments
or other modifications thereto (which OpenBiome may redact as reasonably necessary to protect confidential or highly sensitive information) promptly upon execution of such sublicense, amendment, or other modification (as applicable); 

2.4.4. (a) each sublicense shall be consistent with the terms of this Agreement (including confidentiality, non-disclosure, and non-use provisions at least as restrictive or protective of the Parties as those set forth in this Agreement), (b) each Sublicensee shall undertake, in the
applicable sublicense, to perform its obligations under the sublicense in a manner consistent with the terms of this Agreement, (c) each sublicense shall include a 

  
 11 

 
section requiring Sublicensee to indemnify, defend and hold the Finch Indemnified Parties harmless in accordance with the same terms set forth in Section 9.2, except
that such indemnification shall relate to activities and omissions of such Sublicensee, its Affiliates or Sublicensees rather than those of OpenBiome and (d) each sublicense shall include a provision stating that Finch is a third-party
beneficiary under each such sublicense for purposes of enforcing the rights and obligations granted under each such sublicense; and 

2.4.5. each sublicense shall terminate automatically effective as of the earlier of (a) termination of this Agreement or
(b) the termination of the applicable sublicense agreement. 
 2.5. No Implied Rights. Except as expressly provided in this
Agreement or in the Asset Purchase Agreement, neither Party will be deemed to have granted the other Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Patents, Know-How or other intellectual property rights or information owned or controlled by such Party. 
 2.6.
Data Transfer. Finch will use reasonable efforts to provide to OpenBiome the information included in the Finch Know-How within [***] following the Effective Date and solely to the extent
such Finch Know-How is in Finch’s possession as of the Effective Date; provided, however, that such information will not include (a) any documents protected by attorney-client privilege
or that constitute attorney work-product; (b) any financial, accounting or tax records of Finch or its Affiliates; or (c) any clinical data of Finch or its Affiliates. During the Term and thereafter, OpenBiome shall preserve and maintain
any Finch Know-How it receives from Finch in the form provided to OpenBiome, and OpenBiome shall not destroy, discard or modify such Finch Know-How without the prior
written consent of Finch. 
  

	3.	 PAYMENTS. 

3.1. Royalty Payments. 

3.1.1. Royalties. Subject to the provisions of Section 3.1.2, OpenBiome will make royalty
payments to Finch for any OpenBiome Royalty Products sold by or on behalf of OpenBiome, its Affiliates or Sublicensees in the LMIC Territory during the applicable Royalty Term, calculated by multiplying the applicable royalty rate set forth below in
Table 3.1.1 by the aggregate amount of Net Sales of OpenBiome Royalty Products sold in the LMIC Territory (the royalty payments due with respect to Net Sales of OpenBiome Royalty Products pursuant to this
Section 3.1.1, the “Royalty Payments”). 
 Table 3.1.1 – Royalty Payments 

 

			
	 Aggregate Annual Net Sales of all

OpenBiome Royalty Products in the LMIC Territory
	  	Royalty Rate
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 12 

 3.1.2. Valid Claims. With respect to an OpenBiome Royalty Product in
a country in the LMIC Territory, upon the expiration of the last-to-expire Valid Claim within the Finch Patents Covering such OpenBiome Royalty Product in such country,
the royalty rate for such OpenBiome Royalty Product in such country shall be reduced to [***] for the remainder of the Royalty Term in such country. 

3.1.3. Third Party Royalties. If OpenBiome determines in its reasonable discretion that OpenBiome is required to pay a
royalty to a Third Party to obtain rights under patents owned or controlled by such Third Party that are necessary for OpenBiome’s exercise of its rights under the Finch Intellectual Property hereunder in the LMIC Field in the LMIC Territory,
then OpenBiome shall have the right to deduct up to [***] of the amount of the royalty due to such Third Party thereunder with respect to OpenBiome Royalty Products, against the royalties that are due from OpenBiome to Finch hereunder. 

3.1.4. Royalty Floor. Notwithstanding anything in this Section 3.1 to the contrary and subject
to the representation set forth in Section 7.1, in no event will the Royalty Payments payable to Finch pursuant to this Section 3.1 be less than [***]. 

3.2. Reports and Payments. 

3.2.1. Royalty Statements and Payments. Within [***] after the conclusion of each Calendar Quarter, commencing with the
first Calendar Quarter in which Net Sales are generated in the LMIC Territory, OpenBiome will deliver to Finch a report setting forth the following information: [***]. Concurrent with the delivery of each royalty report, OpenBiome will pay the
amount of the Royalty Payments set forth in such royalty report to Finch in Dollars. 
 3.2.2. Taxes and Withholding.
All amounts to be paid to Finch pursuant to this Agreement shall be without deduction of exchange, collection or other charges, and, specifically, without deduction of withholding or similar taxes or other government imposed fees or taxes, except as
permitted in the definition of Net Sales.. Finch shall reasonably assist OpenBiome in claiming reduction or exemption from such deductions or withholdings, or returns of such deductions or withholdings, by providing OpenBiome with relevant
information, documentation and support as reasonably requested by OpenBiome in preparation of any such filing for tax reduction, exemption or returns. 

3.2.3. Currency; Exchange Rate. All payments to be made by OpenBiome to Finch under this Agreement will be made in
Dollars by electronic funds transfer in immediately available funds to a bank account designated in writing by Finch. Conversion of Net Sales recorded in local currencies will be converted to Dollars at the exchange rate set forth in [***] in which
the applicable payment obligation became due and payable. 
 3.2.4. Late Payments. Any payments or portions thereof
due hereunder that are not paid on the date such payments are due under this Agreement (and are not being disputed in good faith under this Agreement) will bear interest at a rate equal to the lesser

  
 13 

 
of: (a) [***]; or (b) the maximum rate permitted by Applicable Law; in each case, calculated on the number of days such payment is delinquent, [***]. Payment of such interest by OpenBiome
shall not limit, in any way, Finch’s right to exercise any other remedies Finch may have as a consequence of any payment due but unpaid hereunder.  

3.2.5. Financial Records and Audits. 

(a) OpenBiome will maintain, and will cause its Affiliates and Sublicensees to maintain, complete and accurate records in
sufficient detail to permit Finch to confirm the accuracy of the amount of Royalty Payments and other amounts payable under this Agreement. OpenBiome will maintain, and will cause its Affiliates and its Sublicensees to maintain, such records for
[***]. 
 (b) At Finch’s request, OpenBiome will permit an independent certified public accounting firm of nationally
recognized standing (such firm to be mutually agreed upon by the Parties in good faith), to examine, at Finch’s sole expense and upon at least [***] prior written notice, the relevant books and records of OpenBiome, its Affiliates and
its Sublicensees as may be reasonably necessary to verify the amounts reported by OpenBiome in accordance with Section 3.2.1 and all other amounts payable under this Agreement. An examination by Finch under this
Section 3.2.5(b) will be subject to standard confidentiality obligations, will occur not more than once in any Calendar Year, and will be limited to the pertinent books and records for any Calendar Year ending not more than
[***] before the date of the request. The accounting firm will be provided access to such books and records at OpenBiome’s, its Affiliates’ or its Sublicensees’ facility(ies) where such books and records are normally kept and such
examination will be conducted during OpenBiome’s or its applicable Affiliate’s or Sublicensee’s normal business hours and without undue business interruption to OpenBiome, its Affiliates or its Sublicensees. OpenBiome or any of its
Affiliates or Sublicensees may require such accounting firm to enter into a reasonable confidentiality agreement with it prior to the start of any such examination. [***]. 

(c) If such accounting firm concludes that additional amounts were due to Finch, then OpenBiome will pay to Finch such
additional amounts within [***] of the date OpenBiome receives such accountant’s written report. If such accounting firm concludes that OpenBiome made payments to Finch under this Agreement in excess of the amounts due under this
Agreement, then Finch will refund such overpayments to OpenBiome, within [***] of the date Finch receives such accountant’s report. 

3.3. No Deductions or Offsets. Except as otherwise expressly set forth herein or provided for by law, there shall be no deduction
or offset from, any payments owed to Finch under or in connection with this Agreement for any reason (whether or not there is a dispute regarding payment or other rights or obligations under this Agreement). 

  
 14 

 3.4. Expenses. Except as otherwise expressly set forth in this Agreement or as
otherwise agreed to by the Parties in writing, each Party will be responsible for all expenses that it incurs in connection with the performance of this Agreement. 
  

	4.	 DEVELOPMENT, MANUFACTURE AND COMMERCIALIZATION. 

4.1. Development. 

4.1.1. General Responsibilities; Efforts. OpenBiome will have sole responsibility to Develop (and Manufacture for
Development) and seek Regulatory Approval for OpenBiome Royalty Products in the LMIC Field in the LMIC Territory, and will bear all costs associated with such activities. 

4.2. Regulatory Matters. 

4.2.1. Regulatory Reporting. OpenBiome or its designated Affiliate(s) will be responsible for making and filing all
filings, reports and communications with all Regulatory Authorities with respect to any OpenBiome Royalty Products in the LMIC Field in the LMIC Territory, including all reports required to be filed in order to obtain or maintain any Regulatory
Approvals granted for OpenBiome Royalty Products in the LMIC Field in the LMIC Territory. 
 4.2.2. Regulatory
Approvals. OpenBiome or its designated Affiliate(s) will be responsible for preparing and filing applications, in its own name, for Regulatory Approval for OpenBiome Royalty Products in the LMIC Field in the LMIC Territory, including
communicating with any Regulatory Authority both prior to and following Regulatory Approval. 
 4.2.3. Pharmacovigilance
and Safety. Finch shall have no pharmacovigilance obligations with respect to OpenBiome Royalty Products. OpenBiome shall assume all pharmacovigilance activities and obligations for the OpenBiome Royalty Products immediately following the
Effective Date. 
 4.3. Manufacturing. OpenBiome will have sole responsibility for all Manufacturing activities and associated costs
and expenses for the Manufacture of all OpenBiome Royalty Products. 
 4.4. Commercialization. 

4.4.1. General Responsibilities; Efforts. OpenBiome will have sole responsibility for the Commercialization of OpenBiome
Royalty Products in the LMIC Field in the LMIC Territory, and will bear all costs associated with such activities. 
 4.4.2.
Commercialization Reports. On an OpenBiome Royalty Product-by-OpenBiome Royalty Product basis, following the First Commercial Sale of an OpenBiome Royalty Product
in the LMIC Territory, within the first Calendar Quarter of each Calendar Year thereafter, OpenBiome shall provide to Finch a report summarizing the Commercialization activities performed with respect to such OpenBiome Royalty Product

  
 15 

 
during the prior Calendar Year, including description of the sales activities in process, and the planned future sales activities expected to be initiated during the then-current Calendar Year,
in each case by or on behalf of OpenBiome, its Affiliates and Sublicensees. Such reports constitute OpenBiome’s Confidential Information. 

4.5. Activities by Others. Activities conducted by OpenBiome’s Representatives will be considered as OpenBiome’s activities
under this Agreement for purposes of determining whether OpenBiome has complied with its obligations under Sections 4.1.1 and 4.4.1. Any act or omission by a Representative of OpenBiome in the conduct of activities under this Agreement
on behalf of OpenBiome that would be a breach of this Agreement if OpenBiome performed such act or omission will be considered a breach by OpenBiome of this Agreement. 
  

	5.	 INTELLECTUAL PROPERTY. 

5.1. Ownership. 

5.1.1. Subject to OpenBiome’s rights under Section 2.1, as between the Parties, Finch shall own and retain all right,
title, and interest in and to any and all Finch Intellectual Property, and any improvements, enhancements or modifications thereto (whether or not patentable), invented, developed or first reduced to practice solely by a Party or jointly by the
Parties during the Term. In the event that any such improvements, enhancements or modifications to the Finch Intellectual Property are invented, developed or first reduced to practice by OpenBiome during the Term, OpenBiome shall promptly assign to
Finch all right, title and interest in and to any such improvements, enhancements or modifications, provided that such improvements, enhancements and modifications shall be included in the Finch Intellectual Property licensed to OpenBiome
pursuant to Section 2.1.1. Except as otherwise set forth in the foregoing, including as set forth in Section 2.3, OpenBiome shall own and retain all right, title and interest in and to any Technology developed or
acquired by OpenBiome during the Term, and Finch shall have no right, title, license or interest in or under such Technology. 

5.1.2. Any clinical data or study results generated by or on behalf of OpenBiome, its Affiliates or Sublicensees through the
Exploitation of OpenBiome Royalty Products in the LMIC Field and in the LMIC Territory, including any and all patient, safety and efficacy data and all data generated in pre-clinical and Clinical Trials, shall
be owned by OpenBiome. 
 5.2. Prosecution of Finch Patents. 

5.2.1. Prosecution. As between the Parties, Finch shall have the sole right, in its sole discretion, to control the
Prosecution of the Finch Patents. 
 5.2.2. Marking. OpenBiome shall, and shall cause its Affiliates and Sublicensees
to, mark all OpenBiome Royalty Products sold or otherwise disposed of in such a manner as to conform with the patent laws and practice of the country to which such OpenBiome Royalty Products are shipped or in which such OpenBiome Royalty Products
are sold for purposes of ensuring maximum enforceability of the Finch Patents in such country. 

  
 16 

 5.3. Enforcement of Finch Patents. 

5.3.1. Notification. As between the Parties, and subject to any confidentiality obligations of OpenBiome owed to any
Third Party, OpenBiome shall inform Finch promptly in writing of any alleged infringement of the Finch Patents in the LMIC Field in the LMIC Territory of which OpenBiome becomes aware, along with any available evidence thereof. 

5.3.2. Enforcement Right. As between the parties, Finch (or a Third Party licensee or other Person, Finch’s
discretion) shall have the sole right to institute infringement suits under the Finch Patents both inside and outside of the LMIC Field and inside and outside of the LMIC Territory, as well as the sole right to institute all other infringement suits
and to take such other actions as not expressly granted to OpenBiome hereunder (including, for the avoidance of doubt, to enforce and defend the Finch Patents). The total cost of any such infringement actions commenced or defended solely by Finch
shall be borne by Finch, and Finch shall keep any recovery or damages derived therefrom, whether compensatory for past infringement or punitive. 

5.3.3. Cooperation. In any infringement suit which Finch may institute to enforce the Finch Patents under this
Agreement, OpenBiome shall reasonably cooperate in all respects, at Finch’s expense (including the cost and expense of counsel) when reasonably requested by Finch, including having its employees testify when requested, making available relevant
records, papers, information, samples, specimens and the like, but only to the extent necessary for such enforcement action. 
  

	6.	 CONFIDENTIALITY. 

6.1. Confidentiality. The confidentiality terms set forth in the Amended and Restated Master Agreement shall govern the information
provided in connection with this Agreement and the consummation of the transactions contemplated by this Agreement. 
 6.2. Authorized
Disclosure. Notwithstanding the foregoing provisions of Section 6.1: 
 6.2.1. OpenBiome may
disclose Confidential Information belonging to Finch or any of its Affiliates to the extent such disclosure is necessary (a) to Governmental Authorities to obtain or maintain INDs or Regulatory Approvals for any OpenBiome Royalty Product within
the LMIC Territory or (b) to file, prosecute and maintain patents and patent applications in relation to OpenBiome Royalty Products; 

6.2.2. each Party may disclose Confidential Information belonging to the other Party or any of its Affiliates to the extent
such disclosure is necessary in connection with litigation directly related to an OpenBiome Royalty Product in the LMIC Field; 

6.2.3. each Party may disclose Confidential Information belonging to the other Party or its Affiliates to the extent such
disclosure is necessary in responding to a valid order of a court of competent jurisdiction or other competent governmental authority; provided that if practicable, the Receiving Party will first have given to the Disclosing Party notice and
a reasonable opportunity to quash the order or obtain a protective order 

  
 17 

 
requiring that the Confidential Information be held in confidence or used only for the purpose for which the order was issued; and provided further that if such order is not quashed or a
protective order is not obtained, the Confidential Information disclosed will be limited to the information that is legally required to be disclosed; 

6.2.4. each Party may, on a need-to-know basis,
disclose Confidential Information belonging to the other Party (including the terms of the Agreement) to any Affiliate, Sublicensee, potential Sublicensee, or acquirer, buyer or potential acquirer or buyer of such Disclosing Party’s business
that concerns this Agreement (whether by sale of stock or assets, merger, consolidation or otherwise), in each case, who has agreed in writing to non-disclosure and
non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Article 6 and provided that the Party disclosing Confidential
Information belonging to the other Party pursuant to this Section shall be responsible and liable for any breaches of confidentiality by the third party to whom it discloses such Confidential Information; 

6.2.5. each Party may disclose Confidential Information belonging to the other Party to the extent such disclosure is necessary
in order to comply with Applicable Law (including regulations promulgated by securities exchanges); provided that if practicable, the Receiving Party will first have given to the Disclosing Party notice and a reasonable opportunity to obtain
a protective order requiring that the Confidential Information be held in confidence or used only for the purpose set forth in the Applicable Law; and provided further that if such protective order is not obtained, the Confidential
Information disclosed will be limited to the information that is legally required to be disclosed; and 
 6.2.6. each Party
may disclose to its Affiliates and Third Parties a redacted copy of this Agreement, only on a need-to-know basis and solely in connection with the performance by such
Party of its obligations or the exercise of its rights under this Agreement or as evidence of its rights under this Agreement, provided that each disclosee, prior to any such disclosure, must be bound by obligations of confidentiality and non-use at least as protective as those set forth in this Article 6. 
 6.2.7.
Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to Sections 6.2.1, 6.2.2, 6.2.3, 6.2.5, or 6.3, it
will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use reasonable efforts to secure confidential treatment of such information at least as diligently as such Party would use to protect its own
confidential information. In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder, except as permitted under this Agreement. Any information disclosed under this
Section 6.2 shall still be deemed Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of Article 6. 

6.3. SEC Filings and Other Disclosures. Either Party may make a public written disclosure regarding the existence of, or performance
under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) Applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange

  
 18 

 
Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in any country in the LMIC Territory. Before disclosing this Agreement or any of the
terms hereof pursuant to this Section 6.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advance notice as
is feasible under the circumstances, and giving consideration to and using commercially reasonable and good faith efforts to implement the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in
accordance with this Section 6.3, such Party will, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party and
limit its disclosure of such Confidential Information to only that required to comply with Applicable Law. 
 6.4. Public Announcements;
Publications. 
 6.4.1. Announcements. Neither Party will make any public announcement regarding this Agreement
without the prior written approval of the other Party. OpenBiome may release an announcement regarding the signing of this Agreement following the Effective Date upon obtaining the prior written approval of Finch, which it shall not unreasonably
withhold, condition or delay; provided, however, that OpenBiome shall not disclose in such announcement any payment obligations of either Party that are set forth in Article 3. The Parties shall work together diligently and in
good faith to agree upon an announcement so that OpenBiome may release it without undue delay following the Effective Date. 

6.4.2. Publications. During the Term and subject to the terms of this Agreement, OpenBiome may make scientific
publications and presentations to scientific conferences concerning its Development and Commercialization activities with respect to any OpenBiome Royalty Product in the LMIC Field, and in connection with which OpenBiome shall acknowledge that such
OpenBiome Royalty Product was licensed from Finch. Written copies of such proposed publications and presentations will be submitted by OpenBiome to Finch no later than [***] before submission for publication or presentation (the “Review
Period”). At Finch’s option, Finch may provide its comments with respect to such publications and presentations, provided that such comments are provided within [***] of its receipt of such written copy, and OpenBiome shall
consider any such comments in good faith but, in any event, will comply with any request from Finch to delete Finch’s Confidential Information in any such publication or presentation. If Finch does not provide its comments with respect to a
publication or presentation within the [***] period, then Finch shall be deemed to have consented to such publication or presentation. If a public securities filing has been made in accordance with Section 6.3, or a press
release or other public statement has been issued or made in accordance with Section 6.4, in relation to the OpenBiome Royalty Product, then either Party shall have the right to restate any publicized information contained
in the public securities filing or press release or other public statement, without the prior written consent of the other Party. 

  
 19 

	7.	 REPRESENTATIONS AND WARRANTIES. 

7.1. Finch Representations and Warranties. Finch represents and warrants to OpenBiome as of the Effective Date that: 

7.1.1. the Third Party License Fees owed by Finch under the license contemplated herein do not exceed the amounts set forth in
Table 3.1.1; 
 7.1.2. Finch has sufficient title and ownership or other rights to the Finch Intellectual Property as is
necessary to grant the license to OpenBiome pursuant to this Agreement; 
 7.1.3. Finch has not entered into any agreement
with any Third Party or Affiliate that conflicts with the rights granted to OpenBiome under this Agreement, and has not taken any action that would prevent it from granting the rights granted to OpenBiome under this Agreement; and 

7.1.4. No Third Party has made any claim or allegation to Finch or its Affiliates in writing that a Third Party has any right
or interest in or to Finch Patents that are owned by Finch or a Finch Affiliate. 
 7.2. Mutual Representations and Warranties. Each
of Finch and OpenBiome hereby represents and warrants to the other Party as of the Effective Date that: 
 7.2.1. it is duly
organized, validly existing and in good standing under the laws of the jurisdiction of its organization; 
 7.2.2. the
execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any
of its shareholders or other holders of its voting securities or voting interests; 
 7.2.3. it has the power and authority
to execute and deliver this Agreement and to perform its obligations hereunder; 
 7.2.4. this Agreement has been duly
executed and is a legal, valid and binding obligation on such Party, enforceable against such Party in accordance with its terms; 

7.2.5. the execution, delivery and performance by such Party of this Agreement and its compliance with the terms and provisions
hereof does not and will not conflict with or result in a breach of or default under any contractual or other obligation of such Party existing as of the Effective Date; and 

7.2.6. other than the consent of the Massachusetts Attorney General, no consent by any Third Party or Governmental Authority is
required with respect to the execution and delivery of this Agreement by it or the consummation by it of the transactions contemplated hereby. 

  
 20 

 7.3. Covenants of each Party. Each Party hereby covenants to the other Party that,
during the Term: 
 7.3.1. it will perform its obligations under this Agreement in compliance with Applicable Laws; 

7.3.2. it will not be debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act or comparable laws in any
country or jurisdiction other than the U.S. and, to its knowledge, does not, and will not during the Term knowingly, employ or use, directly or indirectly, including through Affiliates or Sublicensees, the services of any person who is debarred or
disqualified, in connection with activities directly relating to any OpenBiome Royalty Product. In the event that OpenBiome becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing
services to OpenBiome, directly or indirectly, including through Affiliates or Sublicensees, which directly relate to activities contemplated by this Agreement, OpenBiome shall promptly notify Finch in writing and OpenBiome shall cease employing,
contracting with, or retaining any such person to perform any such services; 
 7.4. Covenant of OpenBiome. OpenBiome hereby covenants
to Finch that, during the Term, OpenBiome shall not, and shall prohibit its Affiliates and Sublicensees from, in connection with the performance of their obligations under this Agreement, directly or indirectly through Third Parties, paying,
promising or offering to pay, or authorizing the payment of, any money or giving any promise or offering to give, or authorizing the giving of anything of value to, in each case, a public official or entity or other person for purpose of obtaining
or retaining business for or with, or directing business to, any Person, including either Party, in violation of Applicable Law. 
 7.5.
Disclaimer. ALL TECHNOLOGY AND MATERIALS, INCLUDING ALL FINCH INTELLECTUAL PROPERTY, AND INTELLECTUAL PROPERTY RIGHTS, PROVIDED BY FINCH HEREUNDER ARE PROVIDED “AS IS” AND, EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY PATENTS OR KNOW-HOW, FINCH INTELLECTUAL PROPERTY, OR OPENBIOME ROYALTY PRODUCTS,
INCLUDING WARRANTIES OF VALIDITY OR ENFORCEABILITY OF ANY PATENTS, TITLE, QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR USE OR PURPOSE, PERFORMANCE, AND NONINFRINGEMENT OF ANY THIRD PARTY PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS. 

 

	8.	 TERM AND TERMINATION. 

8.1. Term. The term of this Agreement will commence on the Effective Date and extend until the earlier of (a) the termination of
this Agreement in its entirety (or on a country-by-country basis with respect to a termination for material breach) pursuant to Sections 8.2, 8.3,
8.4, 8.5 or 8.6, or (b) on a country-by-country and OpenBiome Royalty
Product-by-OpenBiome Royalty Product basis (in the LMIC Territory), the last to expire Royalty Term for such OpenBiome Royalty Product in such country in the LMIC
Territory (the “Term”). 
 8.2. Termination for Convenience by OpenBiome. Upon at least [***] prior written notice to
Finch, OpenBiome may, at its convenience, terminate this Agreement in its entirety. 

  
 21 

 8.3. Termination for Default. 

8.3.1. Material Breach. In the event that either Party commits a material breach of its obligations under this
Agreement, or OpenBiome commits a material breach of its obligations under the Asset Purchase Agreement, and such Party fails to cure such breach within [***] after receiving notice thereof from the other Party, the
non-breaching Party may terminate this Agreement, immediately after the aforesaid [***] period, by providing written notice to the allegedly breaching Party, unless the allegedly breaching Party disputes such
breach in good faith in accordance with Section 8.4.2; provided however, that in the event of a material breach by OpenBiome of its obligations under this Agreement pertaining to one or more countries (but not the
entire LMIC Territory), then Finch’s termination right pursuant to this Section 8.4.1 shall be limited to such country(ies). 

8.3.2. Material Breach Dispute. Any dispute regarding an alleged material breach of this Agreement shall be resolved in
accordance with Section 10.1 hereof. Notwithstanding anything to the contrary contained in Section 8.4.1 or elsewhere in the Agreement, the applicable cure period for any alleged material
breach that is in dispute shall be tolled from the date that the alleged breaching Party notifies the other Party that it intends to dispute the allegation through the resolution of such dispute pursuant to Section 10.1 and
it is understood and acknowledged that, during the pendency of a dispute pursuant to Section 10.1, all of the terms and conditions of this Agreement shall remain in effect, and the Parties shall continue to perform all of
their respective obligations under this Agreement. 
 8.4. Patent Challenge. If OpenBiome or any of its Affiliates or Sublicensees (or
any Affiliates of such Sublicensees), brings a Patent Challenge, or assists in bringing a Patent Challenge (except (a) as required under a court order or subpoena or (b) as a defense against a claim, action or proceeding asserted by Finch
or its licensees against OpenBiome or any of its Affiliates or Sublicensees), then Finch may immediately terminate this Agreement in its entirety upon written notice to OpenBiome. 

8.5. Insolvency. Either Party may terminate this Agreement immediately upon written notice to the other Party, if the other Party
(a) becomes insolvent and is generally unable to pay, and fails to pay, its debts as they become due for more than [***], (b) files, or has filed against it, a petition for voluntary or involuntary bankruptcy or pursuant to any other insolvency
law that has not been dismissed within [***], (c) makes or seeks to make a general assignment for the benefit of its creditors, or (d) applies for, or consents to, the appointment of a trustee, receiver or custodian for a substantial part of
its property or business. 
 8.6. Effects of Termination. 

8.6.1. Survival. The following sections, together with any sections that expressly survive, will survive expiration or
termination of this Agreement for any reason: Article 1 (Definitions); Section 2.5 (No Implied Rights); Sections 3.2.1-3.2.2 and 3.2.3-3.2.4 (Reports and Payments) (solely with respect to
payment obligations that have accrued prior to the effective date of such expiration or termination); Section 3.2.5 (Financial Records and Audits); Section 3.3 (No Deductions or Offsets);
Section 3.4 (Expenses); Section 6.1 (Confidentiality); Section 6.2 (Authorized Disclosure); Section 6.3 (SEC Filings and Other Disclosures);
Section 6.4.1 (Announcements); Section 7.5 (Disclaimer); Section 8.6 (Effects of Termination); Article 9 (Limitation of Liability; Indemnification and Insurance);
Article 10 (Miscellaneous). 

  
 22 

 8.6.2. Accrued Rights. Expiration or termination of this Agreement
for any reason will be without prejudice to any right which will have accrued to the benefit of either Party prior to such termination, including (a) any and all payment obligations that have accrued prior to the effective date of expiration or
termination, or (b) damages arising from any breach under this Agreement. Expiration or termination of this Agreement will not relieve either Party from any obligation which is expressly indicated to survive such expiration or termination. 

8.6.3. Termination of Licenses. Upon early termination of this Agreement for any reason, all rights and licenses granted
to OpenBiome under the terms of this Agreement will terminate. 
 8.6.4. Sell-Off
Period. If OpenBiome terminates this Agreement in accordance with Section 8.4.1, during the [***] period following notice of termination, OpenBiome and its Affiliates and Sublicensees may, with Finch’s prior
written consent, sell any commercial inventory of OpenBiome Royalty Product(s) which remains on hand as of the effective date of the termination for so long as OpenBiome makes all payments due in accordance with the terms and conditions set forth in
this Agreement. 
 8.6.5. Confidential Information. Within [***] of the effective date of any early termination of
this Agreement, each Party shall, at the Disclosing Party’s option, either return or destroy all materials containing the other Party’s Confidential Information, except to the extent such Confidential Information is necessary to perform
surviving obligations or exercise surviving rights. Notwithstanding the foregoing, the Receiving Party will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes, such copy
to remain subject to Article 6. 
 8.6.6. Sublicenses. Notwithstanding Section 8.6.3, if
this Agreement terminates for any reason, any Sublicensee that is not in breach of its sublicense agreement (shall automatically become a direct licensee of Finch with respect to the rights originally granted under this Agreement that are
sublicensed to the Sublicensee by OpenBiome and Finch shall confirm the foregoing in writing at the request and for the benefit of the Sublicensee; provided that such Sublicensee agrees to comply with all of the terms of this Agreement to the extent
applicable from the rights originally sublicensed to it by OpenBiome, and provided further that Finch shall not be bound by any duties or obligations contained in the sublicenses that extend beyond the duties and obligations assumed by Finch in this
Agreement. 

  
 23 

	9.	 LIMITATION OF LIABILITY, INDEMNIFICATION AND INSURANCE. 

9.1. Limitation of Liability. EXCEPT TO THE EXTENT THAT ANY EXCLUSION OR LIMITATION OF LIABILITY IS VOID, PROHIBITED OR UNENFORCEABLE BY
APPLICABLE LAW, NOTWITHSTANDING ANYTHING IN THIS AGREEMENT TO THE CONTRARY, NEITHER PARTY WILL BE LIABLE TO THE OTHER PARTY HEREUNDER, REGARDLESS OF THE FORM OF ANY CLAIM OR ACTION (WHETHER IN CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE),
FOR ANY INDIRECT, PUNITIVE, INCIDENTAL, RELIANCE, SPECIAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, LOSS OF BUSINESS, REVENUES, PROFITS OR GOODWILL, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD HAVE KNOWN OF THE
POSSIBILITY OF SUCH DAMAGES, PROVIDED, HOWEVER, THAT THIS SECTION 9.1 SHALL NOT LIMIT OR RESTRICT (A) DAMAGES AVAILABLE TO A PARTY FOR BREACHES BY THE OTHER PARTY OF ITS CONFIDENTIALITY AND
NON-USE OBLIGATIONS SET FORTH IN ARTICLE 6, (B) DAMAGES AVAILABLE FOR WILLFUL MISCONDUCT OR GROSS NEGLIGENCE, (C) AMOUNTS OWED TO THIRD PARTIES IN CONNECTION WITH THE INDEMNIFICATION OBLIGATIONS OF
A PARTY PURSUANT TO THIS ARTICLE 9, OR (D) DAMAGES AVAILABLE TO FINCH FOR ANY THIRD PARTY INFRINGEMENT CLAIMS BROUGHT AGAINST FINCH AS A RESULT OF OPENBIOME’S EXPLOITATION OF OPENBIOME LICENSED NATURAL PRODUCTS. 

9.2. Indemnification by OpenBiome. OpenBiome will indemnify, defend and hold harmless Finch and its Representatives (each, a
“Finch Indemnified Party”), from and against any and all third party claims or allegations (whether threatened or pending), judgments, expenses, damages, liabilities, obligations, fees (including the reasonable fees of attorneys and
other consulting or testifying professionals), costs and losses (collectively, “Liabilities”) that the Finch Indemnified Party may be required to pay to one or more Third Parties arising out of or related to: (a) the exercise
of any rights granted to OpenBiome under this Agreement, including the Exploitation or use of any OpenBiome Royalty Product, by, on behalf of, or under the authority of, OpenBiome, any of its Affiliates, any of its Sublicensees or any of their
respective Representatives (including Liabilities that any Finch Indemnified Party may be required to pay to one or more Third Parties arising out of or resulting from any theory of product liability concerning any OpenBiome Royalty Product
Developed, Manufactured, Commercialized or used by OpenBiome, any of its Affiliates or its Sublicensees or any of their respective Representatives pursuant to any right or licensed granted under this Agreement); (b) the gross negligence or willful
misconduct of OpenBiome or any of its Representatives in performing obligations under this Agreement or with respect to any OpenBiome Royalty Product or (c) the material breach of this Agreement by OpenBiome, including any breach of
OpenBiome’s representations and warranties or covenants and agreements hereunder. 
 9.3. Indemnification by Finch. Finch will
indemnify, defend and hold harmless OpenBiome and its Representatives (each, an “OpenBiome Indemnified Party”), from and against any and all Liabilities that the OpenBiome Indemnified Party may be required to pay to one or more
Third Parties arising out of or related to: (a) the gross negligence or willful misconduct of Finch or any of its Representatives in performing obligations under this Agreement or (b) the material breach of Finch’s representations and
warranties hereunder. 
 9.4. Procedure. The Party seeking indemnification under this Article 9 (the “Indemnified
Party”) will notify the other Party in writing promptly upon becoming aware of a claim for which indemnification is sought hereunder (including any governmental investigation)and provide the indemnifying Party with a copy of any complaint,
summons or other 

  
 24 

 
written or verbal notice that the Indemnified Party receives in connection with any such claim. An Indemnified Party’s failure to deliver prompt notice will relieve the indemnifying Party of
liability to the Indemnified Party under this Article 9 only to the extent such delay is prejudicial to the indemnifying Party’s ability to defend such claim. Provided that the indemnifying Party is not contesting the indemnity
obligation, the Indemnified Party will permit the indemnifying Party to control any litigation relating to such claim and the disposition of such claim by negotiated settlement or otherwise and any failure to contest in writing prior to assuming
control will be deemed to be an admission of the obligation to indemnify. The indemnifying Party will act reasonably and in good faith with respect to all matters relating to such claim and will not settle or otherwise resolve such claim without the
Indemnified Party’s prior written consent which will not be withheld, delayed or conditioned unreasonably; provided, that such consent will not be required with respect to any settlement involving only the payment of monetary awards for
which the indemnifying Party will be fully-responsible, or with respect to any settlement that unconditionally releases the Indemnified Party from liability. The Indemnified Party will reasonably cooperate with the indemnifying Party in its defense
of any claim for which indemnity is sought under this Agreement, at the indemnifying Party’s request and reasonable cost and expense. The Indemnified Party may participate in the action with its own counsel at its own expense. 

9.5. Insurance. OpenBiome, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure
sufficiently to provide materially the same level and type of protection) in an amount consistent with sound business practice and adequate in light of its obligations under this Agreement during the Term. OpenBiome shall provide a certificate of
insurance (or evidence of self-insurance) evidencing such coverage to Finch upon request. 
  

	10.	 MISCELLANEOUS. 

10.1. Disputes. 

10.1.1. Initial Negotiation. Any dispute arising out of or relating to the Agreement will be resolved by having
individuals authorized by each Party make a good faith effort to negotiate an amical resolution to the dispute. All negotiations pursuant to this Section 10.1 will be subject to the covenants regarding confidentiality set
forth in Article 6. If the initial negotiations described above do not resolve the issue, binding arbitration as provided in Section 10.1.2 will be the sole and exclusive procedure for the resolution of any such
dispute. 
 10.1.2. Invoking Arbitration and Selecting an Arbitrator. If the Parties fail to agree with respect
to any dispute subject to this Section 10.1.2 within [***] following commencement of the negotiations provided for in Section 10.1.1, at the written request of either Party, the matter in dispute
will be submitted for binding arbitration in the Commonwealth of Massachusetts. One arbitrator will be mutually selected by both Parties. The costs of the arbitrator will be shared equally by the Parties. All other expenses (legal, incidental, etc.)
will be borne by the losing Party or, if both Parties prevail in part, be apportioned by the arbitrator between the Parties. Arbitration proceedings will be governed by the Rules of the American Arbitration Association then in effect. All aspects of
the arbitration shall be treated as confidential; provided that, nothing in this Section 10.1.2 is intended to, or shall, preclude a Party to the arbitration from communicating with, or

  
 25 

 
making disclosures to its lawyers, tax advisors, auditors and insurers, as necessary and appropriate or from making such other disclosures as maybe required by any applicable Law. To the maximum
extent permitted by applicable Law, the decision of the arbitrator shall be final and binding and not be subject to appeal. If a Party against whom the arbitrator renders an award fails to abide by such award, the other party may seek to enforce
such award in any court of competent jurisdiction. The final decision of the arbitrator shall be rendered within [***] of the commencement of the arbitration. 

10.2. Assignment. Subject to OpenBiome’s rights to sublicense as provided in this Agreement, neither Party may assign
or transfer (whether by operation of law or otherwise) this Agreement or any rights (including any rights to payments) or obligations hereunder without the prior written consent of the other Party except that (i) Finch may make such an
assignment, in whole or in part, without OpenBiome’s consent to an Affiliate or to a successor to substantially all of the business to which this Agreement relates, whether in a merger, sale of stock, sale of assets, license, reorganization or
other transaction, and (ii) OpenBiome may make such an assignment, in whole or in part, without Finch’s consent to an Affiliate or to a successor to substantially all of the business to which this Agreement relates, whether in a merger,
sale of stock, sale of assets, license, reorganization or other transaction. Any permitted successor or assignee of obligations hereunder will expressly assume performance of such obligations (and in any event, any Party assigning this Agreement to
an Affiliate will remain bound by the terms and conditions hereof). Any permitted assignment will be binding on and inure to the benefit of the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of
the terms of this Section 10.2 will be null, void and of no legal effect. 
 10.3. Further Actions. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

10.4. Interpretation. Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to
encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words “include”, “includes” and “including” will be deemed to be followed
by the phrase “without limitation”, (c) the word “will” will be construed to have the same meaning and effect as the word “shall”, (d) any definition of or reference to any agreement, instrument or other
document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns, (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be
construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections, or Schedules will be construed to refer to Sections or Schedules of this Agreement, and references to this
Agreement include all Schedules hereto, (h) the word “notice” means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this
Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder “agree,” “consent” or “approve” or the like will require that such agreement, consent or approval be specific and in
writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j) references to any specific law, rule or regulation, or article, section or other
division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term “or” will be interpreted in the inclusive sense commonly associated with
the term “and/or.” 

  
 26 

 10.5. Notices. Any notice to be given under this Agreement must be in writing and
delivered either in person, by (a) air mail (postage prepaid) requiring return receipt, (b) overnight courier, or (c) email or facsimile confirmed thereafter by any of the foregoing, to the party to be notified at its address(es)
given below, or at any address such party may designate by prior written notice to the other in accordance with this Section 10.5. Notice shall be deemed sufficiently given for all purposes upon the earliest of:
(i) the date of actual receipt; (ii) if air mailed, five days after the date of postmark; (iii) if delivered by overnight courier, the next day the overnight courier regularly makes deliveries; or (iv) if emailed or sent by
facsimile, the date of confirmation of receipt if during the recipient’s normal business hours, otherwise the next day. 
 All
correspondence to OpenBiome will be addressed as follows: 
 Microbiome Health Research Institute, Inc. d/b/a OpenBiome 

2147 Massachusetts Ave. 

Cambridge, Massachusetts 02140 

Email: [***] 
 Attention: [***]

 with a copy (which shall not constitute notice) to: 

[***] 
 All correspondence to
Finch will be addressed as follows: 
 Finch Therapeutics, Inc. 

200 Inner Belt Road 

Somerville, MA 02143 
 Email:
[***] 
 Attention: [***] 

with a copy (which shall not constitute notice) to: 

[***] 
 10.6. Amendment.
No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

10.7. Waiver and Non-Exclusion of Remedies. No provision of this Agreement will be waived by any
act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of
any provision hereof by the other Party will not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. The rights and remedies provided herein are cumulative and do not exclude any other right or
remedy provided by Applicable Law or otherwise available except as expressly set forth herein. 

  
 27 

 10.8. Severability. If any clause or portion thereof in this Agreement is for any
reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement will be construed in such fashion as to maintain its existence, validity and
enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained in this Agreement, and there will be deemed substituted therefor such provision as will
most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. 
 10.9.
Descriptive Headings. The descriptive headings of this Agreement are for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement. 

10.10. Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of
Massachusetts, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

10.11. Use of Names. Neither Party shall, without the prior written consent of the other Party, use the name or any trademark or trade
name owned by the other Party, or owned by an Affiliate or parent corporation of the other Party, in any publication, publicity, advertising, or otherwise, except as expressly permitted by Article 6.  

10.12. Entire Agreement. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the
Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof. 

10.13. Independent Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed
to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the
other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 

10.14. Counterparts. This Agreement may be executed in one or more counterparts, each of which will be an original and all of which will
constitute together the same document. Counterparts may be signed and delivered by facsimile or digital (e.g., PDF) file, each of which will be binding when received by the applicable Party. 

  
 28 

 10.15. No Third Party Rights or Obligations. No provision of this Agreement will be
deemed or construed in any way to result in the creation of any rights or obligation in any Person not a Party to this Agreement. 

(Signature page follows.) 

  
 29 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this
Agreement as of the Effective Date. 
  

									
	FINCH THERAPEUTICS, INC.	 	                        	  	MICROBIOME HEALTH RESEARCH INSTITUTE, INC.
					
	By:	 	 /s/ Gregory Perry
	 		  	By:	 	 /s/ Jim Bildner

	Name: Gregory Perry	 		  	Name: Jim Bildner
	Title: Chief Financial Officer	 		  	 Title: Chair of the Independent Special

Committee

 [Signature Page to License Agreement] 

 SCHEDULE 1 

LMIC TERRITORY 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]